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CHAPTER ONE 
INTRODUCTION TO SUPRAMOLECULAR AND MEDICINAL CHEMISTRY 
 When referring to medicinal chemistry, one often does not typically 
think about supramolecular chemistry as a related field. However, medicinal 
chemists are often tasked to synthesize biologically active compounds with 
the objective of targeting a specific cell receptor, anti-body, or an enzyme. 
One should remember that these targets, such enzymes or receptors, are 
host-guest complexes. In a very real sense, these enzymes are 
supramolecular entities that function as hosts that have affinity to specific 
guests that encompass the correct electronic and structural properties to 
complement the macrocyclic host. In supramolecular chemistry, chemists 
build supramolecular complexes to study host-guest chemistry effects, 
attempting to mimic biological systems, drug delivery systems, molecular 
self-assembly techniques to construct lipophilic micelles or vesicles, and 
build macrocyclic tweezers to function as either artificial cell receptors or 
part of a cavity of an enzyme. It is these concepts of host-guest interactions 
that essentially tie medicinal and supramolecular chemistry together, and 
each field truly complements the other.  Supramolecular chemistry is a field 
that will continue to grow, and researchers will continue to develop and 
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revolutionize macrocyclic systems that mimic and improve our 
understanding of biological systems, or to develop new methods to safely 
and efficiently deliver drugs minimizing undesired drug side-effects and 
efficiently eliciting the proper biological response or termination of cancer 
cells. 
 Supramolecular chemistry involves the formation of complex molecular 
entities that have the capacity to participate in specific molecular recognition 
of guest molecules. Supramolecular structures are often pursued due to their 
intrinsic ability to be chiral and to mimic biological systems and dynamics. A 
commonly employed scaffold in supramolecular chemistry is the trimeric 
crown-shaped molecule cyclotriveratrylene (CTV). CTV has been studied 
extensively for its capability of binding a number of smaller organic and 
organometallic guests within its bowl-shaped cleft and has been used as a 
building block enabling the construction of more complex cryptophanes. The 
goal of this research is the synthesis and characterization of novel chiral 
macrocyclic derivatives. These new cyclophanes should have greater 
versatility than the parent CTV hydrocarbon macrocycle including greatly 
enhanced water solubility, the ability to coordinate to metal ligands, the 
potential for use in drug delivery, and unique optical and liquid crystal 
properties. Enantiopurity assessment of a chiral macrocyclic lactam was 
addressed and accomplished using a chiral shift reagent (Chirabite-AR)—
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itself a chiral macrocycle, which has been used for the enantiopurity 
determination of small molecules that can fit into its macrocyclic cleft, but 
not previously for other supramolecular scaffolds. 
  Globally, cancer has affected many people and families and there are 
many types of cancer. The challenge with cancer is to design active 
pharmaceutical compounds to selectively target cancer cells without 
affecting normal healthy cells. It is the ultimate goal for medicinal chemists 
to design such compounds that have high specificity for cancer cells as 
opposed to healthy cells. Normal treatments of cancer involve chemotherapy 
and radiation, however these methods are typically hard on the body 
because they affect normal cells. Often times, cancer patients with weak 
immune systems cannot tolerate radiation or chemotherapy because their 
immune system would severely be affected making them susceptible to 
infections, thus losing the battle against cancer. On the other hand, localized 
delivery of radiation is a targeted therapy that has been gaining much 
attention in the medical community. One of the methods of in situ generated 
of radiation is boron neutron capture therapy (BNCT). Coupling medicinal 
chemistry and BNCT is a powerful tool in delivering boron-based compounds 
to cancer cells, which in combination with a neutron source generate an 
internal source of localized radiation within the cancer cell and ultimately 
destroys cancer cells without affecting normal cells. Within this dissertation, 
4 
 
the objective of this anticancer work was to utilize a potent pharmacophore 
that has the potential to target multiple forms of cancer (brain, prostate, 
ovarian, breast, liver, colon, pancreatic, lung, head/neck, mouth, bone), and 
even rheumatoid arthritis which also involves upregulated matrix 
metalloprotease (MMP) enzymes. Toward accomplishing the generation of 
localized radiation within cancer cells, the essential pharmacophore (missile) 
was coupled with a carborane moiety which is the ultimate source (warhead) 
of the radiation once exposed to neutrons. Targeting cancer cells can be 
accomplished by identifying a cellular receptor or enzyme that is upregulated 
in cancer cells. In this dissertation, the host enzymes that are of interest are 
MMP enzymes since these enzymes are upregulated and are highly over-
expressed in cancer cells. Establishing host-guest relationships of inhibitors 
bound to MMPs is of interest since it is these interactions that allow an active 
compound to be bound to an enzyme. Establishing bioavailability for oral 
dosing is not as important since the boron-containing drug will be 
administered i.v. Within this dissertation is described the synthesis of two 
novel MMP inhibitors that contain a carborane moiety. The key chemistry 
involved installation of the carborane group using Click chemistry. These 
Click carborane products were evaluated by in vitro MMP inhibition testing 
against MMP-1, MMP-2, MMP-9 and showed nanomolar potency against 
MMP-2 and MMP-9 and also sparing MMP-1.  
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 Understanding host-guest interactions is an essential key for medicinal 
and supramolecular chemists. It is these interactions that allows researchers 
to evaluate how specific enzymes functions. From these lessons, the 
researchers generally prepare new substrate analogs to target a specific 
enzyme with the aim that these new analogs will bind more strongly than 
the native substrate. Based on this, molecular modeling also provides 
another powerful tool to assess whether designed guest molecules would 
serve as proper substrates for a given enzyme. Within this research, 
molecular modeling and docking illustrated key structural differences 
between methylated L,L-SDAP ligands inside the active site of succinyl-
diaminopimelate desuccinylase (DapE) that allowed the focus to synthesize 
the best analog (monomethyl L,L-SDAP) for a novel ninhydrin-based assay 
developed within our research group. During route selection of the 
monomethyl substrate, an asymmetric synthesis was accomplished providing 
the alternate L,L-SDAP substrate in high enantiomeric purity. 
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CHAPTER TWO 
FORMATION AND ENANTIOMERIC PURITY DETERMINATION OF BECKMANN-
DERIVED CTV LACTAM WITH CHIRABITE-AR AND ATTEMPTED RESOLUTION 
Section 1: Introduction 
 There are four characteristics1 to be expected in cyclophanes2 and 
supramolecular3 scaffolds. The first is the electronic interaction between 
aromatic rings positioned in a “face-to-face” manner. Second, the 
substitution on one aromatic ring influences reactivity on adjacent rings 
within the cyclophane influencing intramolecular/intermolecular substitution 
reactions of the aromatic rings. Third, intramolecular charge-transfer 
complexes are possible. Lastly, the ring strain, steric strain, and 
transannular strain present in a macrocyclic molecule will dramatically 
impact the chemistry of the entire system. 
Section 2: Introduction to Supramolecular Chemistry with 
Particular Emphasis on Cyclotriveratrylene (CTV) 
 Supramolecular chemistry involves the formation of complex molecular 
entities that have the capacity to participate in specific molecular recognition 
of guest molecules.3 Cyclophanes are supramolecular structures comprised 
of aromatic units with bridging chains forming cage-like structures2 and have 
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found applications in molecular recognition as synthetic receptors, as models 
for intercalation, as building blocks for organic catalysts, and in the 
preparation of crown ethers and cryptands.1 Cyclophanes have been utilized 
as molecular scaffolds in the design of new pharmaceuticals4-7including use 
as cholesterol shuttles to modulate cholesterol metabolism,8 as potent 
human choline kinase (ChoK) inhibitors,9 and as inhibitors of HIV protease.10 
Recently, CTV analogs that have been constructed to be water-soluble motifs 
have been designed to function as drug delivery agents and successfully 
tested against HepG2 (human liver hepatocellular carcinoma) cell lines.11 
Supramolecular entities have received much attention such that they are 
being employed to improve therapeutics by utilizing the macrocycle's ability 
to target and host drugs as guests and provide subsequent delivery of the 
drug based on physiological indicators.12 
 The crown-shaped cyclophane cyclotriveratrylene (CTV, 1, 
hexamethoxy tribenzocyclononene)13 has been employed extensively as a 
scaffold in supramolecular chemistry. This [1.1.1]orthocyclophane is readily 
prepared from the trimerization of veratryl alcohol in acid and has been 
extensively studied for its capability of binding a variety of smaller organic 
and organometallic guests within its bow-shaped cleft.14-16 Many clathrates 
of CTV and of CTV derivatives17-20have been structurally characterized 
including clathrates with anionic C70 dimers.
21 Thioether derivatives of CTV 
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have recently been employed to immobilize C60 onto gold surfaces,
22, 23and 
water soluble CTV derivatives have been developed for biomedical 
applications including the biological delivery of fullerenes24 and selective 
anion sensing.25  Other clathrates of CTV have been structurally 
characterized, including DMSO and ethanol,26 chlorinated organics,18 
xenon,19 lanthanides,20 organometallic complexes,17 C60,
27 and anionic C70 
dimers.21CTV has been employed as a supramolecular building block to 
construct more complex cage-like cryptophanes,28 and as a crystal 
engineering tecton giving network structures of unusual topology.29CTV 
derivatives have also been studied for their mesomorphic properties30 and 
are capable of forming liquid crystals by themselves31 and as complexes with 
C60.31CTV is a natural product and was isolated from the bark of 
Zanthoxylum conspersipunctatum found in New Guinea.32 
Section 3: Background Including Previously-Published 
Work on the Synthesis of Selected CTV Derivatives 
 Our work in supramolecular chemistry is based on the supramolecular 
scaffold cyclotriveratrylene (CTV, 1), which has enjoyed much attention in 
the literature, but almost no focus on functionalization of the apex of the 
structure (see Figure 1). We have focused both on functionalization of the 
apex via oxidation reactions, as well as on a scaffold wherein the three 
apical methylenes are replaced by nitrogen atoms33 (“N3-CTV”). 
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Figure 1. Classic Preparation of CTV13 and designation of apical and 
peripheral regions 
 
 The bowl-shaped crown conformer is essential for host-guest 
chemistry with CTV and its derivatives.  CTV itself exists almost exclusively 
in the crown conformer.  Oxidation of CTV to the monoketone 2 afforded the 
crystalline product, which was shown by X-ray crystallography to crystallize 
in an enantiomerically pure crystal.  Formation of the oxime of the ketone 
afforded two products, surprisingly, which we demonstrated were the crown 
(15) and saddle (16) conformers of the CTV oxime.34  Given the importance 
of the kinetics and thermodynamics for host-guest chemistry, we pursued a 
study of the interconversion of the oxime conformers (see Figure 2), 
followed by proton NMR.  The oxime saddle conformers of 16 are favored in 
CDCl3 (Keq = [saddle]/[crown] = 1.4), whereas the CTV oxime crown 
conformer 15 is favored in three more polar solvents studied (DMSO-d6, 
acetonitrile-d3, acetone-d6).  The t1/2 of the saddle 16 was determined to be 
2.45 ± 0.15 h in CDCl3 at 25 °C, and 3.71 ± 0.07 h in DMSO-d6.
35 
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Figure 2. X-Ray crystal structure of CTV monoketone 2, and the two 
atropisomers of CTV oxime (15 and 16) 
 
 To expand the macrocycle from a 9-membered ring macrocycle to a 
10-membered ring we employed the Beckmann rearrangement of the oxime 
15, which proceeded in high yield with thionyl chloride to generate the 10-
membered lactam 19 (see Figure 3).36 
 
Figure 3. Beckmann rearrangement of CTV-oxime to the ring-expanded 
lactam 
 
 We found that the 10-membered N-acetyl macrocyclic imide 21 
crystallizes as a solid solution of racemic columnar assemblies comprised of 
alternating enantiomers in a stacked-cup array, each as a chloroform 
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monosolvate, but with a random distribution of the columns within the 
crystal leading to whole molecule disorder within the crystal, comprising a  
2-D solid solution (see Figure 4).37 
 
Figure 4. Columns of N-acetyl CTV imide 21 comprising the 2D solid solution 
observed in the X-ray crystal structure 
 
 Interestingly, under certain conditions for the Beckmann 
rearrangement for making the 10-membered lactam 19, a helical pentacycle 
20 was obtained, which arose via an unexpected tandem Beckmann-
Electrophilic Addition cascade sequence (see Figure 5).36 
 
Figure 5. Observation of a Tandem-Beckmann/electrophilic aromatic addition 
cascade 
 
 The observation of the tandem-Beckmann cascade drew our attention 
to the possibility of a synthetically useful intermolecular metal-free tandem 
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Beckmann-electrophilic aromatic substitution cascade affording diaryl 
imines, ketones, amines and quinazolines, which was realized (Figure 6).38 
 
Figure 6. Intermolecular Tandem-Beckmann rearrangement 
 
 Oxidation of cyclotriveratrylene (CTV, 1) to the corresponding diketone 
3 and subsequent bromination resulted in an unexpected rearrangement to 
a highly functionalized 9-aryl-10-bromoanthracene derivative 11 and 12.  
Electroluminescent 9,10-diaryl anthracenes have been shown to be 
promising host and hole-transporting materials in organic 
electroluminescence due to their high thermal stability, electrochemical 
reversibility, and wide band gap useful for organic light-emitting diodes 
(OLEDs), especially blue OLEDs, so we employed Suzuki couplings to 
synthesize a series of 9,10-diaryl compounds (13a-c and 14a-c) that are 
structural analogues of anthracene derivatives used in the preparation of 
OLEDs but are more highly functionalized, including electron-donating 
methoxy groups in addition to substitution by a carboxylic acid moiety (see 
Figure 7).39 
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Figure 7. Electroluminescent 9,10-diaryl anthracenes (13a-c, 14a-c) 
derived from diketone 3 
 
 Furthering the apical functionalization of CTV 1, we also explored the 
apical functionalization of the veratrylene tetramer, cyclotetraveratrylene 
(CTTV, 7), obtaining the CTTV tetraketone 8 (see Figure 8).  Curiously, the 
tetraketone 8 undergoes two distinct trans-annular cyclization reactions, 
depending upon the conditions, either to a bis-spiro lactone 9 reminiscent of 
the closed, lactone form of fluorescein or to 10.  When tetraketone 8 is 
heated with acid, the CTTV tetraketone 8 produces a highly symmetric 
diketone 10 in high yield (see Figure 8).40 
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Figure 8. Preparation of CTTV tetraketone 8 and two different rearrangement 
products 9 and 10. X-ray crystal structures of CTTV tetraketone 8 
 
 Further, as a complementary avenue for apical functionalized analogs 
of CTV 1, we targeted the tris-N derivative (N3-CTV), which conceptually is 
the combination of CTV and the well-known ligand TACN 
(triazacyclononane).  The nitrogen atoms should provide both a handle for 
functionalization on the apex through alkylation, as well as the possibility of 
metal complexation (see Figure 9).41 
 
 
Figure 9. Design of “N3-CTV” as a conceptual combination of CTV and TACN 
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Section 4: Discussion of Current Work Including 
Improvement in the  Synthesis of CTV Analogs 
 This section summarizes advances in the synthesis of cyclotriveratrylene 
(CTV) derivatives that have not already been published.  These novel macrocyclic 
molecules have unique and intriguing properties including pseudorotation, rapid 
nitrogen umbrella inversions, elegant intramolecular transannular cyclizations, the 
ability to crystallize in random columnar assemblies, the ability to undergo ring 
expansions through both traditional and tandem Beckmann rearrangements, 
formation of helical like bonds, oxidative rearrangements, and the possibility of the 
electroluminescent properties which are enhanced by the highly functionalized 
moieties present on the molecules synthesized within this section. 
Cyclotriveratrylene (CTV, 1) was the starting material for the synthesis of various 
CTV derivatives. The synthetic process improvements for CTV analogs of interest 
were monoketone 2, oxime conformers 15 and 16, lactam 19, and 
menthyloxyacetic acid imide 23. 
 One of the oxidized products of CTV, monoketone 2, was previous 
synthesized utilizing either acidic conditions adopted by Cookson and 
Stevens42 or slightly basic conditions. We found that using slightly alkaline 
conditions increased the rate of reaction, made isolation of the desired 
oxidized products easier, and eliminated the formation of spirolactone5. 
Within this work, the process of preparing monoketone was further  
improved using neutral conditions that employed ethyl acetate as the 
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solvent which avoided the use of pyridine. Furthermore, the process 
implemented a simple trituration step for purification of monoketone 2 
rather than resorting to normal phase chromatography. 
 Another intermediate compound prepared in this work was the oxime 
of CTV which exists as the individual crown (15) and saddle (16) conformers 
that were previously isolated and characterized.34 Previous isolation of CTV 
oximes consisted of concentration from pyridine, aqueous workup, and a 
tedious chromatography. Within the present work, the process was improved 
to isolate the CTV oximes as a mixture of atropisomers directly from the 
crude reaction mixture such that both saddle and crown oxime conformers 
were isolated together as a filterable solid. 
The Beckmann rearrangement of CTV oximes to prepare racemic CTV 
lactam 19 has been modified to avoid the use of corrosive thionyl chloride, 
prevent the formation of helical pentacycle (6) and simplify for the 
purification process. Furthermore, previous methods required the use of 
pure crown CTV oxime conformer to achieve high yields of CTV lactam, 
however this work employs a newly-modified procedure where a mixture of 
oxime conforms can be used and still achieve high isolated yields of desired 
CTV lactam 19.  
CTV lactam 19 exists as a mixture of enantiomers (racemate) and 
these supramolecular enantiomers were observed spectroscopically via1H 
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NMR using commercially-available Chirabite-AR chiral shift reagent. 
Furthermore, the CTV lactam racemate (19a + 19b) was derivatized using a 
chiral auxiliary, (-)-menthoxyacetyl chloride, generating an enriched 
diastereomeric imide 23 (87:13) confirmed by 1H NMR and X-ray analysis. 
The use of Chirabite-AR was employed to monitor the chiral purity of CTV 
lactam after hydrolytic removal of the chiral auxiliary. 
Section 5: Oxidations of Cyclotriveratrylene (CTV) 
We are interested in the preparation of novel apex-functionalized 
derivatives of CTV and have reported the isolation and the kinetics and 
thermodynamics of the interconversion of the saddle and crown conformers 
of CTV oxime ,34 and reported the discovery of a new tandem Beckmann-
aromatic addition reaction sequence affording a helical pentacycle 20 from 
the CTV oxime 15.38, 46 We then turned our attention to the preparation of 
the elusive CTV triketone 4 due to the potential applications of this highly 
symmetric molecule as a new supramolecular host molecule as well as its 
potential utility as a synthetic intermediate. 
Cookson and Stevens had reported the isolation of CTV monoketone 2 
and CTV diketone 3 by the direct oxidation of CTV 1 with sodium dichromate 
in acetic acid under reflux.42  Cookson and Stevens additionally reported42 
the isolation of another CTV derivative from this oxidation that they 
indicated was CTV triketone 4. The correct structure was given shortly 
18 
 
thereafter by Baldwin43 as spirocyclic compound 5,44 an isomer of the CTV 
triketone thus giving rise to misleading combustion and mass spectrometry 
analyses.  We believe that the triketone may be produced under the sodium 
dichromate oxidation conditions, but also that the spirocycle 5 results from 
rapid acid-catalyzed electrophilic addition and rearrangement of the 
intermediate diketone 3 or triketone 4. 
Furthermore, it is very well possible and seems more reasonable that 
CTV diketone 3 is the intermediate for the formation of spirocycle 5. Below 
are two schemes which illustrate two different mechanisms for the formation 
of spirocycle 5. Another rationale that diketone 3 may be the precursor to 5 
is that after intramolecular transannular cyclization, the corresponding 
benzylic carbon is even more activated for oxidation to the ketone. CTV 
diketone 3 is difficult to oxidize to the triketone 4 due to the incorrect 
dihedral angles of the benzylic carbon making it an unactivated methylene, 
as discussed below. 
From Schemes 1 and 2, with respect to the formation of spirolactone 
5, the diketone route (see Scheme 2) actually seems more reasonable than 
the triketone route, because when the aryl π-electrons of the diketone 
undergo intramolecular nucleophilic attack on the protonated carbonyl, the 
ortho methylene is electron donating (ortho activated) thus creating a more 
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reactive nucleophilic, in contrast to the triketone which has an electron 
withdrawing group ortho to the aryl π-system.  
Scheme 1. Mechanistic Hypothesis of the possible conversion of CTV 
Diketone 3 to Spirocycle 5 
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Spirolactone 5 was formed via a transannular electrophilic addition of 
a putative intermediate cyclotriveratrylene triketone 4 and is made up of 
both an anthrone and an isobenzofuranone ring that are connected via one C 
atom to form a spiro compound. The anthracene and isobenzofuranone ring 
systems of the spiro compound are both essentially planar and are 
perpendicular to each other, with a dihedral angle of 89.90° between them.  
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Scheme 2. Mechanistic Hypothesis of the Possible Conversion of 
CTVTriketone 4 to Spirocycle 5 
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 Cookson et al.42 described the first synthesis of the spirolactone 
molecule 5. Baldwin & Kelly43 subsequently reported its correct identification 
as the spiro compound by UV and NMR methods.  
 Cookson et al.42 reported the isolation of a CTV derivative from 
oxidation of CTV 1 with sodium dichromate in acetic acid that they thought 
was the CTV triketone 4. The triketone 4, however, has in fact never been 
isolated, and the compound isolated by Cookson and was shortly thereafter 
identified using UV–Vis and NMR-spectroscopic methods43 to have a spiro 
structure (structure 5), produced via acid-catalyzed electrophilic addition 
and rearrangement of the putative triketone under the acidic conditions. 
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Both this spirolactone 5 and the tandem Beckman/electrophilic addition 
products36, 44, 45 are formed via transannular electrophilic addition to 
somehow-related cationic intermediates. Interestingly, the spiro derivative is 
a structural analogue of the cyclized lactone form of the exceedingly useful 
fluorescent spirolactone fluorescein. The spirolactone 5 contains a diaryl 
ketone rather than the diaryl ether of fluorescein. 
 
Figure 10.Structure of Spirolactone (Cmpd 5) 
 
We initially suspected the presence of triketone 4 in the Cookson 
oxidation42 method and isolated a small amount (1.5-3.5%) of high-melting 
yellow solid (mp 338-340ºC) which we thought had C3V symmetry, thus 
displaying only two singlets in the 1H NMR in a ratio of 1:3 at 7.68 and 4.07 
ppm respectively, and only five signals total in the 13C NMR corresponding to 
the carbonyl, the methoxy, and three aryl carbons.  High resolution mass 
spectrometry demonstrated the presence of the appropriate ion for the 
trimeric triketone, although this must have been detection of a minor 
component in the material which was subsequently confirmed to be the 
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known dimeric 2,3,7,8-tetramethoxyanthraquinonone (structure 6). The 
main component was certainly unexpected given the presumed integrity of 
the trimeric CTV system, but we hypothesize that it was formed via a 
reverse electrophilic aromatic substitution under the acidic conditions and 
expulsion of one of the three 3,4-dimethoxybenzyl moieties and re-closure 
to the dimeric anthraquinone 6 (see Scheme 3). 
Scheme 3. Dimeric Anthraquinone 6 via Oxidation of CTV 
 
 Based on the fact that oxidation of CTV 1 itself, or oxidation of the 
mono/diketone analogs (3/4) under acidic conditions afforded the undesired 
spirolactone 5, other means of carrying out the oxidation was investigated. 
Previously, alternative oxidative conditions of CTV 1 (Scheme 4) were 
developed using an excess of KMnO4(36 eq) supported on activated MnO2 
(72 eq) in refluxing pyridine. After 3 h at reflux, the reaction was complete 
and isolation afforded a 35% yield of CTV monoketone 2 and 16% CTV 
diketone 3. These basic conditions were convenient due to the fact that 
spirolactone 5 does not form and chromatography is much easier in terms of 
separating CTV monoketone 2 from diketone 3 after normal phase 
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chromatography. The isolated monoketone 2 and diketone 3 were analyzed 
via X-ray analysis (Figure 11). Interestingly, the monoketone 2 crystallizes 
as a single chiral conformer.35 The X-ray crystal structure of the diketone 3 
has not been published. 
 
Figure 11.X-Ray structure of CTV monoketone (2) and CTV diketone (3). 
Hydrogens were omitted for clarity 
 
Scheme 4. KMnO4 supported on MnO2 oxidation of CTV 
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One drawback of the KMnO4/MnO2 conditions is that when the reaction 
is deemed complete by HPLC and TLC analysis, the crude material after 
filtration is concentrated and the resulting mass balance is always only 50-
60% of the theoretical amount. The low mass balance may be due to that 
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some of the starting material or desired products are decomposing by 
permanganate over-oxidation side reactions, or the desired products exist as 
manganese complex salts, perhaps even as a triketone manganese complex, 
and if true, then the lost mass may represent material that was successively 
oxidized to the triketone. 
Unfortunately, CTV triketone 4 has not yet been isolated from these 
conditions. To investigate the robustness of the KMnO4/MnO2 conditions, CTV 
diketone 3 was treated with 36 eq KMnO4 on activated MnO2 in refluxing 
pyridine or quinoline to determine if CTV triketone 4 can be prepared, but 
only starting material 3 was observed even after seven days of heating. This 
result indicates that perhaps the dihedral angle of hydrogen abstraction on 
the methylene carbon of CTV diketone 3 is not ideal for proper radical 
stabilization.  However, Synder et al.46 is the only report to-date of 
successful preparation of a CTV triketone derivative, and in that report, the 
methoxy moieties were ortho to the benzylic carbon. Synder performed DFT 
calculations of their triketone derivative compared to CTV-derived triketone 
4 (both in protonated form) and showed that the adjacent methoxy groups 
provided better stabilization of the protonated ketone thus discouraging 
unproductive intramolecular transannular cyclization. Based on his findings, 
it is likely that under basic conditions the mechanism may involve radical 
intermediates. If the process is operating under radical type pathway, then 
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the ortho-methoxy groups should also provide proper radical stabilization 
that generates significant twisting allowing the methylene and phenyl ring to 
be perpendicular and in turn this creating the correct dihedral angle for 
oxidation to occur. 
Based on Synder's findings, the synthesis of triketone 4 was no longer 
pursued. However, during screening reaction conditions for triketone 4, it 
was found that some of the results showed high conversion to 
monoketone/diketone and thus the preparation of CTV monoketone can be 
carried out efficiently in a more suitable and more green solvent, ethyl 
acetate. Details about this will be discussed below. 
Section 6: Process Developments for Improving the 
Synthesis and Isolation of CTV Monoketone 
Based on previous methods for the preparation of CTV monoketone, 
there was a need to develop a more suitable process for CTV monoketone 3, 
since that the monoketone is key starting material in subsequent research 
described below, that did not involve the use of sodium dichromate or 
pyridine as the solvent. As mentioned above, during the search for preparing 
CTV triketone, many conditions were investigated which evaluated the effect 
of various solvents, temperatures, and ratio of potassium permanganate and 
manganese dioxide.  Each experiment was monitored by TLC and/or HPLC 
analysis to determine the progress of oxidizing CTV 1 to CTV monoketone 
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2and diketone 3. Table 1 summarizes the results from the solvent screening 
at specified temperatures. 
Table 1. Solvent screening for CTV oxidation to monoketone at various 
temperatures 
 
Experiment* Solvent 
Temp 
(oC) 
TLC Analysis 
Monoketone 2 
Present? 
Comments 
1 pyridine 100 oC Yes  
2 pyridine 65 oC Yes  
3 NMP 100 oC No Only SM. 
4 NMP 65 oC No  
5 MeOH 65 oC No Only SM. 
6 MeOH 25 oC No Only SM. 
7 t-BuOH 65 oC No Only SM. 
8 sulfolane 100 oC Yes  
9 sulfolane 65 oC Yes  
10 MeCN 65 oC Yes  
11 EtOAc 65 oC Yes  
12 EtOAc 80 oC Yes  
13 THF 65 oC Yes (faint spot)  
14 chloroform 65 oC Yes (faint spot)  
15 MeNO2 100 
oC No Only SM. 
16 MeNO2 65 
oC No Only SM. 
17 dioxane 65 oC Yes (faint spot)  
18 dioxane 100 oC Yes (faint spot)  
*All experiments used KMnO4/MnO2 (34 eq/52 eq) and 15 mL of solvent. Each experiment 
was heated for 18 h then analyzed by TLC analysis using EtOAc/DCM (20/80). 
 
 Based on the solvent screening and using TLC analysis to judge the 
presence of monoketone 2, selected solvents that contained monoketone 
were further evaluated and analyzed by HPLC to quantitatively assess how 
much monoketone 2 and diketone 3 formed along with how much unreacted 
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starting material (CTV, 1) remained. Table 2 illustrates the HPLC results 
from this study. 
Table 2. Selected solvents studied for the oxidation of CTV and monitoring 
conversion to monoketone by HPLC analysis 
 
Entry Solvent 
Temp 
(oC) 
Time 
HPLC Analysis 
%CTV 
1 
%MK 
2 
%DK 
3 
1 pyridine 65 oC 3 h 62 25 1 
2 pyridine 65 oC 17 h 43 45 3 
3 pyridine 100 oC 3 h 22 58 6 
4 sulfolane 65 oC 3 h 72 15 3 
5 sulfolane 65 oC 17 h 50 31 10 
6 sulfolane 100 oC 10 h 30 56 7 
7 sulfolane 100 oC 28 h 30 56 7 
8 MeCN 65 oC 3 h 75 17 1 
9 MeCN 65 oC 17 h 75 17 1 
10 EtOAc 65 oC 3 h 74 19 1 
11 EtOAc 65 oC 17 h 42 51 4 
12 EtOAc 80 oC 18 h 16 70 9 
13 EtOAc 80 oC 37 h 15 72 9 
*All experiments used KMnO4/MnO2 (34 eq/52 eq) and 15 mL of solvent. 
 Based on the results in Table 2, performing the oxidation in ethyl 
acetate was superior compared to the other solvents employed in the study. 
The use of ethyl acetate also presents the opportunity to eliminate the use 
of pyridine which is toxic, has a strong disagreeable odor, and can cause 
impotence. Following these results, the next step was to optimize the 
amount of KMnO4/MnO2 in the oxidation of CTV in ethyl acetate. Table 3 
illustrates the results of varying the amounts of KMnO4/MnO2 at specific 
temperatures. 
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Table 3. Optimization of KMnO4/MnO2 in the oxidation of CTV in ethyl acetate 
and subsequent scale up 
 
Entry 
CTV 
Qty. 
KMnO4 MnO2 
Temp 
(oC) 
Time 
HPLC Analysis 
%CTV 
1 
%MK 
2 
%DK 
3 
1 
0.25 g 
11 eq 20 eq 65 oC 
18 h 
9.9 76.4 13.7 
2 11 eq 20 eq 80 oC 0.5 86.4 13.2 
3 20 eq 20 eq 65 oC 9.3 74.3 16.4 
4 20 eq 20 eq 80 oC 0 81.3 18.7 
5 30 eq 20 eq 65 oC 9.6 75.9 14.5 
6 30 eq 20 eq 80 oC 0 79.4 20.6 
7 11 eq 20 eq 65 oC 
37 h 
2.4 83.9 13.6 
8 11 eq 20 eq 80 oC 0.4 86.9 12.7 
9 20 eq 20 eq 65 oC 1.1 80.9 18.0 
10 20 eq 20 eq 80 oC 0 77.3 22.7 
11 30 eq 20 eq 65 oC 1.2 78.7 20.1 
12 30 eq 20 eq 80 oC 0 63.5 36.5 
13 5.00 g 10 eq 20 eq 80 oC 
2 h 41.3 56.6 2.1 
5 h 21.6 72.8 5.6 
19 h 0 91.7 8.3 
14 0.25 g 7 eq 14 eq 80 oC 
2 h 61.3 36.7 2.1 
5 h 43.4 52.3 4.3 
19 h 9.2 83.9 6.9 
15 76.2 g 9 eq 18 eq 80 oC 18 h 0 92.0 8.0 
 
 Table 3 illustrates that performing the oxidation at 65 oC for 18 h did 
not achieve full consumption of CTV 1 even with higher loadings of KMnO4. 
However, when the reactions were carried out at 80 oC for 18 h (entries 2, 4, 
6), HPLC analysis revealed that CTV 1 was completely consumed and higher 
conversion of monoketone 2 and diketone 3 were observed. Increasing the 
reaction time did not show any benefit for enhancing the conversion to 
monoketone, however when increasing the amount of KMnO4 to >11 eq, 
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diketone conversion was enhanced especially at 80 oC. Interestingly, entry 
13 employed slightly lower loadings of oxidizing mixture (10 eq KMnO4/20 
eq MnO2) and after 19 h generated 91.7% of monoketone 2 and 8.3% 
diketone 3. Scaling the oxidation (per entry 15) using 76 g of CTV and 
employing even lower loadings of KMnO4 (9 eq)/MnO2 (18 eq) in ethyl 
acetate at 80 oC generated the same conversions of monoketone/diketone 
as entry 13. 
 The next step was to identify purification conditions for monoketone 2 
without resorting to column chromatography and subsequent 
recrystallization. Fourteen solvents were evaluated using crude monoketone 
(starting purity: 85% pure by HPLC that contained 11% diketone 3) and the 
solvents that showed promise were acetonitrile, n-butanol, toluene, ethyl 
acetate, and xylenes. Ultimately, acetonitrile showed the best results for 
purifying CTV monoketone 2. Recrystallization from acetonitrile provided 
96% purity but with only 46% recovery of monoketone. Performing a 
trituration in acetonitrile (3 volumes) at 70 oC overnight (~16 h), cooling to 
room temperature, and isolating by filtration provided 98% pure 
monoketone with 70% recovery. Scaling the trituration of the crude 
monoketone (51.0 g) in acetonitrile (3 volumes) at 70 oC overnight provided 
the first crop of monoketone (32.5 g, 65% recovery, 98% pure by HPLC). 
The mother liquors were partially concentrated removing about half of the 
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solvent to generate a slurry which was filtered to yield a second crop of 
monoketone (15.8 g, 31% recovery, 95% pure). The overall recovery of 
monoketone was determined to be 96%.  
 It is evident that the process for preparing monoketone has been 
substantially improved compared to previous reported methods. The benefits 
of the improved oxidation method include that the process does not use 
toxic and pungent smelling pyridine but rather the process uses a friendlier 
and less harmful solvent such as ethyl acetate, allows one to use 
considerably less KMnO4/MnO2, allows for higher conversion to monoketone, 
and lastly purification via a trituration in acetonitrile which proved to be very 
efficient and eliminated the need to employ a tedious and time-consuming 
column chromatography purification.  
Section 7: Improved Synthesis for the Beckmann 
Rearrangement of cyclotriveratrylene (CTV) Oxime 
 The preparation of novel apex-functionalized derivatives of CTV (1) is 
of great interest in our research group. Toward this end, we have previously 
synthesized the oxime derivatives of CTV 15/16via the CTV monoketone 
(2) (see Scheme 5). Monoketone (2) was originally prepared utilizing a 
modification47 of Steven’s method42 for oxidation of CTV with sodium 
dichromate in acetic acid under reflux, however this process was improved 
as described above using KMnO4/MnO2 in ethyl acetate and avoiding 
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chromatography. The conversion of 2 to the corresponding oximes 15/16 
was quite sluggish and required an excess of hydroxylamine and overnight 
heating in pyridine to push the reaction to completion. The indolent nature of 
the monoketone in forming the oxime was presumably due to the aryl 
hydrogens ortho to the ketone hindering the approach of the nucleophilic 
hydroxylamine. The ortho hydrogen atoms are almost at contact distance, 
with 2.5 Å between their centers.13Furthermore, the conformational 
flexibility of monoketone may suggest that the pseudorotation also allows 
the phenyl rings to block the electrophilic carbonyl and prevent attack from 
the incoming hydroxylamine.  
Scheme 5. Synthesis of Crown (15) and Saddle CTV-Oximes (16) 
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 Our former procedure for preparation of CTV oximes 15/16 involved 
concentration of pyridine under reduced pressure, performing aqueous 
workup in ethyl acetate, and chromatographic purification over silica gel to 
isolate pure crown CTV oxime conformer 15 in 45-50% yield and pure 
saddle CTV oxime conformer 16 in 45-50% yield. However, since water and 
pyridine are miscible, we found that that CTV oximes 15/16 can be isolated 
as a filterable solid directly from diluting the partially concentrated reaction 
mixture with water and the isolated oxime product can be used in the 
Beckmann rearrangement. HPLC analysis of the filtered oxime solid 
indicated that the mixture was comprised of an 89:11 ratio (normalized) of 
crown to saddle conformers as illustrated in Figure 12. The 11.7 min 
component in the HPLC chromatogram is not the tandem product 20, but 
rather an unidentified impurity that was not characterized.  
We previously found that the Beckmann rearrangement performed on 
pure CTV oxime crown conformer 15 promoted with thionyl chloride in 
dilute solution at 0 oC proceeds in essentially quantitative yield (99%) to 
afford the 10-membered lactam 19. Modified conditions afforded a helical 
pentacycle 20 derived from an unusual tandem Beckmann rearrangement 
and electrophilic aromatic addition followed by demethylation and 
tautomerization as illustrated in Scheme 6.36 
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Figure 12. HPLC chromatogram of isolated CTV oximes 15/16 from 
pyridine/water 
 
 The ring-expanded lactam exists at room temperature exclusively as 
the crown conformer 15 based on the geminal coupling observed in the 
proton NMR [4.67 (1H, d, J = 15.0 Hz), 4.44 (1H, d, J = 15.3 Hz), 3.70 (1H, 
d, J = 15.0 Hz), 3.56 (1H, d, J = 15.3 Hz)], as pseudorotation of the flexible 
saddle conformation 16 is known to lead to magnetic equivalence of the 
geminal benzylic methylene protons. Furthermore, the N-acetyl CTV imide 
21 showed that the 10-membered macrocycle exists in a crown 
conformation.37 Interestingly, the lactam crown conformer 19 is a 
structurally chiral molecule, although lacking chiral tetrahedral carbon atoms 
(Schemes 6 and 7, structure 19).  
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Scheme 6.Beckmann rearrangements of cyclotriveratrylene (CTV) oxime 15 
 
 
 Based on our previous reported work, it is known that the Beckmann 
rearrangement of oxime 15 under certain conditions produces lactam 19 
and helical pentacycle 20 resulting from a tandem Beckmann rearrangement 
and intramolecular electrophilic aromatic addition (see Scheme 7).  
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Scheme 7.Beckmann rearrangement of CTV oxime crown conformer to 
Beckmann lactam 19 and tandem Beckmann/electrophilic aromatic addition 
product 20. 
 
 
 As reported previously, the product distribution in the Beckmann 
rearrangement was dependent upon the reaction conditions36 when 
employing thionyl chloride in a diethyl ether/DCM mixture. Further efforts to 
develop conditions for preparing CTV lactam were evaluated in hope to 
minimize or eliminate the formation of the helical byproduct 20. In addition, 
the previous procedure that used thionyl chloride in large excess required 
the use of pure crown form of CTV oxime 15, plus it was preferred to 
eliminate the use of noxious thionyl chloride from the process. 
 Evaluation of other Beckmann reaction conditions were screened to 
determine if the formation of the tandem product 20 could be prevented. 
Thus, treatment of the oxime 15 with acetic anhydride in xylenes with 
microwave heating to 200–210 oC for 1.5 h under conditions employed by 
Savarin40 to produce isoindoles from oximes gave only 26% of lactam 19 
and none of the tandem product 20. Heating the oxime 15 to 75 oC for 4 h 
with p-toluenesulfonyl chloride and DMAP in pyridine gave a 56% isolated 
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yield of lactam 19, and none of tandem-derived product 20. On the other 
hand, heating the oxime directly in polyphosphoric acid at 140 oC for 7 min 
gave pentacycle 20 in 22% yield with none of the Beckmann lactam 19. 
Subjecting oxime 15 to iodine and triphenylphosphine in acetonitrile at 60 oC 
provided 14.1% conversion by HPLC to lactam 19, and formation of 20 was 
not observed. Reaction of oxime 15 with catalytic ruthenium chloride 
hydrate in MeCN at 80 oC for 20 h resulted in only 17% conversion to CTV 
lactam 19 and unreacted starting material.  
 Ultimately, it was found that reacting CTV oxime 15 with 
carbonyldimidazole (CDI) generated a stable oximo-carbamate intermediate 
22 which was subsequently treated with aqueous trifluoroacetic acid at 70oC 
to generate clean conversion to CTV lactam 19 without formation of the 
tandem-derived product 20 as illustrated in Scheme 8. The 10-membered 
lactam 19 was isolated directly from the reaction mixture in 82-85% yield 
with 95% purity according to HPLC analysis. 
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Scheme 8. Modified Beckmann rearrangement using CDI/TFA/water to 
cleanly access CTV lactam 19 
 
 In conclusion, the Beckmann rearrangement process for preparing 
lactam 15 has been simplified and has been improved mainly by eliminating 
the use of thionyl chloride which required careful quenching of excess 
unreacted thionyl chloride followed by neutralization of hydrochloric acid 
waste streams. The improved procedure does not require the neutralization 
since the resulting waste stream is a mixture of imidazole and trifluoroacetic 
acid and the pH is within allowable disposal limits. Furthermore, the use of 
the improved method also allows one to use mixtures of oxime conformers 
15 and 16 and easily access CTV-lactam 19 rather than using solely crown 
oxime 15 which was required when using thionyl chloride. Note also that the 
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oximes used for this work were isolated directly from the hydroxylamine 
reaction in pyridine by addition of water and the mixture was triturated, 
filtered, and dried to afford oximes as an isolatable solid which is another 
process improvement in its own right. Previous isolation of CTV oximes 
required extractive workup after removing pyridine and subsequent 
chromatography over silica gel which afforded foams or glass solids post 
concentration. Furthermore, the Beckmann rearrangement process can now 
be implemented into our research lab and allow undergraduates to easily 
carry out the preparation of racemic CTV lactam 19 using less hazardous 
conditions. With an improved procedure for CTV lactam, further studies were 
evaluated to determine if resolution of the chiral lactam enantiomers (19a 
and 19b) could be achieved as mention in the next section. 
Reduction of the crown shaped lactam 19 with lithium aluminum 
hydride in THF under reflux gave the corresponded racemic amine 24 in 
quantitative yield (see Scheme 9). The amine could potentially be applied as 
a linker to stationary phases or peptides which lead to the capability of 
allowing host-guest chemistry reactions to occur. In addition, amine 24 is 
envisioned to increase water solubility of the CTV-like scaffold allowing 24 to 
be a potential precursor for drug-delivery systems. 
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Scheme 9. Reduction of 19 with Lithium Aluminum Hydride to afford water 
soluble CTV derivative 24 
 
 
Section 8: Attempted Resolution and Observed Racemization of the 
Beckmann-Derived CTV-Lactam and the Use of Chirabite to 
Determine Optical Purity of the Supramolecular Scaffold 
 Chiral cyclophanes have applications in enantiodiscrimination 
processes including catalysis, recognition and sensing, determination of 
enantiomeric excess, and signaling chiral information of guests,48, 49 as with 
chiral molecular tweezers that exhibit selective binding and chiral recognition 
of specific guests.50  CTV and its [1.1.1]cyclophane congeners in their rigid 
crown conformation are unique bowl-shaped molecules have applications in 
sensors, self-organized materials, liquid crystals, and metallosupramolecular 
chemistry.51  CTV and its cryptophane derivatives are of great interest in 
molecular recognition.52  CTV derivatives are members of a larger family of 
inherently chiral concave molecules that have applications in chiral 
recognition and asymmetric synthesis.49  A chiral CTV derivative bearing 
Kemp’s triacid was shown to induce triple helix formation of collagen 
peptides.53  Chiral CTV derivatives have been used for the dynamic covalent 
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synthesis of chiral nanocubes with potential utility as vessels for 
biomacromolecules,54 and a similar dynamic thermodynamic resolution 
strategy was recently reported of racemic CTV units by remote stereogenic 
centers.55  Helically chiral CTV units have been employed to construct 
enantiopure molecular cages,56 along with a host of elegant CTV-derived 
coordination cages.57  Some of the fascinating supramolecular structures of 
self-assembled cages derived from CTV-type scaffolds have recently been 
reviewed,58 such as a racemic C3-symmetric bipyridyl-bearing CTV ligand 
with zinc shown to self-assemble into triply interlocked chiral catenanes 
within an overall chiral crystal.59  CTV-based host compounds bearing three 
binaphthol moieties have been reported as chiral sensors with recognition of 
sugar derivatives.60 
 The crown form of the cyclotriveratrylene can undergo umbrella 
inversion which inverts chiral derivatives to their enantiomeric structure, as 
Collet demonstrated by observing the slow racemization of structurally chiral 
cyclotriveratrylene derivatives.61  Resolution and NMR studies have been 
performed on the crown and saddle conformers of a CTV derivative toward 
chiral liquid crystals.62  We have studied the kinetics and thermodynamics of 
the crown-saddle equilibria in CTV derivatives.35  Indeed, while most work 
with CTV has focused on peripheral functionalization, we selected to focus on 
apical functionalization, enabling attachment of CTV “bowl-out” receptors on 
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surfaces.63  We observed that CTV-derived oxime 1534 undergoes facile 
Beckman rearrangement to afford the macrocyclic lactam 19 which is chiral 
as the crown conformer and thus potentially resolvable.   
 The great interest in synthetic macrocyclic receptors includes 
applications in chiral analysis and separation,64  and Ema has developed 
chiral selectors with multiple H-bonding sites in macrocyclic cavities65-67 
including the commercially available Chirabite-AR.   
 While the macrocycle of lactam 19 contains a larger 10-membered 
ring, lactam amide resonance68 reduces flexibility through restricting rotation 
around the carbonyl C-N bond.  We were interested if Chirabite-AR, which is 
designed for determining the e.e. of small molecules that can ideally be 
contained within its macrocycle, might be used to determine the e.e. of a 
larger supramolecular scaffold including the CTV-derived lactam 19, and if 
lactam 19 might be resolvable via attachment of a chiral auxiliary through 
N-functionalization of the lactam as in derivative 21. 
Figure 13. Synthesis of the 10-membered CTV-derived Lactam 19 and N-
acetyl imide derivative 21 
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Results and Discussion 
 
 The Beckmann rearrangement of CTV-oxime generates CTV-lactam19 
as a racemic mixture of CTV-lactam enantiomers (19a and 19b). As shown 
in Scheme 10, either of two phenyl rings can migrate (as denoted by either 
a red or green arrow) to form the chiral nitrilium ions (18a-b) which are 
trapped by water leading to a 50:50 mixture of enantiomers19a-b as a 
racemate. 
Scheme 10. Formation and Mechanism for Racemic Cyclotriveratrylene (CTV) 
Lactam19 
 
 
 Assessment of the relative energies of the crown and saddle 
conformers of lactam 19were assessed through calculations on model 
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structures lacking the six methoxy groups.  Density functional theory (DFT) 
calculations (EDF2/6-31G*) were performed using Spartan ’16 
(Wavefunction, Inc., Irvine, CA).  It was found that the crown conformer is 
9.22 kcal/mol more stable than saddle conformer of lactam 19.  AM1 
calculations that we reported earlier for the 9-membered ring CTV 
monoketone2 revealed the saddle conformer as (3.15 to 5.23 kcal/mol, i.e. 
13.2 to 21.9 kJ/mol) higher in energy than the more stable crown 
conformer.35 
a)  b)  
 
Figure 14. DFT energy minimized structures for a) crown conformer, b) 
saddle conformer 
 
 Given that lactam 19 exists as a racemate in the crown form, 
attempting to observe the two enantiomeric lactam components was 
evaluated using 1H NMR and Chirabite-AR as illustrated in Scheme 
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11.Chirabite-AR is a macrocyclic compound that structurally has a unique 
cavity where the hydrogen-bond donor and acceptor sites are well organized 
to facilitate the binding of a wide range of smaller compounds as guest 
molecules. Once the guest molecules interact with Chirabite-AR, the guest 
molecule will experience a strong anisotropic ring-current effect arising from 
the BINOL moiety, which is a chiral source, and which allows the chemical-
shift nonequivalence between the two diastereomeric complexes to be 
distinguished. 
Scheme 11. Resolution of racemic macrocyclic lactam 19 using macrocycle 
chiral shift reagent Chirabite-AR 
 
 
 The racemic macrocyclic lactam 19 was treated with increasing 
amounts Chirabite in CDCl3 solution and examined by 
1H NMR spectroscopy, 
demonstrating that the individual enantiomers could be baseline separated 
in the NMR for ultimate optical purity determination.  The ratio of Chirabite 
was increased from 0.01 equivalent to 0.3 equivalents, and separation was 
already evident with only 0.01 equivalent of Chirabite, but 0.05 equivalent 
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was optimal to provide baseline separation for the proton resonances in the 
aromatic region of the two enantiomers, while only 0.025 equivalent was 
sufficient for baseline separation of some methoxy resonances.  Additional 
quantities of Chirabite (> 0.30 eq) were counterproductive, leading to large 
chemical shift displacements and compromising the ability to assign the 
peaks.  We surmise that Chirabite is interacting most strongly with the 
lactam carbonyl oxygen, which bears a calculated Mulliken charge of -0.489 
au which is the greatest point electron density on the molecule, as expected, 
and should H-bond accept strongly from an H-bond donor of Chirabite. 
Toward resolution of the chiral lactam, analogs of the macrocyclic N-
acetyl imide should be resolvable when utilizing chiral acyl substituent in 
place of the acetyl moiety of 3, since resolving the macrocyclic lactam 2 into 
its enantiomers may provide a new and potentially useful chiral scaffold, 
although admittedly, the cavity of the macrocyclic CTV-lactam or macrocyclic 
N-acetyl imide is modest in size and the asymmetry of the lactam moiety is 
on the apical side of the molecule.  
 Several different chiral auxiliaries were explored for reaction with 
lactam 2, including (1S)-(-)-camphanic chloride, (S)-(+)-ɑ-methoxy-ɑ-
trifluoromethylphenylacetyl chloride, diacetyl-L-tartaric anhydride and 
ketopinic acid chloride, which did not provide N-acylated adducts under a 
number of conditions explored, including heating in pyridine as solvent.  
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However, (-)-menthyloxyacetic acid chloride was successful in providing 
diastereomeric imide adducts in good yield using an excess of 
menthyloxyacetic acid chloride in pyridine at reflux providing a 69% yield of 
the desired imide 23 (see Scheme 12).  
Scheme 12. Preparation of the diastereomeric menthyloxyacetic acid adduct 
23 
 
After purification, the 1H NMR revealed a mixture of diastereomers in 
an 87:13 ratio. Attempts to separate the diastereomers and improve the 
diastereomeric purity using recrystallization and achiral column 
chromatography techniques were unsuccessful. Recrystallization from 
DCM/hexane provided X-ray quality crystals. In fact, the crystal structure 
obtained through X-ray crystallography also confirmed the diastereomeric 
ratio through relative densities and the overall molecular structure including 
the absolute configuration of the chiral bowl-shaped CTV-imide 23. 
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Figure 15. X-ray crystal structure of the menthyloxyacetic acid-CTV imide 
adduct 23 
 
 Cleaving the chiral auxiliary of the 87:13 mix of diastereomers was 
accomplished using aqueous LiOH in THF. Optical rotation of the lactam 
proved to be unsuccessful to determine the rate of racemization from 87:13 
to 50:50. We also used Eu(fod)3, a chiral lanthanide shift reagent, to try to 
show the mix of enantiomers of the chiral CTV lactam in 1H NMR , but, while 
the Eu(fod)3 did complex with the lactam, the peaks were too broad to 
obtain any conclusions. An alternative chiral shift reagent, Chirabite AR, 
functioned significantly better giving better resolution and complexation with 
the chiral CTV lactam entities. 
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Shown below in Figures 16-20 are the overlap of 1H NMR spectra 
showing resolution of racemic CTV-lactam into two enantiomeric components 
at different loading equivalents of Chirabite-AR reagent. 
 
 
Figure 16. Overlap of the 6-10 ppm region for the 1H NMR Spectrum of CTV-
Lactam and different loadings of Chirabite  
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Figure 17. Overlap of the 6.5-7.3 ppm region for the 1H NMR Spectrum of 
CTV-Lactam and  different loadings of Chirabite 
 
 
Figure 18. Overlap of the 3.35-4.05 ppm region for the 1H NMR Spectrum of 
CTV-Lactam and different loading of Chirabite  
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Figure 19. Overlap of the 4.2-4.7 ppm region for the 1H NMR Spectrum of 
CTV-Lactam and different loading of Chirabite 
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Figure 20. Overlap of the 3.2-3.6 ppm region for the 1H NMR Spectrum of 
CTV-Lactam and different loading of Chirabite 
 
 There are multiple regions of the 1H NMR spectra that provide target 
peaks to track and integrate the enantiomeric CTV-lactam components. 
Within the aromatic region (6.5-7.3 ppm) shown in Figures 16 and 17, the 
six aromatic CH peaks all resolved fairly adequately where each of the six 
peaks resolved into 12 separate resonances when 0.125 equiv of Chirabite-
AR was employed. It is even discernible that the lactam NH resonances can 
be differentiated when 0.30 equiv of Chirabite was utilized. Furthermore, the 
aromatic CH peak at 6.7 ppm was resolved quite beautifully giving near 
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baseline separation using very low loading of Chirabite-AR (0.05 equiv). In 
the methoxy region (3.7-4.05 ppm), nearly all the methoxy moieties from 
each enantiomeric lactam component were separated into nearly 12 
separate peaks especially when 0.175-0.20 equivalents of Chirabite-AR was 
used as illustrated in Figure 18. Interestingly when focusing on the apex 
portion of CTV-lactam in Figure 19, the methylene C-H signals can be also 
distinguished into separate enantiomeric peaks when using 0.05 equivalents 
of Chirabite. Furthermore, the remaining methylene C-H peaks that resonate 
at 3.54 and 3.58 ppm also exhibited nearly baseline separation when 0.15-
0.20 equivalents of Chirabite-AR was employed (see Figure 20). 
Furthermore, the NMR resonances for Chirabite-AR did not overlap with any 
of the peaks for CTV-lactam due to the fact that most of the Chirabite 
resonances occurred downfield of 7.27 ppm where there are no peaks 
relating to CTV-lactam 19a-b. 
 Another potential analysis tool to determine chiral purity is the ability 
to do chiral separation by supercritical fluid chromatography (SFC) or chiral 
HPLC. Chiral screening on SFC and HPLC chiral stationary phases were 
evaluated but unfortunately there was not any success in resolving the 
enantiomers of CTV-lactam 19. Based on the fact that 1H NMR spectroscopy 
provided excellent results in distinguishing enantiomeric peaks of racemic 
CTV lactam 19, the next objective was to determine if the enriched CTV 
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menthoxyacetic imide 23 can be hydrolyzed to release the chiral auxiliary 
(menthyloxyacetyl) and in parallel use Chirabite-AR to observe a 87:13 
enantiomeric ratio of the resolved CTV lactam.  
 Before performing the hydrolysis, the time required for complete 
hydrolysis was determined by HPLC and it was confirmed that the hydrolysis 
reaction is completed (> 95% conversion) within 15 min and verified that 
the cleaving the chiral auxiliary group from 23 (retention time at 25.4 min) 
was accomplished giving CTV lactam 19 (retention time at 12.8 min). See 
below the HPLC chromatogram in Figure 21.  
 
 
Figure 21 - HPLC Chromatogram illustrating the hydrolysis of Chiral Auxiliary 
Group on 23 with LiOH in aq THF 
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 As illustrated in Scheme 13, the hydrolysis of chiral auxiliary was 
carried out on enriched CTV menthyloxyacetic imide 23 in aqueous THF 
using lithium hydroxide (3.5 eq) at < 5 o C for 15 min, then the reaction 
mixture was sampled, quickly concentrated, redissolved in CDCl3 containing 
Chirabite-AR (0.30 equiv), and finally analyzed by 1H NMR.  
Scheme 13. Hydrolysis of the enriched diastereomeric menthyloxyacetic 
imide and subsequent enantiomeric purity assessment using Chirabite-AR 
 
 
  
 Shown below in Figure 22 and 23 is the data from 1H NMR analysis 
post cleavage of the menthyloxyacetic group (shown in green), and the data 
showed that the CTV lactam product 19 had racemized to a 50:50 mixture 
based on the two sets of peaks (6.51/6.53 and 6.63/6.69 ppm) that 
integrated with the same area under the curve. In regards to Figure 23, it is 
evident that the set of peaks of interest to monitor enantiomeric purity are 
at 6.63/6.69 ppm and 6.51/6.53 ppm as indicated by the black circles. 
These black circles also illustrate which peaks corresponds to the singlet 
peaks in racemic CTV lactam as denoted in (A). These results suggest that 
once the chiral auxiliary is cleaved that the nitrogen umbrella inversion is 
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quite rapid furnishing a racemate. In more detail regarding Figure 23, there 
are two explanations of why the chemical shifts were different for (B) and 
(D). First explanation is there was an excess of hydroxide used in (B) that 
likely reduced the potency of Chirabite used (0.30 eq), therefore the actual 
amount of Chirabite used in the experiment is < 0.30 eq. Therefore, 
referring to Figure 17 where different loading equivalents of Chirabite was 
studied, the 1H NMR spectrum profile that best fit to (B) was when 0.175 eq 
Chirabite was employed thus indicating that there was about 0.175 eq of 
Chirabite present in (B). The second explanation is that hydroxide is 
competing with CTV lactam and the lactam moieties of the Chirabite scaffold, 
since lactams are an H-bond acceptor, and hydroxide is an H-bond acceptor 
as well.  
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Figure 22.1H NMR spectrum of hydrolyzed 23 in the presence of Chirabite 
showing the integrated peaks that indicate racemization 
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Note. A (purple) shows racemic lactam without Chirabite showing singlets. B (green) shows 
the 1H NMR spectrum of crude reaction mixture (post cleavage of chiral auxiliary group, 
menthyloxyacetate) containing Chirabite (0.30 eq) and excess hydroxide that shows a 1:1 
ratio of singlets revealing sadly racemization of lactam. C (red) illustrates the enantiomeric 
separation of peaks for Racemic CTV Lactam in the presence of 0.175 eq Chirabite which the 
profile closely resembles B likely due to that excess hydroxide is reducing the potency of 
Chirabite. D (blue) illustrates the enantiomeric separation of peaks for racemic lactam using 
Chirabite (0.30 eq) affording two separated singlets at 6.51 and 6.53 ppm. 
 
Figure 23. Post hydrolysis of 23 and using Chirabite-AR to determine 
enantiomeric purity of resolved lactam 19 
 
 In addition to 1H NMR spectroscopy, optical rotation was attempted to 
study if the enriched diastereomeric CTV mentholoxyacetic imide 23 could 
be cleaved such that the chiral purity of the resolved CTV lactam could be 
determined. However, the data generated provided inconclusive results since 
the byproduct of the reaction (mentholoxyacetic acid) is chiral. Attempts to 
run a standard sample of (-)-menthyloxyacetic acid in the same solvent 
medium did not provide satisfactory results and this analytical approach was 
no longer pursued. 
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Section 9: Conclusion 
 Within this work, the previously-reported processes to prepare and 
isolate specific CTV analogs (monoketone 2, oxime 15/16, lactam 19) were 
improved, which allowed the sequential steps to be carried out more 
efficiently. We have shown that racemic CTV lactam 19 can be kinetically 
driven to an enriched diastereomer 23 by reaction of lactam racemate with 
(-)-menthyloxyacetyl chloride affording an 87:13 mixture of diastereomers 
that was confirmed by 1H NMR and X-ray analysis. Furthermore, for the first 
time, we report that Chirabite-AR can be utilized employing 
substoichiometric amounts on a racemic macrocycle providing successful 
observation of the two macrocylic lactam enantiomers 19a-b with nearly 
baseline separation and resolution. Basic hydrolysis of the 87:13 
diastereomeric imide 23, however, proceeded with rapid bowl inversion to 
yield only racemic lactam 19 as confirmed by 1H NMR in the presence of 
Chirabite-AR. 
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Section 10: Experimental 
Cyclotriveratrylene (CTV, 1, hexamethoxy-tribenzocyclononene) 
 
 To a 5-liter glass reactor (3-necked), equipped with an overhead 
mechanical stirrer, J-Kem thermocouple, heating mantle, reflux condenser, 
and nitrogen inlet, was added 3,4-dimethoxybenzyl alcohol (201.7 g, 1.20 
moles). The mixture was heated to 60°C followed by addition of formic acid 
(99%, 3 liters) using a dropping funnel over a period of 15 min which the 
temperature had decreased 40°C. The resulting mixture was a white slurry. 
The slurry was reheated to 60oC and held at 60oC for an additional 3 h to 
give a light blue slurry. The slurry was cooled to room temperature and USP 
purified water (2 liters) was added. The slurry was cooled to < 10oC and 
held at < 10oC overnight. The following day (17 h later), the cold slurry was 
filtered over a fritted funnel and the wetcake was washed with USP purified 
water (4 x 1 liter), pulled dry, and further dried in vacuo at 75oC to provide 
crude CTV (133.51 g, white solids).  
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Recrystallization of crude CTV 
 To a 5-liter glass reactor (3-necked), equipped with an overhead 
mechanical stirrer, J-Kem thermocouple, heating mantle, reflux condenser, 
and nitrogen inlet, was charged crude CTV (132.7 g) and toluene (2.9 L). 
The slurry was heated to reflux (102.8°C) to give a slight hazy solution. 
While at reflux, chloroform (100 mL) and methanol (50 mL) was added 
slowly over 10 min to provide a homogeneous pale yellow solution. The 
solution was allowed to gradually cool to room temperature. After 3.5 h later 
the temperature was 25°C. The white slurry was filtered over a fritted funnel 
and the wetcake was washed with ice cold toluene (2 x 100 mL), pulled dry, 
and further dried in vacuo at 40 °C to provide purified CTV 1 (82.57 g, 
46.2% yield, white solids). HPLC (220 nm): 98.3%. The 1H NMR data is in 
accordance with that reported in the literature.69, 70 
Improved Procedure for the Synthesis of CTV monoketone (10,15-
dihydro-2,3,7,8,12,13-hexamethoxy-5H Tribenzo[a,d,g]cyclononen-
5-one, 2) 
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 To a 5-liter glass reactor (3-necked), equipped with an overhead 
mechanical stirrer, J-Kem thermocouple, heating mantle, reflux condenser, 
and nitrogen inlet was charged in the following order: CTV 1 (76.22 g, 0.17 
moles, 18 eq), ethyl acetate (2 L), activated manganese dioxide (264.7 g, 
3.05 moles), ground potassium permanganate (241.1 g, 1.53 moles, 9 eq) 
and lastly ethyl acetate (0.29 L) as a rinse. The reaction was allowed to stir 
at room temperature to ensure that there was no exotherm. The mixture 
was then heated to reflux and stirred overnight. After 18 h, TLC and HPLC 
analysis indicated that the reaction was deemed complete. Note: the 
reaction solution was colorless (once solids settled) indicating that all KMnO4 
had reacted. The reaction mixture was cooled to 50°C, filtered over a pad of 
Celite (70.6 g), and Celite Cake was rinsed with ethyl acetate (3 x 500 mL) 
and DCM (2 x 500 mL). The filtrate was concentrated under reduced 
pressure at 40-50°C to give crude monoketone (61.91 g, pale yellow solids).  
Purification of crude CTV Monoketone 
 Crude monoketone (51.00 g) was placed into a 250-mL glass reactor 
(2-necked), equipped with a large magnetic stir bar, J-Kem thermocouple, 
heating mantle, and reflux condenser. To the reactor was added acetonitrile 
(150 mL, HPLC grade). Heated mixture to 70 °C and allowed slurry to stir 
(250-300 rpm) at 70°C for 18 h. The slurry mixture was allowed to gradually 
cool to room temperature over 4 h, then continued to stir at room 
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temperature for approximately 3 h. The slurry was filtered over a fitted 
funnel, the wetcake was washed with acetonitrile (60 mL), pulled dry, and 
further dried in vacuo at 60°C overnight to give purified CTV monoketone 2 
(32.54 g  white solids, 65% yield).  
The mother liquor was partially concentrated to remove about 75% of 
the solvent to provide a slurry. The slurry was filtered and the wetcake was 
washed with ethyl acetate/heptane (50/50, 10 mL) and dried to give a 
second crop (15.8 g, 31% yield, white solids) of purified CTV-monoketone 2. 
Total recovery = 96%. Total yield: 74% yield (corrected). The 1H NMR data 
is in accordance with that reported in the literature.35 
10,15-Dihydro-2,3,7,8,12,13-hexamethoxy-5H-
tribenzo[a,d,g]cyclononen-5-oxime,CTV Oxime Crown (15) and CTV 
Oxime Saddle (16) 
 
 To a 500-mL glass reactor (3-necked), equipped with a magnetic stir 
bar, reflux condenser, J-Kem thermocouple, and nitrogen inlet, was charged 
CTV monoketone 2 (19.00 g, 40.91 mmol), hydroxylamine hydrochloride 
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(42.64 g, 613.6 mmol, 15.0 eq), and pyridine (190 mL). The mixture was 
heated to reflux (110 °C) under a nitrogen atmosphere. After 16.5 h, the 
heat was turned off and the reactor was sampled for TLC analysis 
(EtOAc/DCM, 20/80) and showed that the reaction was deemed complete. 
The reaction mixture was transferred to a 500 mL flask (1 neck) and 
partially concentrated at 60°C under reduced pressure to provide a crude 
residue. To the crude residue was added USP purified water (275 mL) and 
the mixture was allowed to triturate at room temperature for about 30 min. 
The slurry was filtered, and the wetcake was washed with USP purified water 
(2 x 50 mL), pulled dry, and further dried in vacuo at 50 °C overnight to 
provide a pure mixture of CTV-oximes (saddle/crown, 17.63 g, white solids, 
90% yield). The filtrate was extracted with ethyl acetate (3 x 75 mL). The 
combined organic extracts were washed with 1N HCl (1 x 50 mL), brine (75 
mL), dried with sodium sulfate, filtered, and concentrated under reduced 
pressure to provide an additional quantity of CTV-oximes (2.29 g). HPLC 
analysis showed a total purity of 96% for both oxime conformers which were 
a ratio of 89:11 (crown:saddle). The 1H NMR data is in accordance with that 
reported in the literature.35 
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Improved Procedure for the Synthesis of CTV-lactam (19) 
(2,3,8,9,13,14-hexamethoxy-11,16-dihydrotribenzo[b,e,h]azecin-
6(5H)-one) 
 
 Based on a similar procedure,36 this process was modified and 
improved. To a 1-liter round bottom flask (3-necked), equipped with an 
overhead mechanical stirrer, nitrogen inlet, and J-Kem thermocouple, was 
added CTV oxime (10.00 g) and acetonitrile (200 mL). The mixture was 
allowed to stir at ambient temperature for 20 min, then carbonyldiimidazole 
(CDI, 7.18 g) was added. Additional acetonitrile (20 mL) was used to rinse 
contents off the reactor flask walls. After 1 hour at room temperature, TLC 
analysis (EtOAc/DCM, 80/20) revealed that the oxime starting material was 
completely consumed and a new spot appeared (oxime O-acyl imidazole 
intermediate 22, Rf = 0.10). The reaction mixture was cooled to < 5
oC and 
de-ionized water (50 mL) was added followed by drop-wise addition of 
trifluoroacetic acid (TFA, 50 mL) over 20 min using a dropping funnel.  After 
20 h at room temperature, TLC analysis (EtOAc/DCM, 80/20) showed 
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complete conversion of acyl imidazole intermediate to CTV-lactam 19 (Rf = 
0.18). To the reaction mixture was added de-ionized water (600 mL) drop-
wise over 30 min providing an opaque pink slurry.  The slurry was allowed to 
stir for 20 h and filtered. The wetcake was washed with water (50 mL), 
pulled dry, and further dried in vacuo at 50 oC to provide CTV-lactam (8.13 
g, 82% yield). HPLC purity (220 nm): 95.2%. The 1H NMR data is in 
accordance with that reported in the literature.36 
5-[1,2,3,4-Tetrahydro-1-[[[(1R,2S,5R)-5-methyl-2-(1-
methylethyl)cyclohexyl]oxy]acetyl]-]acetyl-11,16-dihydro-
2,3,8,9,13,14-hexamethoxy-tribenz[b,e,h]azecin-6(5H)-one (23) 
 
Preparation Method 1: 
 To a solution of CTV lactam 19(175 mg, 0.36 mmol) in pyridine (1.8 
mL) was added (-)-menthyloxyacetic acid chloride (913 mg, 3.92 mmol) at 
room temperature and the solution was heated to reflux for 2 h.  The 
mixture was then concentrated under reduced pressure, and the resulting 
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residue was diluted in dichloromethane and poured onto ice.  The layers 
were separated, and the aqueous layer was extracted two additional times 
with dichloromethane.  The combined organic layers were washed 
successively with 1N hydrochloric acid (2x), saturated aqueous sodium 
bicarbonate, distilled water, brine, dried over sodium sulfate and 
concentrated to afford the crude product as a solid (999 mg).  The mixture 
was passed through neutral alumina (17 g) eluting with ethyl 
acetate/dichloromethane (20/80) to remove excess menthyloxyacetic acid, 
followed by elution of the cyclotriveratrylene lactam starting material that 
was recovered (40 mg, 25% recovered).  The remaining material (477 mg) 
eluted from the alumina was chromatographed on silica gel (24 g) eluting 
with a gradient from pure dichloromethane to ethyl acetate/dichloromethane 
(50/50) to afford the desired imide 23 (167 mg, 69%) as a pale yellow solid.  
The product was crystallized using DCM and hexane yielding an 87:13 
mixture of diastereomers:  mp 200-203 oC; [α]D = -218 
o (c = 2.4 g/100 
mL);  IR  2998.6, 2953.5, 2927.6, 2868.3, 1723.0, 1696.3, 1608.0 , 
1517.9, 1463.1 cm-1. 1H NMR (400 MHz, CDCl3): δ 6.87 (bs, 2H), 6.71 (bs, 
0.12H), 6.69 (bs, 0.11H), 6.68 (bs, 0.11H), 6.67 (bs, 0.13H), 6.60 (bs, 
0.22H), 6.59-6.52 (complex, 3.2H), 6.47 (bs, 0.13H), 6.46 (bs, 0.13H), 6.39 
(bs, 0.45H), 6.38 (bs, 0.55H), 5.07 (bs, 0.19H), 5.03 (bs, 0.26H), 4.98-4.84 
(m, 0.87H), 4.80 (bs, 0.27H), 4.76 (0.20H), 4.47 (bs, 0.03H), 4.42 (bs, 
67 
 
0.04H), 4.37 (bs, 0.04H), 4.32 (bs, 0.31H), 4.29 (bs, 0.28H), 4.26 (bs, 
0.24H), 4.23 (0.26H), 4.16 (bs, 0.04H), 4.13-4.11 (complex, 0.27H), 4.10-
4.05 (complex, 0.45H), 4.04-4.02 (complex, 0.52H), 4.01-3.97 (complex, 
0.43H), 3.95-3.91 (complex, 6.2H), 3.90 (bd, 1H), 3.87 (bd, 1H), 3.83 (bs, 
1H), 3.81 (bs, 0.43H), 3.80-3.78 (complex, 1.2H), 3.74 (bd, 3.2H), 3.73 
(bs, 3.2H), 3.71-3.60 (complex, 6.4H), 3.62-3.58 (complex, 1H), 3.55 (bd, 
1H), 3.49 (bs, 0.30H), 3.45 (bd, 0.54H), 3.42 (bs, 0.28H), 3.33-3.27 (td, 
1.1H), 3.20-3.07 (complex, 0.32H), 2.41-2.24 (complex, 1.35H), 2.25-2.19 
(complex, 1.23H), 2.12-2.00 (complex, 0.55H), 1.68-1.58 (complex, 5.4H), 
1.46-1.18 (complex, 8H), 1.08-0.71 (complex, 22.2H). 13C-NMR (75 MHz, 
CDCl3):  δ 16.1, 16.2, 16.3, 20.9, 21.0, 21.1, 21.9, 22.1, 22.3, 23.2, 23.3, 
25.4, 25.5, 25.6, 29.6, 31.5, 33.8, 33.9, 34.2, 34.4,  34.5, 35.7, 35.8, 40.0, 
40.2, 48.2, 48.3, 55.5, 55.6, 55.7, 55.8, 55.9, 56.0, 56.1, 56.2, 70.9, 71.2, 
76.6, 77.0, 77.2, 77.4,  80.1, 80.5, 80.6, 109.2, 109.4, 111.2, 111.3, 
111.5, 111.6, 111.7, 111.9, 112.1, 112.2, 112.5, 113.6, 114.2, 114.3, 
115.4, 127.5, 128.1, 128.8, 129.9, 130.0, 130.5, 130.8, 131.0, 131.1, 
131.3, 146.8, 147.4, 147.7, 147.8, 148.3, 148.8, 149.6, 173.4, 174.4  MS: 
Calculated for C39H50NO9
+ [M+H]: m/z 676.3, found 676.3. 
Preparation Method 2: 
 To a solution of CTV lactam 19 (400 mg, 0.83 mmol)  in pyridine (4.1 
mL) was added commercially available (-)-menthyloxyacetic acid chloride 
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(0.75 mL, 0.78 g, 3.35 mmol) at room temperature and the solution was 
heated to 80 oC  for 2 h.  The mixture was then concentrated under reduced 
pressure to give a crude residue.  The residue was diluted in ethyl acetate 
(30 mL), washed with 1N HCl (20 mL), 5% aqueous NaHCO3 (2 x 20 mL), 
saturated brine solution (20 mL), dried with sodium sulfate, filtered, and 
concentrated under reduced pressure to give crude product (1.20 g) as a 
dark yellow glass solid. The crude product was dissolved in DCM (20 
mL)/triethylamine (0.5 mL) and silica gel (2.1 g, 60-200 micron) was added 
and the resulting mixture was concentrated to dryness to provide crude 
product adsorbed onto silica gel which was loaded into a solid loading 
cartridge (60 g). Purification was accomplished on a Teledyne Isco Rf200 
unit using a 40 g RediSep Rf Gold silica gel cartridge column and an ethyl 
acetate/n-heptane gradient containing 0.5% triethylamine to afford the 
desired imide 23 (205 mg, 36% yield). The product was recrystallized using 
DCM/heptane or ethyl acetate affording an 87:13 ratio of diastereomers.  
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Hydrolysis of Imide 23 and the use of Optical Rotation to determine 
resolution of CTV-Lactam: 
 
CTV Lactam 19 from hydrolysis of the imide23 
 To enriched CTV-menthyloxyacetic imide 23 (24 mg, 0.037 mmol), at 
0 °C in THF/water (3:1, v/v, 0.75 mL), was added lithium hydroxide (3 mg, 
0.911 mmol) and stirred for 15 min.  The mixture was extracted with 
dichloromethane (3 x 20 mL).  The combined organic layers were washed 
with distilled water (10 mL), brine (10 mL), filtered over sodium sulfate, and 
concentrated under reduced pressure to afford a solid (24 mg).  The product 
was filtered through alumina eluting with ethyl acetate/dichloromethane 
(20/80) to isolate CTV lactam 19 (17 mg);  [α]D = 0
o (3.4g/100mL). 
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Hydrolysis of Imide and the use of Chirabite-AR to determine 
resolution of CTV-Lactam: 
 
CTV Lactam 19 from hydrolysis of the imide23 
 To enriched CTV-menthyloxyacetic imide 23 (13.2 mg, 0.019 mmoles) 
was dissolved in THF (0.75 mL) and then cooled to 0-5 °C using an ice-water 
bath. A solution of 0.24 M lithium hydroxide monohydrate (0.275 mL, 0.068 
mmol, 3.5 eq) was added. The mixture was allowed to stir at 0-5 °C for 15 
min, then the reaction mixture was transferred to a 20 mL scintillation vial 
and concentrated under high vacuum for 5 min. The residue was dissolved in 
CDCl3 (0.75 mL) followed by addition of 0.10 M Chirabite-AR solution in 
CDCl3 (60 µL, 0.006 mmol, 0.3 equiv.) and this mixture was placed in a NMR 
tube. Two min later, NMR analysis started. 1H NMR analysis showed that the 
resolution was lost and the mixture was a racemate based on that the two 
peaks at 6.51 and 6.53 ppm were 1:1 by integration and peak height.  
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Chirabite-AR Study with Racemic CTV-Lactam 
 
To racemic CTV-lactam 19 (20 mg, 0.042 mmoles) was added CDCl3 
(1.0 mL) to provide a solution and this solution was transferred to a 400 
MHz tube. A solution of 0.10 M Chirabite-AR in CDCl3 was prepared by 
mixing Chirabite-AR (38 mg, 0.05 mmoles) in CDCl3 (0.5 mL). 
Below in Table 4 denotes the following equivalents of Chirabite-AR 
solution added to the NMR tube. The equivalents of Chirabite-AR that were 
evaluated were 0.01, 0.025, 0.050, 0.075, 0.10, 0.125, 0.150, 0.175, 0.20, 
and 0.30 equiv. After addition of the specified amount of Chirabite solution 
into the NMR sample containing racemic CTV-lactam, the sample was placed 
into the NMR spectrometer, analyzed, then proceeded to the next charge of 
Chirabite solution. 
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Table 4. Loading of Chirabite-AR Solution 
Loading of  
Chirabite-AR 
Solution 
(0.10 M in CDCl3) 
MW 
Loading 
equiv. 
Total              
Volume                      
uL 
Vol to be 
added 
portion-wise 
to NMR 
Sample 
mmole 
Chirabite-AR 
Solution in CDCl3 
759.72 0.010 4.2 4.2 0.0004 
Chirabite-AR 
Solution in CDCl3 
759.72 0.025 10.4 6.3 0.0010 
Chirabite-AR 
Solution in CDCl3 
759.72 0.050 20.9 10.4 0.0021 
Chirabite-AR 
Solution in CDCl3 
759.72 0.075 31.3 10.4 0.0031 
Chirabite-AR 
Solution in CDCl3 
759.72 0.100 41.7 10.4 0.0042 
Chirabite-AR 
Solution in CDCl3 
759.72 0.125 52.1 10.4 0.0052 
Chirabite-AR 
Solution in CDCl3 
759.72 0.150 62.6 10.4 0.0063 
Chirabite-AR 
Solution in CDCl3 
759.72 0.175 73.0 10.4 0.0073 
Chirabite-AR 
Solution in CDCl3 
759.72 0.200 83.4 10.4 0.0083 
Chirabite-AR 
Solution in CDCl3 
759.72 0.300 125.1 41.7 0.0125 
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CHAPTER THREE 
CARBORANE HYDROXAMATE MMP INHIBITORS FOR TREATMENT OF 
CANCER AND RHEUMATOID ARTHRITIS EMPLOYING BNCT 
Section 1: Introduction 
 Antimicrobial therapy has saved millions of lives over the past 80  
years, yet our arsenal of effective antibiotics is increasingly diminished by 
the alarming rise of bacteria that are resistant to all currently available  
antibiotics.1 Over two million people annually in the United States acquire 
infections that are resistant to antibiotics, and at least 23,000 people die as 
a result, according to are port issued by the Centers for Disease Control and 
Prevention.2 In the U.S., antibiotic resistance adds $20 billion in additional 
direct health care costs, with lost productivity as high as an additional $35 
billion annually.2   
 There is an urgent need for antibacterial agents with new cellular 
mechanisms of action, yet the pharmaceutical industry shows little interest 
in antibiotic R&D due to the high cost of development and the typically 
short-term treatment regimen of antibiotics which is considered to be less 
profitable than the treatment of chronic diseases.3 
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 The sharp increase in mortality and morbidity due to rising bacterial 
infections caused by antibiotic-resistant bacteria4 underlines the need to 
discover and identify previously-unexplored enzymes as novel antibiotic 
targets with the goal of developing new molecular leads.  For example, 
invasive methicillin-resistant Staphylococcus aureus (MRSA) is a serious and 
growing health problem.5  Several newly discovered strains of MRSA show 
antibiotic resistance even to vancomycin, which has been considered for 
decades as the last line of defense for the treatment of systemic infections.6 
 An attractive bacterial target is the dapE-encoded N-succinyl-L,L-
diaminopimelic acid desuccinylase (DapE, E.C. 3.5.1.18),7 which is a 
member of the lysine biosynthetic pathway in bacteria (see Figure 24) that 
provides lysine and meso-diaminopimelate (m-DAP),8 both of which are 
essential for peptidoglycan cell-wall synthesis. 
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Figure 24. Biosynthetic pathways producing mDAP and lysine in bacteria 
 
As illustrated in Figure 25, DapE catalyzes the hydrolysis of N-succinyl-
L,L-diaminopimelic acid (L,L-SDAP) to succinate and L,L-diaminopimelic acid 
(L,L-DAP), and is ultimately responsible for synthesizing lysine for bacterial 
peptide synthesis, and for providing both mDAP and lysine for peptidoglycan 
cell wall formation in both Gram-negative and most Gram-positive bacteria.8 
Deletion of the DapE gene is lethal to Helicobacter pylori and Mycobacterium 
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smegmatis, demonstrating the indispensable role of this bacterial enzyme in 
pathogens.9,10  Furthermore, lack of a similar pathway in humans suggests 
that inhibition of DapE may be selectively toxic to bacteria but not to human 
hosts, eliminating the concern of mechanism-based toxicity and making 
DapE a very promising target for the development of antibiotics with a new 
mechanism of action.7 
 
Note. L,L-SDAP (1a) and analogs N6-methyl SDAP (1b), and N6-acetyl-SDAP (1c) with 
formation of hydrolysis products succinate (2) and L,L-diaminopimelic acid derivatives (3a-
c).  Hydrolysis was not observed for N-acetyl analog 1c 
 
Figure 25. Hydrolysis of L,L-SDAP and analogs by HiDapE 
 
 Previously, it was shown that DapE isozymes exhibit >60% of their 
maximal activity towards L,L-SDAP when only one Zn(II) ion is present in its 
active site,11 with the tighter binding site confirmed by high-resolution X-ray 
crystallography.  These structures obtained from X-ray crystallography have 
enabled further refinement of a mechanistic hypothesis of amide bond 
cleavage by DapE enzymes, which have facilitated inhibitor identification.12A 
small, focused screen of compounds containing zinc-binding groups 
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identified the thiol-containing ACE inhibitor captopril as a low micromolar 
competitive inhibitor (IC50 = 3.3 µM) of the DapE from Haemophilus 
influenza (HiDapE) along with several other small molecule inhibitors 
including 3-mercaptobenzoic acid (IC50 = 35 µM), phenylboronic acid (IC50 = 
107 µM), and 2-thiopheneboronic acid (IC50 = 92 μM).
13  A high-resolution 
(1.8 Å) X-ray crystal structure of captopril bound to the DapE from Neisseria 
meningitidis (NmDapE) revealed a thiolate-bridged dinuclear Zn(II) active 
site providing a model for in silico approaches to identifying potential 
inhibitors of DapEs.14 
 The most widely used DapE assay monitors amide bond cleavage of 
L,L-SDAP spectrophotometrically at 225 nm.13   While this assay is simple 
and reliable for simple molecules, it cannot be used to test potential 
inhibitors that absorb strongly in the UV region, precluding its use in testing 
many of the preferred medicinal chemistry leads and analogs.  While several 
assays have been developed for evaluating inhibitors of DapEs, these assays 
are technically troublesome and/or difficult to reproduce.15  For example, 
Gelb et al.16 exploited the fact that L,L-DAP reacts somewhat faster with 
ninhydrin than L,L-SDAP; however, this assay suffers from poor 
reproducibility.   Two alternative assays were also reported, the first of 
which employed14C-labeled L,L-SDAP while the second was a coupled assay 
that utilizes porcine succinate thiokinase and inositol triphosphate to convert 
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liberated succinate to succinyl-CoA (CoA = coenzyme A) and inositol 
diphosphate.  The inositol diphosphate was then detected by its reaction 
with phosphoenolpyruvate to yield liberated pyruvate, itself being detected 
spectrophotometrically using lactate dehydrogenase.  The 14C-labeled 
substrate assay requires working with radioactivity, necessitating extra 
safety protocols and waste disposal issues, while the coupled assay is 
cumbersome and expensive while also being technically difficult and 
therefore challenging to reproduce.  Moreover, none of these assays is 
amenable to high-throughput screening studies, a necessity for the 
discovery of new lead compounds with antibacterial properties. 
 Recognizing the ease and reliability of ninhydrin-based assays to 
detect primary amino groups, such as that formed upon the hydrolysis of 
L,L-SDAP, and the importance of the N6-amino group of L,L-SDAP,17 we 
synthesized L,L-SDAP derivatives with partially blocked free amino groups to 
prevent ninhydrin side reactions.  N6-Acetylated, N6-methylated, and N6,N6-
dimethyl derivatives of L,L-SDAP were investigated and prioritized using 
molecular docking and modeling.  Based on these data, a new enzymatic 
assay for HiDapE is described using N6-methylated L,L-SDAP, which we have 
shown is simple, robust, and amenable to high-throughput screening.  These 
data open the door to medicinal chemistry efforts toward the discovery of 
HiDapE inhibitors that can function as a new class of antibiotics.  
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Section 2: Existing Synthetic Preparations of 
2,6-Diaminopimelic Acid (DAP) 
 The 2,6-diaminopimelic acid (DAP) analogs are relatively difficult to 
synthesize by conventional routes, due to the fact that the spacing of the 
groups on synthetic intermediates tends to favor intramolecular ring closure 
to form a piperidine system. For instance, one can envision the possible 
synthesis of 2,6-diaminopimelic acid from either 2,6-dibromopimelic acid or 
2,6-dibromopimelate ester in the presence of ammonia or some other 
amine, however once one molecule of ammonia attacks one of the carbons 
bearing the bromo group, the resulting primary amine has the opportunity to 
undergo an intramolecular ring closure attacking the other carbon bearing 
the bromo substituent which generates a 2,6-disubstituted piperidine 
derivative rather than the seven-carbon linear chain structure that bears the 
equally spaced amino groups.18-23 
 In 1964, a patent was awarded to Dow Chemical24 for a synthesis of 
racemic DAP starting with either glutaraldehyde or 2,6-
dihydroxypimelonitrile to furnish trimethylene-1,3-bis(5-hydratoin). The 
process of forming the bis-hydantoin starting from glutaraldehyde requires 
the use of sodium sulfite (2.1 eq) and sodium cyanide (2.04 eq) in water 
which, after extractions with diethyl ether, provides 2,6-
dihydroxypimelonitrile  in 90% yield, which is then converted to a bis-
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hydantoin using a pressure bomb reactor at 85 oC in the presence of 
ammonium carbonate and 14N ammonium hydroxide. Subsequent reaction 
of the intermediate hydantoin under high temperature acidic or alkaline 
hydrolytic conditions (48% HBr or 50% NaOH at 175-185 oC in a stainless 
steel bomb) hydrolyzed the hydantoin intermediate to a mixture of 
diastereomers of 2,6-diaminopimelic acid which then required purification on 
ion-exchange resin and recrystallization from ethanol/water to access the 
DAP as the bis-ammonium salt in 37% yield. This procedure is most likely 
the commercial route for preparing racemic DAP; however, this route in an 
academic setting is not ideal due to the use of cyanide, pressure bombs, and 
elevated temperature of volatile mixtures (acidic/alkaline) which are serious 
safety concerns leaving many researchers little choice except to purchase 
synthetic DAP. However, it still raises concerns for individual working in 
manufacturing who are assigned to carry out this process. 
 Developing a method to synthesize sufficient quantities of DAP and 
SDAP materials for the ninhydrin-based assay developed by Dr. Tahirah 
Heath at Loyola University Chicago was a challenging process that would 
have required the use of synthetic processes that were generally low yielding 
and inefficient if only making use of the known methodology. Alternatively, 
L,L-DAP can be purchased at significantly higher costs and associated lead 
times. We needed the synthetic flexibility to produce specific derivatives of 
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L,L-DAP and L,L-SDAP that were not possible from the commercial material.  
Thus, there was an urgent need to develop a safer, scalable and more 
flexible process for the asymmetric synthesis of DAP, SDAP, and related 
analogues. 
Section 3: SDAP Route Comparisons and Improvements 
 Previous synthetic routes of L,L-N-succinyl-diaminopimelic acid (L,L-
SDAP) were generally tedious and non-stereoselective involving multiple 
purifications that ultimately made the synthesis a very low throughput 
process. Typically, one needed to start with D,L-diaminopimelic acid (DAP) 
isoforms and perform multiple recrystallizations using naphthalene- β -
sulfonic acid25to produce a 1:1 mixture of L,L and D,D-DAP isoforms. The 
general approach for preparation of diastereomerically pure L,L-SDAP 
consisted of a laborious and time consuming process as illustrated in 
Scheme 14 below. 
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Scheme 14. General Preparation of L,L-SDAP 
 
 
 This process of preparing L,L-SDAP required separation of D,D and L,L-
isoforms from the D,L/L,D isoforms through a classical recrystallization 
method using naphthalene-β-sulfonic acid25,26 to form sparingly-soluble 
ammonium salts in 1N HCl. To ensure that the D,L/L,D-DAP isoforms are 
removed, in excess of six recrystallizations from 1N HCl were required, with 
no indication in the literature of percent recovery after each 
recrystallization.26  The subsequent step required conversion to the free base 
of the resolved D,D/L,L-isoforms using 15% pyridine in ethanol for 2 days at 
room temperature releasing naphthalene-β-sulfonic acid. Installation of the 
succinyl group on D,D/L,L-DAP then required the method of Lin et al15 which 
involved treatment of D,D/L,L-DAP with potassium bicarbonate (2.2 eq) in 
water in the presence of succinic anhydride (1.01 equiv) and, after overnight 
at room temperature, the reaction mixture was adjusted to pH 2 with dilute 
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hydrochloric acid, concentrated, and loaded onto a purification column 
packed with microcrystalline cellulose that was eluted with a quaternary 
solvent system (methanol/water/concentrated HCl/pyridine). After 
purification over cellulose, the corresponding fractions were analyzed using 
TLC on cellulose plates, and pure D,D/L,L-SDAP fractions were then pooled 
and concentrated. The resulting concentrate was further purified by ion-
exchange chromatography using H+ form resin to eliminate residual 
succinate as well as pyridinum hydrochloride. After ion-exchange 
purification, a yield of 41% was reported which provided 1.1 g of DL-SDAP 
ammonium salt. The ion-exchange purification required about 1 liter of 
water and 3M ammonium hydroxide to flush the product from the resin. 
After this step, the final step still required reverse-phase chiral HPLC on an 
expensive chiral HPLC column (Chirobiotic T column, Alltec) to separate the 
D,D and L,L-SDAP isomers. It is evident that this process for achieving 
diastereomerically pure L,L-SDAP is highly inefficient and exhaustive due to 
issues involving multiple recrystallizations of nosylate salts (naphthalene-
sulfonic/DAP salts), purification over cellulose, low-throughput purification 
over ion-exchange resin, and finally extremely low throughput and a time-
consuming separation to isolate the L,L-isoform followed by concentration of 
aqueous streams to isolate desired L,L-SDAP isoform via chiral reverse 
phase HPLC.  
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Section 4: Development of Routes to Access L,L-DAP, L,L-SDAP, 
N6-Monomethyl-SDAP, and N6,N6-Dimethyl-SDAP 
as Potential DapE Substrates 
 Previous attempts in our lab to prepare monomethyl and dimethyl-
SDAP involved the direct methylation of racemic SDAP or L,L-SDAP, which 
produced an inseparable mixture of unreacted starting material, 
monomethyl, dimethyl, and quaternary ammonium salt as illustrated below 
in Scheme 15. Depending on the conditions, methylation of the carboxyl 
moieties was also of concern since formation of methyl ester(s) are possible. 
Reductive amination of racemic SDAP was difficult since isolation of the 
monomethyl or dimethyl products was troublesome due to high water 
solubility of the products, combined with the need for isolation from 
inorganic salts. Based on these synthetic difficulties for preparing 
monomethyl SDAP, alternative routes were outlined to develop a scalable 
process.  
Scheme 15. Attempts to form Monomethyl and Dimethyl SDAP 
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 During literature searching, it was observed that many syntheses 
focused on the synthetic preparation of diaminopimelic acid (DAP) or 
acylated derivatives.27 Hlavácek demonstrated that racemic DAP (R,S)-2,6-
diaminopimelic acid) can be selectively protected which required the free 
amino group to be protected with a Boc group and the carboxyl groups 
protected as benzyl esters using N,N´-diisopropyl-O-benzylisourea (Scheme 
16).  This fully protected material is much more soluble in many organic 
solvents compared to its parent, unprotected structure (diaminopimelic acid) 
which has poor organic solubility and requires polar solvents (such as water, 
methanol, DMF, or DMSO) to ensure material is dissolved and allow chemical 
transformations to occur more readily in a homogeneous manner. The Boc 
moieties were removed under acidic conditions followed by mono-protection 
of one of the free amino groups using Cbz-Cl giving a 37% yield over the 
two steps of Boc deprotection and carbamate formation after extensive 
purification. At this point, the mono-acylated free amino component was 
then acylated with an anhydride, hydrogenated to cleave the benzyl groups, 
and then purified by achiral reverse-phase HPLC followed by chiral reverse 
phase HPLC to afford limited quantities of pure L,L-SDAP with high 
diastereomeric purity. This method offered some advantages, however the 
use of racemic DAP did not seem appealing since reverse-phase 
chromatography is typically a low-throughput method, and higher quantities 
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were required for the ninhydrin assay. Furthermore, the mono-protection 
step using Cbz-Cl is low yielding, and based on the expense of purchasing 
DAP, this route would not be useful in preparing sufficient quantities of 
monomethylated SDAP. 
Scheme 16. Hlavácek synthesis of SDAP and its analogs 
 
 One of the methods of producing orthogonally-protected S,S-DAP was 
accomplished via olefin cross-metathesis which was reported by Blicher.28 
Drawbacks of this method included a challenging selective hydrogenation of 
the alkene in the presence of the Cbz groups, and also the need to minimize 
the self-crossed metathesis byproducts which depends on the generation of 
Grubb's catalysts used. In relation to Blicher's route, a similar synthesis 
reported by Takahata29 which demonstrated that protected meso-DAP can 
be prepared by cross metathesis of the Garner aldehyde-derived vinyl 
glycine with protected allyl glycine in the presence of Grubb’s second-
generation catalyst. Based on this Blicher's method, the proposed route 
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shown below in Scheme 17 (Route A) illustrates how Blicher's method could 
be employed to prepare monomethylated SDAP. The proposed route was 
modified such that the Cbz group could be exchanged for a Boc group.  This 
would simplify the hydrogenation because the alkene and Cbz groups could 
be selectively reduced in the presence of succinic anhydride to generate the 
succinate amide. However, in order to perform the cross metathesis 
reaction, the requisite starting materials would need to be prepared, 
specifically the N-methylated Boc protected vinyl glycine and N-Cbz vinyl 
glycine. It was decided not to pursue this route since formation of self-cross 
metathesis products is a significant drawback that would give rise to a 30-
40% yield loss of desired product as reported by Blicher28 and Takahata.29 
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Scheme 17. Proposed Route A for the Preparation of Monomethyl L,L-SDAP 
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 Another interesting approach to preparing diastereomerically pure 
monomethyl SDAP is illustrated in Scheme 18 (Route B). The synthesis 
starts with the commercially-available and inexpensive starting material, 
methyl L-methioninate hydrochloride, which reacts with methyl succinyl 
chloride to form the succinate amide methyl ester. The subsequent step 
involves the oxidation of the sulfide using sodium periodate to form the 
sulfoxide component. Under high temperatures and/or high 
temperature/high pressure conditions either in a microwave reactor or 
continuous flow, the sulfoxide is eliminated to afford the corresponding 
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alkene. The generated alkene after elimination of the sulfoxide would couple 
with the N-methyl-N-Boc allyl glycine in a cross-metathesis reaction using a 
Grubb’s II generation catalyst. Upon formation of the desired alkene, this 
product would undergo hydrogenation to reduce the alkene to the saturated 
form, then global deprotection of the trimethyl ester to the corresponding 
carboxylic acid and removal of the Boc group to afford the monomethyl 
SDAP ammonium salt. This proposed route was conceptually attractive, 
however the generation of the alkene via sulfoxide elimination might be a 
problematic step since these reactions require high temperatures and it is 
not known whether the succinate amide would epimerize through alkene 
isomerization of the double bond, which would prefer to be conjugated to the 
carbonyl ester system with generation of an enamide. Based on these 
concerns, this route was not pursued.  
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Scheme 18. Proposed Route B for the Preparation of Monomethyl L,L-SDAP 
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 The next proposed route illustrated in Scheme 19 (Route C) for 
preparation of diastereomerically pure monomethyl SDAP was designed 
around the preparation of an aldehyde through the use of commercially-
available N-Boc-L-allylglycine. This route is very similar to the route 
ultimately selected for preparation of monomethyl SDAP (refer to Route D), 
however this route primarily is designed around an alternative preparation of 
the aldehyde. The first step requires the formation of the methyl ester 
followed by installation of the methyl group onto the N-Boc moiety. Next, 
the hydration of the allyl group then proceeds via hydroboration followed by 
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oxidation of the primary alcohol to aldehyde using either PCC/PDC or Swern 
conditions. This route relies on the fact that aldehydes and 
phosphonoglycine esters can couple efficiently to form enamides through the 
use of the Horner-Emmons-Wadsworth olefination reaction. The subsequent 
step involving hydrogenation of the Cbz group followed by succinylation 
yields the succinate amide. Lastly, aqueous acid to perform global 
deprotection via hydroylsis is expected to furnish the monomethyl-SDAP 
salt, however the hydrolysis of the trimethyl ester may require lower 
temperature/lower acid concentration to prevent hydrolysis of the amide 
group. This route does seem promising for the preparation of monomethyl 
SDAP, however there are a few concerns regarding the initial two steps such 
as installation of methyl group onto the Boc-amide group. Installation of the 
methyl group using silver(I) oxide could be problematic since silver(I) 
species interact with olefins which could complicate the desired methylation 
of Boc-amide. Alternatively, methylation under alkaline conditions using 
DMAP/MeI or NaTMDS/MeI could be employed but there is the risk that 
alkene isomerization will occur, which would affect the hydroboration 
reaction leading to incorrect functionalization of the hydroxyl moiety and 
thus leading to formation of ketone rather than desired aldehyde.  
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Scheme 19. Proposed Route C for the Preparation of Monomethyl L,L-SDAP 
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 A synthesis of diaminosuberic acid (DAS) was developed by Nájera et 
al30using a palladium-catalyzed allylic double substitution which could be 
applied to the synthesis of DAP. This approach generates a 1:1 mixture of 
diastereomers and thus is not appropriate for the preparation of 
diastereomerically pure diaminopimelic acid (DAP). Other known 
preparations of diaminopimelic acid (DAP) have been cited, however these 
preparations generally give a mixture of diastereomers.31-33 
 An orthogonally synthetic method for producing a protected meso-DAP 
derivative was reported by Fukase.34 Fukase's synthetic methodology 
focused on the use of a Kocienski-modified  Julia olefination that effectively 
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coupled a homologated-serine based Garner aldehyde, itself derived from 
Boc-protected D-serine35 and a modified Julia sulfone (also derived from Cbz 
protected D-serine)36 to yield a key seven-carbon backbone intermediate 
that leads to the formation of a protected meso-DAP derivative after 5 
additional chemical steps. Thus, Fukase reported an elegant synthesis in 
which no epimerization was observed, however this route is not amenable 
toward the synthesis of monomethyl L,L-SDAP since the homologated 
Garner aldehyde starting material (L or D-serine) requires 7 chemical 
steps35, 37 to access the homologated Boc-protected Garner aldehyde and 
attempting to install a methyl group during the first three steps route will 
prohibit the formation of Garner aldehyde. Thus, the only means to form the 
N-methyl would be at a time before reducing the methyl ester to the 
aldehyde/alcohol. The installation of a methyl group for the sulfone 
precursor is also not attractive due the requirement of a multi-step approach 
to furnish a monomethyl starting material. Granted that Fukase's method 
proved successful for his objectives, the synthesis is not practical for 
preparation of monomethyl L,L-SDAP at larger scale due to the high cost and 
time-demanding multi-step synthesis to furnish a monomethyl adduct.  
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Scheme 20. Proposed and Selected Route D for the Preparation of 
Monomethyl L,L-SDAP 
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 Proposed route D (see Scheme 20) was partly based on the previous 
work by Hruby38 which demonstrates that DAP can be enantiomerically 
synthesized through asymmetric hydrogenation of an enamide precursor. In 
this route, the starting material, Boc-L-Glu-OtBu, was selected due to its 
commercially availability and low cost. The methyl ester could have been 
purchased, however this was not as commercially available, and the cost 
was higher compared to the free acid. The preparation of the methyl ester 
can be accomplished by a variety of methods, however the simplest 
approach was using methyl iodide or dimethyl sulfate. Methyl iodide and 
potassium carbonate in DMF was selected for the formation of the methyl 
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ester for the work described herein. The next step to install a methyl group 
on the N-Boc moiety was planned to be carried out in the same pot to avoid 
aqueous workup of the methyl ester. Following Hruby's method of reducing 
the methyl ester to the aldehyde using DIBAL at cryogenic conditions, it was 
found that this method was not applicable for the N-methyl-Boc substrate 
due to the formation of mixtures, thus alternative methods for a high-
yielding reduction/reoxidation protocol were investigated.  The next step 
incorporated the Horner-Emmons-Wadsworth olefination by treating the 
prepared aldehyde with Cbz-α-phosphonoglycine ester and DBU. The 
Horner-Emmons reaction using Cbz-α-phosphonoglycine dimethyl ester free 
carboxylic acid was also attempted but this approach was unsuccessful with 
no conversion of starting materials observed.  The asymmetric reduction 
seemed very promising for the monomethyl-SDAP since it was determined 
that Rh-DUPHOS is an effective chiral catalyst to access the enantiomerically 
pure L,L-DAP scaffold. The subsequent step requires removal of the Cbz 
group using hydrogenation followed by succinylation using succinic 
anhydride and triethylamine in DCM. Lastly, based on literature precedent, 
the concurrent hydrolysis of the methyl ester, Boc group, and t-butyl ester 
can be accomplished using aqueous hydrochloric acid or aqueous 
hydrobromic acid, which Hruby employed for hydrolysis of the methyl ester 
and Cbz groups to access diaminopimelic acid (DAP).  
96 
 
 Executing the proposed route for preparation of monomethyl L,L-SDAP 
followed a similar approach  of Hruby38 but the route was modified and 
significantly improved as needed for subsequent scale-up for preparation of 
intermediates, finally yielding enantiomerically pure monomethyl L,L-SDAP. 
Scheme 21 depicts the modified synthetic routes utilized for preparation of 
monomethyl L,L-SDAP denoted as 1b.HCl and 1b.TFA for the hydrochloride 
and trifluoroacetate salts, respectively. 
Scheme 21. Asymmetric synthesis of N6-Methyl-L,L-SDAP 1b. Synthetic 
route for preparation of monomethyl substrate analog as the hydrochloride 
salt (1b.HCl) via the methyl ester or the trifluoroacetate salt (1b.TFA) via 
the benzyl ester 
 
 
97 
 
 N2-Succinyl-N6-methyl-L,L-DAP 1b was prepared enantioselectively 
with the key olefination and asymmetric hydrogenation steps38 modeling the 
synthesis of diaminopimelic acid, which lacks the N6-methyl as well as the 
succinate.  In addition, the present route avoids any use of ion exchange 
chromatography that was used in previous smaller-scale work.38 The first 
step involves the one-pot methylation of the BOC-L-glutamic acid t-butyl 
ester 4 with potassium carbonate and methyl iodide, in the presence of 
silver oxide, to afford the N-methylated ester 5.  Reduction of the methyl 
ester with sodium borohydride afforded the primary alcohol 6, which was 
oxidized to the aldehyde 7 with PCC or PDC, or under Swern conditions.  The 
oxidation using PCC or PDC was more convenient than Swern conditions 
which typically formed an impurity (believed to be a mixed thioacetal) that 
was difficult to remove by normal-phase chromatography and resulted in 
lower yields of the desired aldehyde. Furthermore, the use of PDC appeared 
to be more facile and typically produced less baseline material as determined 
by TLC analysis. Attempts to access the aldehyde directly from the methyl 
ester using DIBAL were unsuccessful and typically gave mixtures of starting 
material, aldehyde, and alcohol. Oxidation of alcohol to aldehyde with 
activated manganese dioxide was also not successful. Horner-Wadsworth-
Emmons olefination with Cbz-α-phosphonoglycine ester (Cbz = 
carboxybenzyl) gave the enamide in excellent yield. Alternatively, the 
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Horner-Emmons reaction using Cbz-α-phosphonoglycine dimethyl ester free 
carboxylic acid was attempted but this approach was unsuccessful with no 
conversion of starting materials. The enamide product was enantioselectively 
hydrogenated in the presence of catalytic amounts of 1,2-bis[(2S,5S)-2,5-
diethylphospholano]benzene(1,5-cyclooctadiene)rhodium(I) 
trifluoromethanesulfonate affording the L,L-Cbz-protected amino acid 9a in 
93% yield.  This asymmetric hydrogenation and catalyst selection follows 
previous work that established an asymmetric synthesis of diaminopimelic 
acid.38 The asymmetric hydrogenation of the enamide described within this 
work was accomplished using lower hydrogen pressure (50 psi) compared to 
Hruby's method which employed 70 psi of hydrogen using a Parr Shaker. 
Furthermore, the asymmetric hydrogenation process described within this 
work was executed safely using lower hydrogen pressure and the process 
was carried out in a more controlled manner where the pressure vessel was 
equipped with mechanical agitation and better thermal control throughout 
the duration of the reaction. Removal of the Cbz protecting group by 
hydrogenolysis followed by reaction with succinic anhydride afforded the 
succinamide derivative in 99% yield, which was subjected to hydrolysis with 
aqueous HCl to afford N6-methyl L,L-SDAP as the hydrochloride salt 
(1a.HCl) in 97% yield. The hydrochloride salt was very hygroscopic, and 
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eventually the material became an un-weighable solid and the quality of the 
product declined presumably due to desuccinylation.  
 In more detail, the overall route to monomethyl SDAP was modified 
and improved based on Hruby's method, since that installation of the methyl 
group on the N-Boc moiety was required. Hruby's method of accessing the 
aldehyde strictly depended on the bis-Boc-amide which under reductive 
conditions using DIBAL gave primarily the aldehyde. It was found that once 
the methyl ester-N-methyl-Boc 5 was prepared, the reduction of methyl 
ester  to aldehyde using DIBAL was problematic producing a mixture of 
aldehyde, alcohol, and unreacted starting material methyl ester which could 
be oxidized to primarily aldehyde using PDC/PCC but made isolation of 
aldehyde very difficult. Furthermore, carrying forward the methyl ester 
starting material as an impurity would lead to its hydrolysis if carried to the 
final step, which would create problems downstream during the synthetic 
sequence. Therefore, conditions for accessing the aldehyde were modified 
and then accomplished by reducing the methyl ester cleanly to the alcohol 
using sodium borohydride followed by an efficient oxidation to aldehyde 
using either PDC/PCC or Swern conditions. Furthermore, the use of sodium 
borohydride left the tert-butyl ester unaffected due to the bulky nature of 
the t-butyl group. 
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 The use of hydrobromic acid in acetic acid, based on literature 
method,38 to hydrolyze the methyl ester and Cbz group was not amenable 
for the hydrolysis of monomethyl SDAP due to the fact that the succinyl 
group was also hydrolyzed affording monomethyl-diaminopimpelic acid as an 
impurity which proved to be an inhibitor in the ninhydrin assay. Given that 
the combination of acid and heat does increase the risk of epimerization of 
the amino substituent(s), two alternative methods were developed to control 
epimerization and prevent hydrolysis of the succinyl group. The two methods 
evaluated were the use of 6M HCl at ambient temperature to control the 
epimerization but this method also eventually produced small amounts of 
desuccinylated by-product giving a primary amine. The second method is 
based on the benzyl ester analog (discussed below) that consisted of non-
aqueous conditions using trifluoroacetic acid to cleave both the t-butyl and 
Boc groups that generated the mono-methyl SDAP analog cleanly without 
any desuccinylated impurity and with better control in avoiding 
epimerization.  
 The Horner-Emmons-Wadsworth monomethyl product did show 
evidence of cis-trans alkene isomers based on 1H NMR analysis, although the 
ultimate enantioselectivity was not compromised. During the asymmetric 
hydrogenation of the monomethyl enamide intermediate, 1H NMR was 
employed to monitor the progress of the reaction. Isomerization of the 
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alkene was not observed, and both E/Z enamides were hydrogenated to 
achieve high e.e. as described and supported by Burk's study.39, 40 
 The use of the benzyl ester route proved to be more amenable to 
large-scale reactions as the benzyl moiety can easily be deprotected after 
the asymmetric hydrogenation. Conversely, the intrinsic substrate selectivity 
for asymmetric hydrogenation of the methyl ester was actually better than 
for the benzyl ester enamide scaffold, as determined by HPLC analysis; the 
methyl ester chiral purity was 97.4% e.e. whereas 92.0% e.e. was achieved 
for the benzyl ester. The benzyl ester still remained the most attractive 
procedure since hydrolysis of the methyl ester is often accompanied by 
desuccinylation generating a primary amino moiety which dramatically 
affects the ninhydrin assay, therefore the benzyl ester enamide route proved 
to be superior in generating cleaner, mono-methyl SDAP, combined with the 
fact that a final crystallization in the benzyl ester route afforded material 
over very high e.e., as detailed below. 
 A second route was also developed that was an improvement, based 
on yield, over the initial methyl ester route by utilizing a benzyl ester.  In 
this synthetic scheme, the Wadsworth-Emmons reaction of the aldehyde 7 
with benzyl 2-{[(benzyloxy)carbonyl]amino}-2-(dimethoxyphosphoryl)
acetate (R = Bn) afforded enamide 8b, which was enantioselectively 
hydrogenated in the presence of catalytic 1,2-bis[(2S,5S)-2,5-
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diethylphospholano]benzene(1,5-cyclooctadiene)rhodium(I) 
trifluoromethanesulfonate to afford the L,L-Cbz-protected amino acid benzyl 
ester 9b in 97% yield. Hydrogenolytic removal of both Cbz and benzyl 
groups followed by reaction with succinic anhydride gave the succinate 
amide (92-97% for 10b).  Removal of the tert-butyl ester with 
trifluoroacetic acid in methylene chloride gave the trifluoroacetate salt of 1b 
in nearly quantitative yield. Overall, the benzyl ester route proved to be 
more amenable for large scale reactions, although the intrinsic substrate 
diastereoselectivity for asymmetric reduction of the methyl ester yielded 
material of 97.4% e.e. for methyl ester 9a, compared to 92.0% e.e. for the 
benzyl ester 9b. Nevertheless, crystallization at a later stage ultimately 
afforded the final product 1b in >99% e.e. from the benzyl ester, and the 
methyl ester route was often accompanied by desuccinylation generating a 
primary amino-containing impurity which would negatively affect the 
ninhydrin assay, therefore the benzyl ester route was the superior route. 
Furthermore, the benzyl ester route provides the TFA salt which was not 
observed to be hygroscopic, in contrast to the hydrochloride salt from the 
methyl ester route which is very hygroscopic and converts to a sticky and 
un-weighable solid over time in storage.  
 Based on molecular modeling data performed by Dr. Cory Reidl and 
Estefany Guzman, N6-methyl-L,L-SDAP #1b is predicted to retain an overall 
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similar binding pose to L,L-SDAP #1a, making it a likely substrate analog 
while N6-acetyl-L,L-SDAP #1c suffers significant binding alterations due to 
the presence of the acetyl group, in addition to loss of the positive charge on 
the nitrogen.  Therefore, N2-succinyl-N6-methyl-L,L-DAP #1b was prepared 
enantioselectively, as illustrated in Figure 26. 
 
Note. The diaminopimelate moiety is depicted in yellow and the succinate in turquoise.  A) 
Native substrate L,L-SDAP, B) N6-methyl-L,L-SDAP, and C) N6-acetyl-L,L-SDAP.  The 
catalytic domain of Chain A is depicted in green, whereas the dimerization domain of Chain 
B is shown in orange. 
 
Figure 26. Minimized substrate/analogs docked and modeled in the HiDapE 
active site 
 
Section 5: Novel Preparation of N6,N6-Dimethyl-L,L-SDAP 
 Based on the developed route for asymmetric preparation of 
monomethyl L,L-SDAP, the synthesis of N6,N6-dimethyl-L,L-SDAP was 
executed starting with a protected DAP intermediate 9a as illustrated in 
Scheme 22 below. 
 
 
 
104 
 
Scheme 22. Preparation of N6,N6-dimethyl-L,L-SDAP 
 
 The synthesis of dimethyl L,L-SDAP begins with deprotection of the 
Boc moiety from 9a using 4N HCl in dioxane which cleanly removes the Boc 
group. After overnight reaction at room temperature and subsequent 
concentration of the reaction mixture, the crude residue was dissolved in 
DCM and the hydrochloride salt was precipitated by addition of diethyl ether 
affording an 83% yield of 14. HPLC analysis of the resulting hydrochloride 
salt 14 showed a 96% purity for the desired product plus 4% of a 
component where both Boc and t-butyl groups were cleaved. Subjecting the 
monomethyl hydrochloride 14 to reductive amination provided the dimethyl-
DAP intermediate 15 in 96% yield after extractive workup which provided 
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100% purity by HPLC, and MS analysis confirmed the correct molecular ion 
for the desired dimethyl-DAP bis-ester 15. Subsequent hydrogenation of 15 
(N6,N6-dimethyl-DAP bis-ester) provided the free amine 16 in quantitative 
yield followed by succinylation which yielded the protected N6,N6-dimethyl-
L,L-SDAP analog 17 in quantitative yield. Finally, hydrolysis of protected 
dimethyl L,L-SDAP analog 17 in 6M HCl provided N6,N6-dimethyl-L,L-SDAP 
HCl salt 18 in 90% yield. This chemistry was developed during process 
development of monomethyl L,L-SDAP and it was also found that the 
dimethyl L,L-SDAP HCl salt was hygroscopic as well. However, the benzyl 
ester route was not applied in the synthesis of dimethyl L,L-SDAP TFA salt. 
In the future, it is recommended that the synthesis be executed using the 
route proposed illustrated below in Scheme 23. 
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Scheme 23. Proposed Route to Improve the Synthesis for Dimethyl L,L-SDAP 
 
 
 
Section 6: Conclusion 
 Overall, the described novel synthesis of the N6-monomethyl-L,L-SDAP 
DapE substrate proved to be a scalable process, which will allow our group 
and the scientific community at large to easily synthesize large quantities of 
this new DapE substrate. Furthermore, this synthesis will enable other 
research groups to use our newly-developed ninhydrin assay and easily 
access the monomethyl substrate through synthesis or purchase from a 
commercial supplier such as Regis Technologies. Process improvements 
which have been achieved with this new synthesis of monomethyl L,L-SDAP 
include higher atom economy due to the asymmetric hydrogenation, and 
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that the process does not require the use of expensive and time-consuming 
reverse-phase chromatographic separations or ion-exchange resin 
purifications, and lastly this process employs very low loadings of normal 
phase silica gel which increases throughput and reduces cost, and finally, 
that organic solvents used in the purification can be easily removed in 
contrast to aqueous media. 
 In summary, N6-methyl-L,L-SDAP 1b was predicted to be a potential 
substrate for HiDapE whereas N6,N6-dimethyl-L,L-SDAP was predicted to 
suffer significant binding alterations due to the presence of the second 
methyl group based on molecular modeling.  Two synthetic routes to DapE 
substrate 1b were developed enabling the synthesis of 1b in nearly 
quantitative yield on a multi-gram scale.  Kinetic studies proved that 
substrate 1b can be hydrolyzed by HiDapE at comparable rates to the 
endogenous substrate, L,L-SDAP, establishing 1b as a viable substrate for 
DapE enzymes and for our new ninhydrin-based assay.  Since the amine-
containing product of the hydrolysis of 1b contains only one primary amine, 
conditions that selectively modify the primary amine versus the secondary 
amine with ninhydrin were developed, resulting in a new spectrophotometric 
assay for DapE enzymes that is inexpensive, robust and reproducible.  The 
newly discovered DapE substrate,1b, coupled with ninhydrin development, is 
superior to the standard UV-based (225 nm) assay which uses L,L-SDAP as 
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the substrate, as it is alleviates interference from potential inhibitor 
absorption at 225 nm, a common absorption region for aryl containing 
compounds that are of interest to medicinal chemists.  The feasibility of the 
new 1b-ninhydrin-coupled DapE assay was established by accurately 
determining IC50 values of known HiDapE inhibitors.  In summary, this new 
ninhydrin-based assay provides a method for the discovery of lead 
compounds for DapE enzymes and for driving medicinal chemistry structure-
activity relationships (SAR) and thus provide a critical tool for the discovery 
of a new class of antibiotics that target DapE enzymes. 
Section 7: Experimental 
Materials and Methods 
 All solvents were distilled prior to use and all reagents were used 
without further purification unless otherwise noted. All synthetic reactions 
were conducted under a nitrogen or argon atmosphere. The term reactor 
refers to a large round-bottom flask.  Silica gel 60 Å, 40−75 μm (200 × 400 
mesh) or 60-200 μm (Silicycle), was used for column chromatography. 
Aluminum-backed silica gel 200 μm plates were used for TLC (thin-layer 
chromatography). 1H NMR spectra were obtained using a 300, 400, or 500 
MHz spectrometer with trimethylsilane (TMS) as the internal standard. 13C 
NMR spectra were obtained using a 75, 100, or 125 MHz spectrometer. The 
purity of all compounds was determined to be ≥95%, unless otherwise 
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noted, by high performance liquid chromatography (HPLC) employing a 
mobile phase A = 0.1% TFA in water and a mobile phase B = 0.1% TFA in 
acetonitrile with a gradient of 60% B increasing to 95% over 10 min, holding 
at 95% B for 5 min, then returning to 60% B and holding for 5 min. Chiral 
purities were determined using Chiral HPLC on various chiral HPLC columns 
using varying chromatographic conditions, therefore for any procedure that 
reports chiral purity will describe the chiral HPLC method used. HRMS 
spectra were measured on a TOF instrument by electrospray ionization 
(ESI). HRMS spectra were collected using a Waters Acquity I class UPLC and 
Xevo G2-XS QTof mass spectrometer with Waters Acquity BEH C18 column 
(1.7 µm, 2.1x50 mm).  Mobile phase A was 0.05% formic acid in water and 
mobile phase B was 0.05% formic acid in acetonitrile.  A gradient of 5% to 
90% B over 5 min was applied.   
Organic Synthesis 
(2S,6S)-2-(3-Carboxypropanamido)-6-(methylamino)heptanedioic 
acid hydrochloride (1b.HCl) 
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To a 100 mL reactor was added 10a (1.50 g, 3.16 mmol) and a freshly 
prepared 6M HCl solution (30 mL). The reaction mixture was allowed to stir 
at 25°C for 5 h and concentrated under reduced pressure (0.1-10 mbar) at 
25°C on a rotary evaporator and triturated in acetonitrile overnight at room 
temperature.  The resulting slurry was filtered and dried under reduced 
pressure overnight to provide 1b as the hydrochloride salt (1b.HCl, 1.04 g, 
97%, deliquescent solid) as a white foam.1H NMR (400 MHz, D2O): δ 4.35 
(q, 1 H, J = 9.0, 5.0 Hz), 3.95 (t, 1 H, J = 6.2 Hz), 2,73 (s, 3 H), 2.64 (m, 2 
H), 2.58 (m, 2 H), 2.03-1.88 (m, 3 H), 1.81-1.72 (m, 1 H), 1.58-1.46 (m, 1 
H), 1.43-1.36 (m, 1 H). HRMS (IT-Tof): m/z calcd for 
C12H21N2O7
+[M+H]+:305.1349, found 305.1309. 
 (2S,6S)-2-(3-Carboxylatopropanamido)-6-
(methylamino)heptanedioate, 2,2,2-trifluoroacetate salt (1b.TFA) 
 To a solution of succinyl t-butyl ester 10b (0.608 g, 1.32 mmol) in 
DCM (5.75 mL) was added TFA/DCM solution (30/70, 15 mL) under argon. 
The mixture was stirred at room temperature for 4 hours and concentrated 
under reduced pressure. The resulting residue was dissolved in dry methanol 
(1.0 mL) and slowly added to diethyl ether (50 mL) with vigorous stirring to 
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precipitate TFA salt. The slurry was filtered and the wetcake was rinsed with 
diethyl ether (2.0 mL), hexane (10 mL), and dried in vacuo at 35oC 
overnight to provide the mono-methyl SDAP TFA salt (550 mg, 99.6% yield) 
as a white solid. 1H NMR (400 MHz, D2O): δ 4.36 (dd, 1H, J = 9.2, 5.2 Hz), 
3.76 (t, 1H, J = 6.4 Hz), 2.72 (s, 3H), 2.69-2.66 (m, 2H), 2.66-2.59 (m, 
2H), 1.98-1.92 (m, 3H), 1.80-1.77 (m, 1H), 1.52-1.50 (m, 1H), 1.44-1.42 
(m, 1H).  13C NMR (100 MHz, D2O): δ 176.9, 175.6, 174.9, 172.3, 62.1, 
52.3, 31.5, 30.0, 29.9, 29.0, 28.2, 20.5. HRMS (ESI-ToF): m/z calcd for 
C12H21N2O7
+[M+H]+: 305.1349, found: 305.1365. Achiral HPLC purity: 
100%. Chiral HPLC purity: 100% (100% e.e.). Chiral HPLC was performed 
using either two methods. Chiral HPLC method 1: a RegisPack column 
(250x4.6 mm, 5 micron) eluting with an isocratic gradient of hexane/IPA 
(90/10) + 0.1%TFA at 1.5 mL/min and monitoring at 210 nm. Chiral HPLC 
method 2: Chirosil SCA(-) column (150 mm x 4.6 mm, 5 micron) with 
isocratic elution employing 84% MeOH in water containing 5 mM HClO4 with 
an elution time of 15 minutes with column temp at 25oC and a flow rate of 
0.75 mL/min monitoring at a wavelength of 210 nm. 
Scale-up of the TFA Salt: 
To a solution of succinyl t-butyl ester 10b (6.08 g, 14.8 mmol) in DCM 
(60 mL) was added a TFA/DCM solution (30/70, 135 mL) under nitrogen. 
The mixture was stirred at room temperature for 6 h and concentrated on a 
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rotary evaporator at 35-40oC. The resulting residue was dissolved in 
anhydrous methanol (6.0 mL) and slowly added to anhydrous diethyl ether 
(450 mL, HPLC grade, inhibitor-free) with vigorous stirring to precipitate the 
TFA salt.  The slurry was allowed to stir overnight at room temperature. The 
slurry was filtered, and the wet cake was rinsed with anhydrous diethyl ether 
(50 mL), n-hexane (100 mL), and dried in vacuo at room temperature 
overnight to provide 1b as the mono-methyl L,L-SDAP TFA salt (L,L-succinyl 
diaminopimelate trifluoroacetate; 6.06 g, 98% yield) as a white solid. 
1-(tert-Butyl) 5-methyl (tert-butoxycarbonyl)-L-glutamate (5) 
 
According to the general and herein improved method of Glinka,41 to a 
2 L reactor was added Boc-L-Glu-OtBu (4) (95.65 g, 315.3 mmol), milled 
K2CO3 (69.72 g, 504.5 mmol), and anhydrous DMAC (480 mL).  To the 
reaction mixture was added methyl iodide (49.3 g, 21.2 mL, 112 mmol). The 
reaction was agitated with mechanical stirring (300 rpm) at 25oC for 18 h 
which 1H NMR and TLC analysis confirmed that the reaction had gone to 
completion. To the reaction mixture was added methyl iodide (228 g, 100 
mL, 1.61 mol) followed by Ag2O (110.0 g, 474.7 mmol). The resulting 
reaction mixture was stirred at 400 rpm with a water bath (15oC) in place to 
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control the exotherm and allowed to further stir overnight (12 hours) and 
gradually warm to room temperature.  1H NMR analysis confirmed that the 
reaction had gone to completion. The reaction mixture was then diluted with 
EtOAc (750 mL) and treated with Celite (43 g), stirred for 15 min, filtered 
over a fritted funnel (fine porosity) containing a pad of Celite. The filter was 
washed with EtOAc (500 mL). The filtrate was concentrated under reduced 
pressure at 40oC to remove EtOAc and DMAC to provide crude residue oil 
(168.0 g). The crude oil was diluted with EtOAc (500 mL) and heptane (400 
mL) and subsequently washed with 50 wt% sodium thiosulfate pentahydrate 
solution (2 x 500 mL), USP purified water (3 x 500 mL), brine (500 mL), 
dried with sodium sulfate (40 g)/silica gel (20 g), filtered, and concentrated 
to provide title compound 5 (101.6 g, 97%) as a colorless oil. HPLC purity: 
97.7%.1H NMR(400 MHz, CDCl3) δ 4.59 (m, amide rotamer, 0.50 H), 4.37 
(m, amide rotamer, 0.50 H), 2.77 (d, mixture of amide rotamers, 3H), 2.38-
2.20 (m, 3H), 2.00 (m, 1H), 1.45 (s, 18H).  13C NMR (100 MHz, CDCl3): δ 
173.4, 173.3, 170.4, 170.3, 156.3, 155.8, 81.6, 81.5, 80.3, 80.0, 59.5, 
58.4, 51.7, 31.3, 31.2, 30.9, 30.5, 28.4, 28.1, 24.3, 24.1. HRMS (ESI-
ToF): m/z calcd for C16H29NNaO6
+ [M+Na]+: 354.1887, found: 354.1920. 
HRMS also found [M+Li]+ : 338.2166  and [M+K]+: 370.1658. 
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tert-Butyl-(S)-2-((tert-butoxycarbonyl)(methyl)amino)-5-
hydroxypentanoate (6) 
 
 
To a 3 L 3-necked reactor was added methyl ester 5 (100.0 g, 301.7 
mmol) and ethanol (HPLC grade, 1500 mL) and the mixture was cooled to < 
5oC in an ice water bath.  Sodium borohydride (57.6 g, 1520 mmol) was 
added in 5 portions over 15 minutes. The reaction was allowed to stir at < 
5oC and subsequently allowed to gradually warm to room temperature 
overnight while the cooling bath remained in place.  After 20 hours, TLC 
analysis showed complete consumption of methyl ester starting material.  To 
a 12 L reactor containing a cold solution of 50% aqueous ammonium 
chloride solution (3000 mL, < 5oC) was slowly added the reaction mixture 
over a period of 15 min such that the temperature remained < 15oC. The 
mixture was allowed to stir at 15-20oC for 30 min, then EtOAc (1000 mL) 
was added. The organic layer was separated, and the aqueous layer was 
further extracted with EtOAc (3 x 1000 mL). The combined organic layers 
were washed with brine (300 mL), dried with sodium sulfate, filtered, and 
concentrated to a colorless oil (90.77 g). The crude oil was dissolved in 
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EtOAc/heptane (20/80, 100 mL), which was purified through a silica gel plug 
(1000 g) and the plug was flushed with EtOAc/heptane (20/80, 2 L) and 
EtOAc/heptane (40/60, 6 L) to afford the title alcohol 6 (88.60 g, 97%) as a 
colorless oil. 1H NMR: (400 MHz, CDCl3): δ 4.65 (m, amide rotamer, 0.50 
H), 4.35 (m, amide rotamer, 0.50 H), 3.68 (t, 2H, J = 6.4 Hz), 2.78 (m, 
mixture of amide rotamers, 3H), 2.04-1.71 (m, 3H), 1.69-1.53 (m, 2H), 
1.45 (s, 18H).  13C NMR(100 MHz, CDCl3): δ 171.1, 171.0, 156.6, 155.9, 
81.4, 81.4, 80.2, 80.0, 62.2, 62.1, 59.7, 58.4, 30.6, 29.4, 29.3, 28.5, 28.1, 
25.5, 25.3.  MS: M+1 (304 m/z), M+23 (326 m/z), M+39 (342 m/z), and 
2M+23 (629 m/z). HRMS (ESI-ToF): m/z calcd for C15H29NNaO5
+[M+Na]+: 
326.1938, found: 326.1969. 
tert-Butyl (S)-2-((tert-butoxycarbonyl)(methyl)amino)-5-
oxopentanoate (7) 
 
To a 250 mL reactor containing alcohol 6 (6.09 g, 20.1 mmol) was 
added DCM (90 mL) followed sequentially by PCC (pyridinium 
chlorochromate, 6.50 g, 44.1 mmol) and silica gel (60-200 micron, 7.00 g) 
with DCM (18 mL) as a rinse. The mixture was allowed to stir at room 
116 
 
temperature for 1 hour after which time TLC showed complete consumption 
of starting material. The reaction mixture was filtered through a plug of silica 
gel (60-200 micron, 90.00 g) packed in heptane, and product was eluted 
through plug with a gradient of DCM (350 mL), 20% EA/heptane (500 mL), 
40% EA/heptane (500 mL), and 100% EA (250 mL) to afford aldehyde 7 
(5.67 g, 94%) as a colorless oil.  1H NMR (400 MHz, CDCl3): δ 9.78 (d, 1H, 
amide rotamer), 4.59 (m, amide rotamer, 0.50 H), 4.34 (m, amide rotamer, 
0.50 H), 2.77 (d, mixture of amide rotamers, 3H), 2.51-2.40 (m, 2H), 2.28-
2.22 (m, 1H), 1.98 (m, 1H), 1.46 (s, 18H).  13C NMR  (100 MHz, CDCl3): δ 
201.4, 201.1, 177.8, 170.3, 170.2, 156.5, 155.9, 81.8, 80.6, 80.3, 59.4, 
59.4, 58.6, 58.4, 40.8, 40.4, 31.4, 31.3, 30.8, 30.4, 28.5, 28.1, 24.1, 24.0, 
21.7, 21.5.  HRMS (ESI-ToF): m/z calcd for C15H27NNaO5
+ [M+Na]+: 
324.1781, found: 324.1816. HRMS also detected [M+Li]+: 308.2084, 
[M+K]+: 340.1542 and [M+Cr]+: 354.4117. 
Scale-up using alternative oxidation conditions using Pyridinium 
Dichromate (PDC) 
To a 3-L 3-necked reactor containing alcohol 6 (62.5 g, 206.01 mmol) 
was added DCM (1.6 L) and cooled to < 10oC. To the reaction mixture was 
added PDC (116.2 g, 309.0 mmol) and silica gel (60-200 micron, 100 g). 
The mixture was allowed to stir overnight (16 hr) and allowed to gradually 
warm to room temperature while the cooling bath was in place. The reaction 
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mixture was then partially concentrated to remove approximately 1 L of 
DCM. The reaction mixture was loaded onto a silica plug (940 g, 60-200 
micron) packed in EtOAc/heptane (10/90) followed by flushing the plug with 
EtOAc/heptane (20/80, 2.5 L), EtOAc/heptane (30/70, 2.5 L), and 
EtOAc/heptane (40/60, 2.5 L) to furnish aldehyde 7 (57.43 g, 92.5%) as a 
colorless oil. 
Scale-up using alternative Swern oxidation conditions 
To a 1-L 3-necked reactor was equipped with a mechanical stirrer, J-
Kem thermocouple, dropping funnel, nitrogen inlet, and a dry-ice Dewar 
bath. The reactor was placed under a nitrogen atmosphere and was charged 
with anhydrous DCM (170 mL) and anhydrous DMSO (13.2 mL, 14.5 g, 186 
mmol). This mixture was cooled to -78 oC (dry ice/acetone). To the 
cryogenic solution (stir rate: 200 rpm) was slowly added oxalyl chloride 
(8.00 mL, 11.8 g, 93.3 mmol) using a syringe over a period of 6 minutes 
such that the temperature was maintained < -65oC. The resulting mixture 
was allowed to stir at -78oC for an additional 15 minutes, then a solution of 
alcohol 6 (14.00 g, 46.15 mmol) in anhydrous DCM (100 mL) was added 
over 15 minutes. An additional portion of anhydrous DCM (20 mL) was used 
to quantitatively transfer all alcohol to the reactor. The reaction continued to 
stir at -78 oC for an additional 45 minutes. The rate of stirring was increased 
to 550 rpm, then triethylamine (57 mL, 41.61 g, 411.2 mmol) was slowly 
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charged to the reactor over 15 minutes such that the temperature was 
maintained < -65 oC. The reaction mixture was allowed to stir at -78 oC for 
30 minutes, then allowed to warm to room temperature, stirred an 
additional 30 minutes at ambient temperature, and quenched with 25 wt% 
ammonium chloride solution in USP purified water (400 mL). The pH of the 
mixture was adjusted to 7 using 2M HCl, then the organic layer was 
separated. The aqueous stream was extracted with DCM (2 x 100 mL). The 
combined organic layers were successfully washed with USP purified water 
(300 mL), brine (300 mL), dried with sodium sulfate, and concentrated 
under reduced pressure to provide crude aldehyde (14.93 g) as a golden 
yellow oil. The crude aldehyde was purified using a glass gravity column 
using silica gel (400 g, 60-200 micron) and the desired product was eluted 
with an EtOAc/Heptane gradient (0/100 to 30/70) to furnish purified 
aldehyde (10.8 g, 77.6% isolated yield, pale yellow oil). 
(S,Z)-7-tert-Butyl 1-methyl 2-(benzyloxycarbonylamino)-6-(tert-
butoxycarbonyl(methyl)amino)hept-2-enedioate (8a) 
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In a 250 mL round-bottom reactor was placed, under an argon 
atmosphere, (±)-Cbz-α-phosphonoglycine trimethyl ester 11 (3.96 g, 11.92 
mmol) and DCM (30 mL), then DBU (1.71 g, 11.21 mmol) was added 
followed by a DCM rinse (7 mL).  The mixture was allowed to stir at room 
temperature for 45 min and subsequently added to a solution of aldehyde 
(3.00 g, 9.93 mmol) in DCM (40 mL) over 2 minutes to give a pale-yellow 
solution. The reaction was allowed to stir for 2 hours and then concentrated 
under reduced pressure at 40-45 oC. The residue was dissolved into 
isopropyl acetate (100 mL) and was washed with 6% citric acid (3 x 100 
mL), USP purified water (75 mL), brine (75 mL), dried with sodium sulfate 
for 30 min, filtered, and concentrated to give a crude oil. The crude oil 
(dissolved in EtOAc/heptane, 20/80) was purified over a glass gravity 
column (10 in x 2.75 in) packed with silica gel (Silicycle, 60-200 micron, 125 
g) in heptane. The column was eluted with EtOAc/heptane gradient (10/90 
to 40/60). Appropriate fractions containing pure product were combined and 
concentrated to afford the enamide 8a (4.55 g, 90% yield, viscous colorless 
oil).  HPLC purity: 96.4%.  1H NMR (400 MHz, CDCl3): δ 7.36-7.31 (m, 5 
H), 6.76 (bs, amide rotamer, 0.70 H), 6.59 (m, 1 H), 6.28 (bs, 0.30 H), 5.12 
(m, 2 H), 4.55 (m, 0.60 H), 4.30 (m, 0.40 H), 3.76 (bs, 3 H), 2.77-2.71 (s, 
3 H, amide rotamers), 2.23 (m, 2 H), 2.01 (m, 1 H), 1.86 (m, 1 H), 1.45 
(bs, 18 H). 13C NMR (100 MHz, CDCl3): δ 170.4, 165.1, 164.9, 156.9, 
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155.8, 154.6, 154.0, 136.4, 136.2, 135.9, 128.7, 128.6, 128.5, 128.3, 
128.2, 128.1, 81.6, 80.4, 80.3, 67.5, 67.2, 59.5, 58.0, 52.4, 52.3, 30.7, 
30.6, 28.3, 28.0, 27.6, 26.6, 25.2, 24.8.  HRMS (ESI-ToF): m/z calcd for 
C26H38N2NaO8 [M+Na]
+: 529.2520, found: 529.2553. HRMS also detected 
[M+K]+: 545.2288. 
1-Benzyl 7-(tert-butyl) (S,Z)-2-(((benzyloxy)carbonyl)amino)-6-
((tert-butoxycarbonyl)(methyl)amino)hept-2-enedioate (8b) 
 
To a 500 mL reactor was added benzyl Z-phosphinoglycine dimethyl 
ester 13 (22.00 g, 54.00 mmol) and DCM (100 mL).  At ambient 
temperature, DBU (7.88 g, 51.65 mmol) was added to the mixture under 
argon.  After 30 minutes, a solution of aldehyde 7 (14.15 g, 84% pure based 
on 1H NMR, 39.44 mmol) in DCM (150 mL) was slowly added via dropping 
funnel over 10 min.  The reaction mixture was allowed to stir at room 
temperature for 21 h and subsequently was concentrated, diluted with ethyl 
acetate (350 mL), and washed with USP purified water (175 mL).  The 
aqueous stream was extracted with ethyl acetate (2 x 85 mL).  The 
combined organic streams were successively washed with 6% citric acid 
(110 mL), saturated sodium bicarbonate (110 mL), brine (110 mL), dried 
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with sodium sulfate and concentrated to provide the crude enamide product 
(30.67 g) as a yellow oil.  The crude product dissolved in diethyl ether (350 
mL) and silica gel (48 g, 60-200 micron) were combined and concentrated to 
dryness to afford a dry-loaded material that was placed in a 750 g cartridge 
coupled to another cartridge containing silica gel (615 g, 60-200 micron) 
equilibrated with heptane.  Purification was performed on a Teledyne Isco Rf 
Flash chromatography unit eluting with a step-gradient of 100% heptane (2 
CV), 2% IPA in heptane (5 CV), and 5% IPA in heptane (4.5 CV) at 200 
mL/min providing pure enamide Horner-Emmons product 8b (21.40 g, 93%) 
as a colorless viscous oil.  HPLC purity: 98.4%.  1H NMR  (400 MHz, 
CDCl3): δ 7.34 (bm, 10H), 6.77 (bs, amide rotamer, 0.60H), 6.62 (m, 1H), 
6.29 (bs, amide rotamer, 0.40H), 5.19 (s, 2H), 5.11 (d, amide rotamer, 2H), 
4.55 (m, amide rotamer, 0.60 H), 4.29 (m, amide rotamer, 0.40 H), 2.73 (d, 
mixture of amide rotamer, 3H), 2.24 (m, 2H), 2.02 (m, 1H), 1.98 (m, 1H), 
1.85 (m, 1H), 1.43 (s, 18H).  13C NMR (100 MHz, CDCl3): δ 170.5, 164.5, 
164.4, 156.9, 155.8, 154.6, 154.1, 136.7, 136.2, 136.0, 135.7, 135.5, 
128.6, 128.6, 128.5, 128.3, 128.2, 81.7, 80.4, 80.4, 67.5, 67.4, 67.3, 67.2, 
59.6, 58.2, 30.7, 28.4, 28.1.  HRMS (ESI-ToF): m/z calcd for 
C32H42N2NaO8
+[M+Na]+:605.2833, found: 605.2928. HRMS also detected 
[M+K]+:621.2646. 
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(2S,6S)-7-tert-Butyl 1-methyl 2-(benzyloxycarbonylamino)-6-(tert 
butoxycarbonyl(methyl)amino)heptanedioate (9a) 
 
To a Mettler Toledo RC1e system equipped with a MP06-HC 1.2-liter 
pressure glass reactor, mechanical stirrer, and an external temperature 
control unit under nitrogen was added a solution of enamide 8a (4.00 g, 
7.90 mmol) in HPLC-grade methanol (110 mL, degassed with argon). A 
solution of Rh(I)(COD)(S,S)-Et-DuPHOS catalyst (86 mg, 0.12 mmol) in 
degassed methanol (HPLC grade, 10 mL) was added and the reactor was 
pressurized with nitrogen (3x) and hydrogen (3x), then placed under 50 psi 
of hydrogen. The mixture was agitated with mechanical stirring (500 rpm) at 
25°C for 25 h after which 1H NMR indicated complete consumption of the 
alkene. The reaction mixture was purged with nitrogen three times and then 
concentrated under reduced pressure. The crude residue (4.04 g) was 
dissolved in ethyl acetate/heptane (50/50, 8 mL) and passed through a silica 
gel plug (20.5 g) eluting with ethyl acetate/heptane (50/50, 200 mL) to 
afford Cbz-protected amino acid derivative 9a (3.74g, 93% yield) as a 
colorless viscous syrup. HPLC purity (achiral): 100% AUC (area under the 
123 
 
curve).  Chiral HPLC: e.e. = 97.4%. Chiral HPLC was performed using a 
Chiralpak AD-H column (250x4.6 mm, 5 micron) eluting with a gradient of 
hexane/EtOH (90/10 to 30/70) over 20 min at 1.0 mL/min and monitoring at 
210 nm.  1H NMR (400 MHz, CDCl3): δ 7.36-7.30 (m, 5 H), 5.30-5.10 (s, 3 
H, amide rotamers), 4.60 (m, 0.55 H), 4.34 (m, 1.45 H, amide rotamer), 
3.74-3.68 (s, 3 H, amide rotamers), 2,76-2.71 (s, 3 H, amide rotamers), 
1.83 (m, 2 H), 1.74 (m, 2 H), 1.44-1.26 (m, 20 H).  13C NMR (100 MHz, 
CDCl3): δ 172.9, 172.8, 170.9, 170.7, 156.5, 156.0, 155.8, 136.2, 128.5, 
128.1, 81.4, 81.3, 80.1, 79.9, 67.0, 59.4, 57.9, 53.7, 53.6, 52.4, 32.1, 
31.9, 30.5, 28.4, 28.0, 21.8.  HRMS (ESI-ToF): m/z calcd for 
C26H40N2NaO8
+ [M+Na]+: 531.2677, found: 531.2726. 
1-Benzyl-7-(tert-butyl) (2S,6S)-2-(((benzyloxy)carbonyl)amino)-6-
((tert-butoxycarbonyl)(methyl)amino)heptanedioate (9b) 
 
To a Mettler Toledo RC1e system equipped with a MP06-HC 1.2-liter 
pressure glass reactor, mechanical stirrer, and an external temperature 
control unit under nitrogen was added a solution of enamide 8b (19.9 g, 
34.1mmol) in HPLC grade methanol (110 mL, degassed with argon). This 
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mixture was sparged with argon for an additional 30 min. A solution of 
Rh(I)(COD)(S,S)-Et-DuPHOS catalyst (378 mg, 0.52 mmol) in degassed 
methanol (HPLC grade, 50 mL) was added and the reactor was pressurized 
sequentially with nitrogen (3x), hydrogen (3x), and finally placed under 50 
psi of hydrogen. The mixture was agitated with mechanical stirring (500 
rpm) at room temperature for 21 hours after which 1H NMR indicated 
complete consumption of the alkene. The reaction mixture purged with 
nitrogen three times, then concentrated under reduced pressure. The crude 
residue (19.7 g) was dissolved in ethyl acetate/heptane (50/50, 45 mL) and 
passed through a silica gel plug (106 g) using ethyl acetate/heptane (50/50, 
600 mL) to afford Cbz-protected amino acid derivative 9b (19.3 g, 97% 
yield) as a colorless viscous oil. HPLC analysis (achiral): 95.1%.  Chiral 
HPLC: e.e. = 92%. Chiral HPLC was performed using a RegisPack column 
(250x4.6 mm, 5 micron) eluting with an isocratic gradient for 15 minutes 
consisting of hexane/IPA (70/30) + 0.1%DEA at 1.5 mL/min and monitoring 
at 220 nm. 1H NMR(400 MHz, CDCl3): δ 7.35 (m, 10 H), 5.28 (t, 0.89 H, J = 
8.0 Hz, amide rotamer), 5.17-5.10 (m, amide rotamer, 4.10 H), 4.56 (m, 
0.53 H, amide rotamer), 4.41 (m, 0.90 H, amide rotamer), 4.23 (m, 0.58 H, 
amide rotamer), 2.71 (d, mixture of amide rotamers, 3H), 1.89-1.59 (m, 4 
H), 1.50-1.25 (m, 20 H).  13C NMR (100 MHz, CDCl3): δ 172.4, 172.3, 
170.9, 170.8, 156.6, 156.1, 156.0, 155.9, 136.3, 135.4, 135.3, 128.7, 
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128.6, 128.5, 128.4, 128.3, 128.2, 81.5, 81.4, 80.2, 80.0, 67.3, 67.3, 67.1, 
59.6, 58.1, 54.0, 53.8, 32.2, 32.0, 30.6, 28.6, 28.5, 28.1, 22.02. HRMS 
(ESI-ToF): m/z calcd for C32H44N2NaO8
+ [M+Na]+: 607.2990, found: 
607.3088. HRMS also detected [M+K]+:623.2815. 
4-((2S,6S)-7-tert-Butoxy-6-(tert-butoxycarbonyl(methyl)amino)-1-
methoxy-1,7-dioxoheptan-2-ylamino)-4-oxobutanoic acid (10a) 
 
To a 250 mL reactor under argon was added a solution of 9a (3.15 g, 
6.19 mmol) in HPLC grade methanol (85 mL). The mixture was sparged with 
argon for 10 min followed by addition of 10% Pd/C (320 mg). The reactor 
was flushed with argon for 5 min, hydrogen for 5 min, then placed under 
balloon pressure of hydrogen and allowed to stir overnight (16 h) at room 
temperature, when TLC analysis (EtOAc/DCM/MeOH, 20/75/5) indicated 
complete consumption of starting material. The mixture was sparged with 
argon, filtered over a pad of Celite®, rinsed with methanol (50 mL) and the 
resulting filtrate was concentrated and chased with toluene to provide the 
free deprotected amino methyl ester (2.34 g, 100%) as a colorless oil. 1H 
NMR (400 MHz, CDCl3): δ 4.60 (m, 0.50 H, amide rotamer), 4.32 (m, 0.50 
H, amide rotamer), 3.72 (s, 3H), 3.47 (m, 1H), 2.77 (s, 3H, amide rotamer), 
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1.90-1.60 (m, 6H), 1.47 (m, 20H).  13C NMR (100 MHz, CDCl3): δ 176.5, 
171.2, 171.0, 156.5, 156.0, 81.4, 81.3, 80.2, 79.9, 59.6, 58.3, 54.4, 54.3, 
52.1, 34.4, 34.4, 30.7, 28.8, 28.5, 28.1, 22.4. HRMS (ESI-ToF): m/z calcd 
for [M+H]+ for C18H35N2O6
+: 375.2490, found: 375.2514.   
 To a 250 mL reactor was added Cbz-deprotected amine (2.25 g, 6.01 
mmol), succinic anhydride (0.66 g, 6.60 mmol), and DCM (50 mL).  The 
mixture was cooled to < 5oC and triethylamine (0.92 mL, 6.60 mmol) was 
added dropwise over 2 min. The cooling bath was removed, and the reaction 
was allowed to stir overnight at room temperature. After 24 hours, the 
reaction mixture was diluted with DCM (50 mL), washed sequentially with 
6% citric acid (2 x 50 mL), brine (25 mL), dried with sodium sulfate, filtered, 
and concentrated under reduced pressure and chased with DCM and heptane 
to furnish 10a (2.90 g, 99%) as a colorless viscous syrup, which was used 
without further purification.1H NMR (400 MHz, CDCl3): δ 6.43 (d, 0.50H, J = 
8.0 Hz, amide rotamer), 6.32 (d, 0.50H, J = 8.0 Hz, amide rotamer), 4.69-
4.57 (m, 1.5H, amide rotamer), 4.36-4.32 (m, 0.50H, amide rotamer), 3.75 
(d, 3H, mixture of amide rotamers), 2.83-2.72 (m, 4H), 2.65-2.42 (m, 3H), 
1.88-1.70 (m, 5H), 1.46-1.44 (m, 19H).  HRMS (ESI-ToF): m/z calcd for 
C22H38N2NaO9
+ [M+Na]+: 497.2470, found: 497.2493. 
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4-(((2S,6S)-1-(Benzyloxy)-7-(tert-butoxy)-6-((tert-
butoxycarbonyl)(methyl)amino)-1,7-dioxoheptan-2-yl)amino)-4-
oxobutanoic acid (10b) 
 
To a 500 mL reactor was added Cbz-protected amino acid 9b (10.65 
g, 18.2 mmol) and methanol (275 mL).  The mixture was sparged with 
nitrogen for 10 min followed by addition of 10% Pd/C (1.04 g). The reactor 
was flushed with nitrogen for 5 min, hydrogen for 5 min, then placed under 
balloon pressure of hydrogen for 6 h. The mixture was treated with Celite® 
(5.0 grams) and sparged with nitrogen for 10 min, filtered over a pad of 
Celite®, and rinsed with methanol (200 mL).  The resulting filtrate was 
concentrated to provide the free amino acid intermediate 10b (6.39 g, 
97% yield) as an off-white solid.  HPLC purity: 100%. UPLC/MS analysis of 
the free amino acid: [M+H]+ = 361.3. HRMS (ESI-ToF): m/z calcd [M+H]+ 
for C17H33N2O6
+: 361.2333, found: 361.2377. HRMS also detected [M+Na]+: 
383.2194 and [M+K]+: 399.1936. The crude free amino acid 
intermediate10b was carried forward without any further purification. 
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 To a 500 mL reactor was added the free amino acid intermediate 
10b (6.02 g, 16.7 mmol), succinic anhydride (1.73 g, 17.3 mmol), and DCM 
(175 mL).  The mixture cooled to < 5°C and triethylamine (3.66 g, 36.17 
mmol) was added dropwise over 3 min. The cooling bath was removed, and 
the reaction was allowed to stir for 2 h at room temperature.  
HPLC/UPLC/TLC analysis showed that the reaction was deemed complete. 
The reaction mixture was concentrated, diluted with EtOAc (300 mL), 
washed sequentially with 0.10 N HCl (390 mL), USP purified water, (250 
mL), brine (200 mL), dried with sodium sulfate, filtered, and concentrated to 
provide crude 10b (7.40 g). The crude product 10b was dissolved in EtOAc 
(25 mL) and was purified by passing through a silica gel plug (52 g, 60-200 
micron, equilibrated with EtOAc/THF then EtOAc). The silica plug was flushed 
with EtOAc (100 mL) and EtOAc/THF (1:1, 250 mL). Appropriate fractions 
were combined, concentrated, and chased with DCM followed by anhydrous 
1,4-dioxane affording pure succinamide adduct 10b (7.10 g, 92% yield). 
HPLC purity: 98.6% AUC.  Chiral HPLC: e.e. = 100%. Chiral HPLC was 
performed using a RegisPack column (250x4.6 mm, 5 micron) eluting with 
an isocratic gradient for 15 minutes consisting of hexane/IPA (90/10) + 
0.1%TFA at 1.5 mL/min and monitoring at 210 nm. 1H NMR (400 MHz, 
CDCl3): δ 10.74 (bs, 2H), 7.10 (d, 1H, J = 8.0 Hz), 4.65-4.51 (m, amide 
rotamer, 1.5H), 4.29-4.27 (m, amide rotamer, 0.5H), 2.78-2.49 (m, mixture 
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of amide rotamers, 7H), 1.87-1.60 (m, 4H), 1.45 (d, 18H), 1.38-1.16 (m, 
2H). 13C NMR (100 MHz, CDCl3): δ 176.5, 176.5, 175.5, 175.4, 173.1, 
172.9, 170.8, 157.1, 156.8, 81.7, 81.0, 80.8, 67.1, 59.9, 58.4, 53.5, 52.5, 
52.1, 31.3, 30.7, 30.6, 30.4, 29.7, 28.5, 28.3, 28.1, 22.3, 21.7. HRMS 
(ESI-ToF): m/z calcd for C21H36N2NaO9 [M+Na]
+: 483.2313, found: 
483.2368. HRMS also detected [M+K]+: 499.2093. 
(±)-Cbz-α-phosphonoglycine dimethyl ester (12) 
 
According to a reported patent procedure,42 to a 1 L 3-neck reactor 
equipped with a mechanical stirrer, J-Kem thermocouple, nitrogen inlet, and 
water bath (20-25oC), were added (±)-Cbz-α-phosphonoglycine trimethyl 
ester 11 (33.13 g, 100.0 mmol), MeOH (180 mL), and USP purified water 
(20 mL). To the slightly hazy mixture was added a solution of 1N aq NaOH 
(102 mL, 102.0 mmol) via dropping funnel over a period of 1 hr to give a 
homogeneous mixture. The resulting mixture was allowed to stir for an 
additional 1 hr at room temperature and subsequently concentrated under 
reduced pressure at 25-30oC to remove methanol. The aqueous residue was 
polish filtered through filter paper and pH adjusted to pH 1.5 with 1N 
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H2SO4solution (100 mL) to provide a white murky solution. The mixture was 
extracted with EtOAc (4 x 150 mL) and the combined organic streams were 
washed with brine (150 mL), dried with magnesium sulfate, and 
concentrated under reduced pressure to afford (±)-Cbz-α-phosphonoglycine 
dimethyl ester 12 (30.98 g, 98%) as a viscous oil that solidifies to a white 
solid upon standing. HPLC purity: 97.4%. 1H NMR (400 MHz, CDCl3): δ 
7.90 (bs, 2H), 7.36-7.29 (m, 5H), 5.96 (d, 1H, J = 12.0 Hz), 5.16 (d, 1H, J 
= 12.0 Hz), 5.11 (d, 1H, J = 12.0 Hz), 5.00 (dd, 1H, J = 24.0, 8.0 Hz), 3.84 
(d, 3H, J = 8.0 Hz), 3.79 (d, 3H, J = 8.0 Hz). HRMS (ESI-ToF): m/z calcd 
for C12H17NO7P
+ [M+H]+: 318.0737, found: 318.0782. HRMS also detected 
[M+Na]+: 340.0599 and [M+K]+: 356.0319. 
Benzyl 2-(benzyloxycarbonylamino)-2-
(dimethoxyphosphoryl)acetate (13) 
 
According to the general and herein improved procedure of 
Nakanishi,43 a 500 mL 3-neck reactor was charged with (±)-Cbz-α-
phosphonoglycine dimethyl ester 12 (30.77 g, 97.00 mmol), ACN (80 mL), 
and DBU (15.2 g, 21.0 mL, 99.9 mmol) to provide a clear solution. To the 
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reaction mixture was added benzyl bromide (17.4 g, 102 mmol) dropwise 
over 5 min which a cooling bath (ambient temperature) was used to control 
the exotherm. After 2 hours at room temperature, the reaction mixture was 
concentrated under reduced pressure and diluted with EtOAc (350 mL). The 
organic mixture was washed with USP purified water (130 mL), 3% citric 
acid solution (1 x 110 mL), saturated NaHCO3 solution (100 mL), brine (100 
mL), dried with sodium sulfate, and concentrated under reduced pressure to 
give crude product (43.5 g). The crude product was dissolved in 
EtOAc/heptane (1:1, 90 mL) at 45oC, seeded, and diluted with heptane (350 
mL) and the resulting slurry was allowed to stir an additional 1 hr at ambient 
temperature, and filtered.  The filter cake was washed with heptane (50 mL) 
and pulled dry to give benzyl 2-(benzyloxycarbonylamino)-2-
(dimethoxyphosphoryl)acetate 13 (38.7 g, 98%) as a white solid. HPLC 
purity: 95.9% AUC. 1H NMR: (400 MHz, CDCl3): δ 7.35 (m, 10H), 5.62 (d, 
1H, J = 12.0 Hz), 5.29 (d, 1H, J =12.0 Hz), 5.22 (d, 1H, J = 12.0 Hz), 5.14 
(dd, 2H, J = 12.0, 4.0 Hz), 4.96 (dd, 24.0, 12.0 Hz), 3.72 (d, 6H. J = 12.0 
Hz). HRMS (ESI-ToF): m/z calcd for C19H23NO7P
+ [M+H]+:408.1207, 
found: 408.1255. HRMS also detected [M+Na]+: 430.1061 and [M+K]+: 
446.0810. 
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(2S,6S)-6-(Benzyloxycarbonylamino)-1-tert-butoxy-7-methoxy-N-
methyl-1,7-dioxoheptan-2-aminium chloride (14) 
 To a 20 mL scintillation vial was added Boc-protected monomethyl DAP 
Bis-ester 9a (400 mg, 0.80 mmol), magnetic stirring bar, and anhydrous 
1,4-dioxane (4 mL). The mixture was purged with argon and then cool to 0-
5 oC, then a solution of 4N HCl in 1,4-dioxane (0.8 mL, 3.2 mmol) was 
added. The thick slurry was allowed to stir at 0-5 oC for 20 minutes then 
allowed to stir overnight at room temperature. After 26 hours at ambient 
temperature, the reaction mixture was deemed complete by HPLC analysis. 
The reaction mixture was concentrated under nitrogen, diluted with DCM (3 
mL), and diethyl ether (4 mL) was added to precipitate the desired product. 
The slurry was allowed to stir overnight at room temperature. The following 
day, the slurry was filtered and the filter cake was washed with diethyl ether 
(2 x 4 mL), pulled dry, and further dried in vacuo at room temperature to 
provide the monomethyl hydrochloride product 14 (290 mg, 83% yield) as a 
white solid and taken forward without further purification.  HPLC purity: 
96% AUC. MS (ESI): m/z calcd for C21H33N2O6
+ [M+H]+: 409.5, found: 
409.5. 
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(2S,6S)-7-tert-Butyl 1-methyl 2-(benzyloxycarbonylamino)-6-
(dimethylamino)heptanedioate (15) 
 To a 10 mL vial was added monomethyl HCl salt 14 (150 mg, 0.34 
mmol), magnetic stirring bar, sodium acetate (29 mg, 0.35 mmol), and 
methanol (HPLC grade, 1.0 mL). The mixture was allowed to stir for 5 
minutes at room temperature, then a solution of 35% formaldehyde in water 
(40 µL, 0.50 mmol, stabilized with methanol) was added. The mixture was 
allowed to stir 15 minutes at room temperature, then sodium 
triacetoxyborohydride (STAB, 143 mg, 0.67 mmol) was added in 5 portions. 
The reaction mixture was allowed to stir overnight at room temperature. 
After 17 hours, the reaction was sampled for HPLC analysis which indicated 
that the reaction was complete. The reaction mixture was added to ethyl 
acetate (10 mL) and to this mixture was added USP purified water (6 mL). 
The mixture was allowed to stir for 5 minutes, then a saturated aqueous 
sodium bicarbonate solution (2 mL) was added to adjust the pH of the 
aqueous phase to pH 8-9. The organic layer was separated and the aqueous 
phase was extracted with ethyl acetate (3 x 4 mL). The combined organic 
layers were washed with brine, dried with sodium sulfate, and concentrated 
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under reduced pressure to afford dimethyl DAP bis-ester product 15 (136 
mg, 96% yield) as a colorless oil and taken forward without further 
purification. HPLC purity: 100% AUC. MS (ESI): m/z calcd for C22H35N2O6
+ 
[M+H]+: 423.5, found: 423.5. 
(2S,6S)-7-tert-Butyl 1-methyl 2-amino-6 
(dimethylamino)heptanedioate (16) 
 To a 10 mL vial were added dimethyl DAP bis-ester product 15 (117 
mg, 0.26 mmol), a magnetic stirring bar, and ethyl acetate (3 mL). The 
solution was sparged with argon for 5 minutes at room temperature then 
10% Pd/C (20 mg) was added. The mixture was sparged for an additional 2 
minutes with argon, then sparged with hydrogen for 5 minutes, and finally 
placed the reaction mixture under hydrogen atmosphere (~1 atm, balloon 
pressure). After 5 hours at room temperature, TLC analysis showed 
complete consumption of Cbz-protected starting material (Rf = 0.35 in 
EtOAc/DCM/MeOH, 20/75/5). The reaction mixture was filtered over a pad of 
Celite®, the filter cake was washed with ethyl acetate (2 x 5 mL), and the 
corresponding filtrate was concentrated under reduced pressure to provide 
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the free amine 16 (76 mg, 100% yield) as a colorless viscous oil. The free 
amine product was taken forward without any further purification.  
4-((2S,6S)-7-tert-Butoxy-6-(dimethylamino)-1-methoxy-1,7-
dioxoheptan-2-ylamino)-4-oxobutanoic acid (17) 
 To a 10 mL vial containing free amine 16 (76 mg, 0.26 mmol) was 
added DCM (2 mL) and a magnetic stirring bar. To the reaction mixture was 
added succinic anhydride (26 mg, 0.26 mmol) and DCM (1 mL) as a rinse. 
The resulting reaction mixture was allowed to stir overnight at ambient 
temperature. After 16 hours, the reaction mixture was analyzed by TLC 
analysis (EtOAc/CHCl3/MeOH/H2O/AcOH, 50/24/18/5.5/2.5, ninhydrin stain) 
which revealed that the free amine (Rf = 0.07, red spot) was entirely 
consumed and a new spot appeared (desired succinate amide, Rf = 0.28, 
yellowish-peach spot). The reaction mixture was concentrated under reduced 
pressure to provide protected dimethyl L,L-SDAP 17 (103 mg, 100% yield) 
as a colorless glass film and was carried forward without any further 
purification.  
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(1S,5S)-1,5-Dicarboxy-5-(3-carboxypropanamido)-N,N-
dimethylpentan-1-aminium chloride  (18) 
 To a 10 mL vial containing protected dimethyl L,L-SDAP 17 (102 mg, 
0.26 mmol) was added a magnetic stirring bar, and 6M HCl (2 mL). Purged 
with nitrogen and the reaction mixture was allowed to stir at room 
temperature. After 7 hours at room temperature, 1H NMR analysis revealed 
that the reaction mixture contained 96% desired product and 4% unreacted 
starting material. The reaction mixture was concentrated under reduced 
pressure to provide dimethyl L,L-SDAP HCl salt 18 as a white foam (82 mg, 
90% yield). 1H NMR: (400 MHz, CDCl3): δ 4.41 (dd, 1H, J = 8.0, 4.0 Hz), 
3.87 (dd, 1H, J = 12.0, 8.0 Hz), 2.95 (bs, 3H), 2.92 (bs, 3H), 2.71-2.60 (m, 
4H), 2.05-1.93 (m, 3H), 1.87-1.76 (m, 1H), 1.62-1.41 (m, 2H).
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CHAPTER FOUR 
PROCESS-SCALE ASYMMETRIC SYNTHESIS OF L,L-DAP, N6-MONOMETHYL-
L,L-SDAP, AND N6,N6-DIMETHYL-L,L-SDAP ENABLING A NEW DAPE 
INHIBITION ASSAY 
 Carboranes are boron cage molecules that have found use in the 
treatment of diseases including various cancers and rheumatoid arthritis, 
most notably through boron neutron capture therapy (BNCT).  Carboranes 
are also distinguished with a rich and diverse synthetic chemistry.1  BNCT is 
a useful binary cancer treatment, in which a drug containing 10B atoms is 
selectively transported into tumor cells and then irradiated with thermal 
neutrons.  Thereupon, a 10B nucleus absorbs a neutron to form an excited11B 
nucleus that undergoes decay via fission, emitting an α-particle (4He2+) as 
well as a 7Li3+ ion, both with high kinetic energy.  These highly charged 
particles damage the surrounding tissue, but they have a range of only 
about one cell diameter (5-9 μm), which limits the radiation damage to the 
cell in which they arise, thus avoiding damage to the surrounding tissue.2 
 As noted recently,3BNCT is a very promising treatment for cancers 
given its exquisitely ability to target cancer cells, given that it relies on the 
induced fission of boron within tumor cells.  Ideally, a BNCT agent should 
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concentrate in tumor cells while avoiding healthy cells. The U.S. FDA-
approved BNCT drugs boronophenylalanine (BPA), sodium borocaptate and 
sodium decahydrodecaborate and sodium decahydrodecaborate, which were 
developed in the 1950’s and 1960’s are neither tumor-specific nor do they 
accumulate with in tumor cells.3  Thus, there is an urgent need for boron-
containing therapeutics that both contain a higher density of boron atoms, 
i.e. which have a high neutron-capture cross section, and which are selective 
for tumor cells.  Similarly, agents are needed for boron neutron capture 
synovectomy for the treatment of severe cases of rheumatoid arthritis, 
which works through the same principle and mechanism as BNCT for 
cancer.1 
 Matrix metalloproteinases (MMPs) are a family of zinc-dependent 
endopeptidases that are involved in the remodeling and degradation of all 
components of the extracellular matrix (ECM).4  MMP enzymes play a key 
role in normal development, morphogenesis, bone remodeling, wound 
healing, and angiogenesis, yet inappropriately high MMP activity has been 
implicated in a number of disease states including tumor growth and 
metastasis and in the degradation of articular cartilage in arthritis.5 Thus, 
MMP enzymes are over expressed in both tumors and in arthritic cartilage.  
In order to halt disease progression resulting from exaggerated matrix 
remodeling mediated by MMPs, MMP inhibitors (MMPi's) have been 
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extensively explored with the goal of discovering and developing potent, 
selective, and druggable MMP inhibitors.6-8 
 MMPs are known to be over expressed in tumors and also in articular 
cartilage in patients suffering from rheumatoid and osteoarthritis.  
Interestingly, MMP inhibitors have been used in the imaging of cancer cells 
by binding tightly and specifically to MMP receptors.9  The goal of this 
research is to discover orally bioavailable MMP inhibitors that bind with high 
potency and selectivity to MMP enzymes, for it is these enzymes that are 
over expressed in tumors and in arthritic tissues enabling the delivery of a 
high density of boron atoms to tumor and/or arthritic tissue, thus with a 
high neutron-capture cross section, to enable binary treatment of tumors 
utilizing BNCT as well as the treatment of RA with neutron therapy.  In 
addition, it is appropriate to target potent inhibitors of a several MMP 
enzymes specifically, including the collagenase MMP-13 and the gelatinases 
MMP-2 and MMP-9, but with much lower potencies at MMP-1 and MMP-7 
enzymes, enabling these inhibitors to inhibit angiogenesis, invasion, and 
metastasis of tumors as well as inhibiting the MMP-induced destruction of 
articular cartilage. 
 The presence of fluorine (19F) atoms in several derivatives among the 
presently-described ligands enables the use of magnetic resonance 
spectroscopy for the detection and localization of fluorinated drug in tumors, 
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which will be very valuable in demonstrating the localization of tissues to be 
irradiated with neutrons in therapy.10 
Section 1: Synthesis of BNCT Analogs and Discussion 
 Carborane-containing MMP inhibitors to be applied in BNCT have been 
designed and synthesized. A multitude of synthetic targets were explored 
intellectually, and some were carried out experimentally. The synthesis of 
carborane derived analogs were constructed by utilizing the alkyne moiety of 
the THP-protected hydroxamate (Cmpd9). The nature and reactivity of 
alkynes, both internal and terminal, enables the use of many different types 
of chemistry to covalently bind carboranyl clusters. In this work, the 
chemistry focuses on the use of ortho-closo-carboranes. The chemistries 
that were evaluated focused around the reactivity of alkynes with specific 
reactants carrying the carboranyl cluster. More specifically, the chemistries 
evaluated include the reaction of alkynes with an activated decaborane 
complex (B10H12*2MeCN) forming ortho-closo-carboranes, reaction of 
alkynes and azides either via thermal Huisgen 1,3-dipolar cycloaddition or 
copper-mediated azide-alkyne cycloaddition (CuAAC), or the ruthenium-
catalyzed azide alkyne cycloaddition (RuAAC) affording triazole compounds, 
as well as reaction of alkynes with thiols affording alkenyl sulfides.  
 The chemistry begins with the preparation of THP-MMP-18 (Cmpd 9). 
The synthetic route was based on the literature preparation of THP-MMP-
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187,8 and the route was improved during process development. In order to 
prepare carboranyl derivatives using the THP-MMP-18 scaffold, sufficient 
quantities of the MMP-18 starting material was synthesized. The alkyne was 
selected based on the fact that decaborane can react to produce carboranyl 
derivatives, but the alkyne can also be used in Click chemistry to produce 
triazolecarboranyl derivatives.  
Section 2: Preparation and Process Development 
of THP-MMP-18 (Cmpd 9) 
 Preparation of the THP-MMP-18 (Cmpd 9) was accomplished using a 
modified procedure based on Becker et al.7,8 The improved preparation of 
THP-MMP-18 is illustrated in Scheme 24.  
Scheme 24. Improved Synthetic Route to THP-MMP-18 (Cmpd 9)  
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1) THPONH 2S
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 Step 1 involved the formation of the disulfide (Cmpd 1) and the 
isolation procedure was improved such that the yield increased dramatically 
if the product slurry was chilled prior to isolation. Step 2 required the 
formation of the enolate anion 2 which was subsequently reacted with the 
disulfide 1 to produce the corresponding sulfide adduct (Cmpd 3). Step 3 
involved oxidation of the sulfide 3 to the sulfone (Cmpd 4) using recently-
developed novel oxidative conditions.11 During the development of Step 2, it 
was determined that the sulfone (Cmpd 4) can accessed directly by reaction 
of enolate 2 with 4-fluorophenyl sulfonyl chloride as shown below (Scheme 
25). The reaction proved to be successful in cleanly producing the desired 
product in 80% yield. For future preparation, this route can be used as an 
alternative route to access the sulfone directly from 2 either in batch or 
potentially in continuous flow mode.  
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Scheme 25. Enolate and Sulfonyl chloride to produce Sulfone Adduct 4 
LDA, - 78 oC
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 Step 4 entailed removal of the BOC moiety using hydrogen chloride 
gas in isopropyl acetate to access the ammonium hydrochloride salt (5). 
Step 5 involved installation of the propargyl group via N-alkylation using 
propargyl bromide and potassium carbonate to give exclusively the tertiary 
amine product (6). Step 6 involved the preparation of the diaryl ether (7) 
using SNAr conditions. Step 7 involved alkaline hydrolysis of the ethyl ester 
to the carboxylic acid (8) which required overnight heating to achieve >90% 
conversion by HPLC. This ester is highly hindered, and it was surprising that 
this reaction did not go to completion. This type of reaction would be highly 
amendable for flow chemistry at high temperatures. The final step, Step 8 is 
a peptide coupling reaction to form the protected hydroxamate material (9) 
which also required 2-3 days to fully consume the starting material.   
 As shown in Scheme 24, the synthesis commences with the reaction of 
inexpensive and commercially available ethyl N-Boc-piperidine-4-carboxylate 
(2) with Lithium Diisopropylamide (LDA) under cryogenic conditions to 
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produce the enolate anion that subsequently reacts with disulfide (1) to 
produce the sulfide adduct (3). The preparation of disulfide (1) was easily 
achieved by the reaction of 4-fluorothiophenol in DMSO. It is noteworthy 
that the process and yield of the disulfide (1) was drastically improved by 
isolating the disuflide at 0-5 oC providing crystalline material as a low 
melting solid. The corresponding sulfide adduct (2) was originally oxidized to 
the sulfone (3) using MCPBA and required chromatographic purification.7,8 
However, the process for oxidation of the sulfide to the sulfone was 
significantly improved with the use of the newly-developed, safe and 
efficient, scalable, and cost-efficient urea hydrogen peroxide (UHP)/phthalic 
anhydride system11 in ethyl acetate, which allowed this oxidation to be easily 
carried out on 180 g scale and enabled facile isolation of highly pure sulfone 
via an extractive workup eliminating the need for chromatography. The 
corresponding N-Boc sulfone (4) was reacted with hydrogen chloride gas in 
isopropryl acetate to cleave the Boc protecting group producing the 
piperidine as the hydrochloride salt (5), which is then alkylated with 
propargyl bromide and potassium carbonate in DMF to cleanly produce the 
propargylamine adduct (6) in high yield. SNAr reaction of propargylamine 
(6) with 4-(trifluoromethoxy)phenol and potassium carbonate in DMF cleanly 
produced the diphenyl ether adduct (7) in high yield. Alkaline hydrolysis of 
diphenyl ether (7) in ethanol required an excess (10 equiv. of NaOH) of 
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hydroxide and overnight heating to achieve at least 90% conversion of ester 
to carboxylic acid (8). Lastly, the reaction of carboxylic acid (8) with O-
(tetrahydro-2H-pyran-2-yl)hydroxylamine using EDC, HOBt and DIPEA in 
DMF afforded pure protected hydroxamate (9) after purification via normal 
phase chromatography. 
Section 3: Borane-Alkyne Reactions and Synthesis 
of the 1,2-C2B10Carborane Cluster 
 The reaction involving alkynes and decaborane have been a useful 
method of covalently attaching boron clusters to carrier molecules12 for a 
wide range of chemical fields including electronics, nanomaterials, and 
medicine. There are a variety of methods of carrying out reactions of alkynes 
and decaborane to prepare ortho-closo-carboranes. The classical method 
requires the formation of an activated decaborane complex, B10H12(MeCN)2, 
which can be prepared in situ or isolated and can be stored at ambient 
temperature for some time, however the isolated yield of activated 
decaborane complex is undesirably low with yields of only 20-40% isolated 
yield. B10H12(MeCN)2 is typically prepared in toluene and acetonitrile 
(typically in excess) and the generated B10H12(MeCN)2 complex can be 
isolated as a solid with a moderate shelf-life when stored under an inert 
atmosphere, or the B10H12(MeCN)2 complex can be prepared in situ for direct 
carborane synthesis. Preparation of the B10H12(MeCN)2 complex is usually 
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performed at 80-120oC for at least 1 hour. Over the course of the reaction 
hydrogen gas is generated as a byproduct and 2 molar equivalents of 
acetonitrile as a Lewis base replaces the liberated hydrogen. Subsequent 
reaction of B10H12(MeCN)2 and an alkyne at 80-120 
oC affords the closo-
carboranyl derivative, usually requiring overnight heating to fully consume 
the alkyne starting material. However, the reaction can be accelerated when 
a catalytic amount of silver nitrate is added reducing the reaction, reducing 
the reaction time to 1-4 hours.13 In addition, direct reaction of alkynes with 
decaborane can be carried out efficiently using ionic liquids as the 
solvent/activator, and this process does not require the use of a Lewis base 
to form a B10H12(Lewis base)2 complex. The use of an ionic liquid allows 
complete conversion in much shorter timeframe at 100-120oC, which makes 
this process amendable for flow chemistry since it is a fast reaction, and the 
toxic decaborane can be more safely handled. 
 It was projected that the reaction of THP-MMP-18 and B10H12(MeCN)2 
would serve as a convenient pathway to prepare and isolate carboranyl 
targets for BNCT. However, we eventually realized that the reaction was not 
as straightforward as one might perceive. A significant amount of time was 
spent on scoping process conditions in attempt to form the desired 
carboranyl product (Cmpd 24) as illustrated in Scheme 26. Conditions that 
were evaluated included temperature, solvent, prior preparation of the B-
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10H12(MeCN)2 complex, in situ generation of the B10H12(MeCN)2 complex, 
stoichiometry of B10H12(MeCN)2, and catalytic addition of silver nitrate. Table 
4 summarizes the results from the reaction of THP-MMP-18 with decaborane 
in attempt to form the closo-carborane. Pilot reactions performed were 
monitored by HPLC and TLC analysis. 
The results summarized in Table 5 showed that the reactions 
performed generated a multitude of products which were not identified or 
characterized. It was postulated that the hydroxamate moiety was 
undergoing chelation with decaborane or the corresponding decaborane 
activated complex.  
Scheme 26. Reaction of THP-MMP 18 with decaborane activated complex to 
form Compound 24 
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Table 5. Reaction Conditions for the coupling of Decaborane with THP-MMP-
18 (Cmpd 9) 
 
Pilot Reactions Conditions Temp Time HPLC/TLC Result 
Pilot 1                
PR075-
113 
B10H14 (1.2 equiv)                                
ACN (100 equiv)                              
Toluene                                               
THP-MMP-18 (1 equiv) 
110oC 21 h Highly complex mixture 
Pilot 2                
PR075-
133 
B10H14 (1.2 equiv)                                
ACN (100 equiv)                              
Toluene                                               
THP-MMP-18 (1 equiv) 
50oC 13 h Highly complex mixture 
Pilot 3                
PR075-
148 
B10H14 (2 equiv)                                
ACN (100 equiv)                              
Toluene                                               
THP-MMP-18 (1 equiv) 
40oC 
21 h                     
37 h                        
11 days 
Highly complex mixture                                   
Highly complex mixture                      
Highly complex mixture 
110oC 
7 h                     
22 h                        
2.5 days 
Highly complex mixture                                   
Highly complex mixture                      
Highly complex mixture 
Pilot 4               
PR075-
149 
B10H14 (3 equiv)                                                              
Toluene                                                      
ACN (100 equiv)                                     
THP-MMP-18 (1 equiv) 
40oC 
21 h                     
37 h                        
11 days 
Highly complex mixture                                   
Highly complex mixture                      
Highly complex mixture 
110oC 
7 h                     
22 h                        
2.5 days 
Highly complex mixture                                   
Highly complex mixture                      
Highly complex mixture 
Pilot 5               
PR075-
150 
B10H14 (3 equiv)                                
Toluene                                                       
ACN (100 equiv)                                     
THP-MMP-18 (1 equiv)                       
AgNO3 (0.10 equiv) 
25oC 
21 h                     
32 h                        
11 days 
Highly complex mixture                                   
Highly complex mixture                      
Highly complex mixture 
110oC 2 h Highly complex mixture 
Pilot 6               
PR075-
156 
B10H14 (0.5 equiv)                                
ACN (100 equiv)                                     
THP-MMP-18 (1 equiv) 
40oC 15 h Highly complex mixture 
110oC 
7 h                                         
2.5 days 
Highly complex mixture 
Pilot 7                
PR075-
157 
B10H14 (0.5 equiv)                                
Toluene                                                       
ACN (100 equiv)                                     
THP-MMP-18 (1 equiv)                       
AgNO3 (0.10 equiv) 
40oC 15 h Highly complex mixture 
110oC 2 h Highly complex mixture 
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Pilot Reactions Conditions Temp Time HPLC/TLC Result 
Pilot 8                
PR075-
164 
B10H12(MeCN)2 (0.5 equiv)                             
Toluene                                                                  
THP-MMP-18 (1 equiv)  
110oC
2 h                         
16 h                                          
2 days 
Highly complex mixture 
Pilot 9                
PR075-
165 
B10H12(MeCN)2 (1.2 equiv)                             
Toluene                                                                  
THP-MMP-18 (1 equiv)  
110oC
2 h                         
16 h                                          
2 days 
Highly complex mixture 
Pilot 10                
PR075-
166 
B10H12(MeCN)2 (1.2 equiv)                             
Toluene                                                                  
THP-MMP-18 (1 equiv)  
110oC
2 h                         
16 h                                          
2 days 
Highly complex mixture 
 
 According to Kliegel et al,14 reaction of 9-BBN with a THP protected 
hydroxymate can generate boron chelates14 (illustrated in Scheme 27) and 
based on this precedent, it was suspected that this chelation behavior was a 
contributing factor to the complex reaction of THP-MMP-18 with decaborane 
or B10H12(MeCN)2. Kliegel et al
14 showed that hydroxamic acids chelate 9-
BBN, but he also demonstrated that O-THP protected hydroxamates can 
chelate to Lewis acidic boron compounds such as 9-BBN, BF3, and 
diphenylborinic anhydride. Based on the work by Kliegel et al14 showing that 
O-THP protected hydroxamates chelate to boron containing compounds, it 
was hypothesized that the reaction of THP-MMP-18 with decaborane or the 
decarborane activated complex resulted in cleavage of the THP group as 
illustrated in Scheme 28. Further evidence for the deprotection of THP ethers 
were reported by Yung15 who employed the use of catalytic amounts of 
decaborane in various solvents (MeOH, EtOH, MeOH/THF) to cleave THP 
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ethers. Gigg et al. also reported that boric acid at 90oC cleaves THP ethers.16 
Furthermore, the use of borane in THF cleaves tetrahydropyranyl ethers at 
room temperature according to Cossy et al.17 
Scheme 27. 9-BBN Reaction with Free Hydroxamic Acid (based on 
ChemischeBerichte, 116(7), pg 2616, 1983) 
 
 
 
 
Scheme 28. Proposed undesired reaction of THP-MMP-18 (Cmpd 9) with 
decaborane/decaborane activated complex 
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 Given that hydroboration of decaborane and THP-MMP-18 (Cmpd 9) 
proved undesirable, an alternative approach was considered. The alternative 
approach, illustrated in Scheme 29, involved hydroboration of ethyl ester (7) 
with B10H12(MeCN)2 which proved successful in generating the ortho-closo-
carborane ethyl ester adduct 20. In addition to the carboranyl ethyl ester 
(20), a side-product was formed and identified to be the nido ethyl ester 
form (23). Nido formation is typically a result of deboronation of the 
carborane cluster under alkaline conditions (> pH 9) either with alkali 
hydroxide or organic amines. Given that ethyl ester carborane (22) does 
contain an organic amine moiety from the piperidine scaffold, the formation 
of the nido complex is likely due to the presence of the piperidine scaffold. It 
has been shown that treatment of boron clusters in toluene and 
triethylamine at reflux generate the nido form.18 Additionally, Viñas et al. 
showed that using piperidine in ethanol generated nido carboranes.19 
 Since electron donors (such as MeCN, SEt2, or Et3N) coordinate to 
decaborane to form decaborane activated complexes, it is quite possible that 
B10H12(MeCN)2 underwent an exchange with the piperidine nitrogen to eject 
one equivalent of acetonitrile. This swapping reaction could also explain why 
the HPLC/TLC analysis resulted in a significantly complex mixture of 
byproducts or why lower isolated yields for ethyl ester carboranyl adduct 
were achieved.  
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Scheme 29. MMP-18 Ethyl Ester (Cmpd 7) Reaction with Activated 
Decaborane 
 
 
 The reaction of MMP-18 ethyl ester (Cmpd 7) with activated 
decaborane was monitored by HPLC analysis. After 19 h at 80-85 oC, the 
reaction completely consumed starting material and resulted in a 70% 
conversion to the desired carborane (Cmpd 20) along with 16% of a major 
impurity which was identified and assigned as the nido ethyl ester species 
(Cmpd 21) based on HRMS analysis. Purification by flash chromatography 
afforded the desired MMP-18 carboranyl ethyl ester (Cmpd 20) in 35% yield 
and >98% purity. It is still undetermined why the isolated yield is lower than 
expected since the conversion was 70% by HPLC. Based on the observation 
that ethyl ester 7 coupled effectively to decaborane, the interaction of the 
alkyne moiety of Cmpd 9 with decaborane should proceed as expected, and 
shows that Lewis acidic decaborane was probably chelating to the 
hydroxamate moiety.  
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 With experiment PR074-052 (see Scheme 30 below), direct access to 
MMP-18 carboranyl acid (Cmpd 22) was explored by using an MMP-18 
carboxylic acid (Cmpd 8) and activated decaborane which led to essentially 
complete consumption of MMP-18 carboxylic acid (Cmpd 8) after 17 h at 
80oC. The resultant reaction mixture contained only 18% of the desired 
carboranyl acid 22. The HPLC chromatogram for this reaction of MMP-18 
carboxylic acid and activated decaborane is shown in Figure 27.  
Scheme 30. Reaction of MMP-Carboxylic Acid (Cmpd 8) with activated 
decaborane 
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Figure 27. Reaction of MMP-18 carboxylic acid and activated decaborane 
 
 The next step was to determine if the ethyl ester carborane (Cmpd 20) 
can be hydrolyzed to its corresponding carboxylic acid derivative (Cmpd 22). 
The first attempt to hydrolyze the ethyl ester using sodium hydroxide in 
aqueous ethanol at room temperature proved unsuccessful since 
deboronation occurred much faster than hydrolysis of the hindered ester 
group leading to the nido form as the major component. See below in Figure 
28, Figure 29, and Table 6 that show two HPLC chromatograms and 
tabulated data which illustrate that deboronation occurred faster than ester 
hydrolysis and that a significant amount of ethyl ester starting material 
remained unreacted even after 210 h at room temperature. Heating this 
alkaline mixture was not explored since deboronation is likely to be 
enhanced leading to an even higher population of nido ester or nido acid. 
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Note that the nido form is of interest in the future for preparing water 
soluble MMP carboranyl inhibitors, however the initial goal of this project is 
to prepare the analogs that encompass the closo-carborane cage. 
 
Figure 28. Alkaline Hydrolysis of Ethyl Ester Carborane at 44 hrs at RT 
 
 
Figure 29. Alkaline Hydrolysis of Ethyl Ester Carborane at 210 hrs at RT 
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Table 6. Alkaline Hydrolysis and Deboronation of Ethyl Ester Carborane over 
210 hours at RT 
 
Time  
at RT 
 
HPLC 
Carboranyl 
Ester Cmpd 20 
(%AUC) 
HPLC 
Desired Carboranyl 
Acid 
Cmpd 22 
(%AUC) 
HPLC 
Nido Ester 
Cmpd 21 
(26.4 mins) 
(%AUC) 
44 h 85 4 10 
84 h 82 5 12 
108 h 73 7 18 
162 h 64 9 22 
210 h 58 11 29 
 
 The steric hindrance of MMP-18 Ethyl Ester contributed to the very 
slow hydrolysis using sodium hydroxide in aqueous ethanol at 60oC 
overnight. This demonstrates that the ester would prove to be very difficult 
to completely convert to the carboxylic acid. 
 As it appeared that alkaline hydrolysis of carboranyl ester (Cmpd 20) 
is not a viable pathway to access the carboxylic acid carborane, since 
deboronation and nido formation would predominate, conditions employing 
acidic hydrolysis were pursued. Below in Table 7 is summarized the process 
development toward hydrolysis of the hindered ethyl ester using acidic 
mixtures employing conventional thermal heating in batch mode. 
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Table 7. Screening Results for Hydrolysis Hindered MMP-18 Carboranyl Ethyl 
Ester 
 
Reaction Conditions HPLC (%AUC) 
Comments 
Experiment 
Solvent          
Medium 
Temp Time 
Ester 
Cmpd 
20                
Acid 
Cmpd 
22      
Nido 
Ester 
Cmpd 
21 
Nido        
Ester 
Isomer       
Nido        
Acid       
Arachno        
Acid       
Pilot 1               
PR075-
147-A 
33% 
HBr in 
aq 
AcOH                    
sealed 
vial 
100 
oC
27 h 61 30 2 2 0 0 
 
48 h 56 33 3 2 0 0 
 
80 h 42 37 3 2 1 0 
recharged with 
additional water 
and 33% HBr 
Pilot 2             
PR075-
147-B 
6M HCl 
(aq) in 
AcOH    
sealed 
vial 
100 
oC 
15 h 76 15 2 0 3 0 
 
49 h 76 16 1 0 3 0 
 
71 h 66 21 2 0 3 0 
recharged with 
additional water 
and 33% HBr 
Pilot 3            
PR075-
153 
6M HCl 
(aq) in 
AcOH    
sealed 
vial 
100 
oC 
2 
days 
52 15 13 0 0.6 0 
 
3 
days 
38 13 21 0 8 0 
 
7 
days 
20 22 4 0 15 16 
 
Pilot 4           
PR075-
168 
70% 
H2SO4 
in 
AcOH     
sealed 
vial 
100 
oC 
6 h 92 8 0 0 0 0 
 
1 
day 
69 31 0 0 0 0 
 
3 
days 
44 56 0 0 0 0 
 
4 
days 
31 68 0 0 0 0 
 
5 
days 
21 79 0 0 0 0 
 
Pilot 5             
PR075-
169 
50% 
MsOH 
in 
AcOH     
sealed 
vial 
100 
oC 
6 h 96 4 0 0 0 0 
 
1 
day 
85 15 0 0 0 0 
 
3 
days 
61 39 0 0 0 0 
 
4 
days 
51 48 0 0 0 0 
 
5 
days 
45 55 0 0 0 0 
 
 
Pilot 6 
PR075-
170 
 
33% 
HBr in 
aq 
AcOH                    
 
100 
oC 
6 h 50 18 10 11 0 1 
 
1 
day 
18 47 9 12 0 1 
 
2 
days 
4 61 10 12 0 2 
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Reaction Conditions HPLC (%AUC) 
Comments 
Experiment 
Solvent          
Medium 
Temp Time 
Ester 
Cmpd 
20                
Acid 
Cmpd 
22      
Nido 
Ester 
Cmpd 
21 
Nido        
Ester 
Isomer       
Nido        
Acid       
Arachno        
Acid       
sealed 
vial 
3 
days 
0 43 18 15 0 2 
 
 
 As seen in Table 7, acids that were screened included hydrochloric 
acid, hydrobromic acid, sulfuric acid, and methanesulfonic acid. Screening 
was limited to 100 oC, limited by the boiling point of water and given the 
azeotropic nature of aqueous acetic acid mixtures. The addition of acetic acid 
was necessary to ensure that the mixtures remained homogeneous. During 
screening of these acids in batch mode at 100 oC (standard thermal 
heating), the acids screened generated the desired carboxylic acid as well as 
the nido carborane ethyl ester and carboxylic acid forms. However, the 
formation of the nido ethyl ester and carboxylic acid forms depended on the 
acid used. For instance, hydrochloric acid generated larger amounts of nido 
carboxylic acid form, whereas sulfuric acid generated lower levels of nido 
carboxylic acid. Interestingly, methanesulfonic acid also generated larger 
amounts of nido carboxylic acid form compared to sulfuric acid. Solubility of 
the carborane ethyl ester in mineral acids and methanesulfonic acid was 
relatively poor and required the addition of acetic acid to ensure complete 
dissolution. Given that the batch reaction was excessively slow, the use of 
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microwave heating at elevated temperature was evaluated. During the 
evaluation using microwave heating, only sulfuric acid/acetic acid conditions 
were employed since these conditions appeared to form less of the nido 
ethyl ester or carboxylic acid form(s). Note that the nido carboxylic acid 
form is a degradation product from deboronation of the desired carboranyl 
carboxylic acid. Table 8 summarizes the HPLC results of the hydrolysis of 
carboranyl ethyl ester (Cmpd 20) under microwave irradiation. 
Table 8. Microwave Irradiation of Carboranyl Ethyl Ester 20 using sulfuric 
acid/acetic acid 
 
Sample 
H2SO4 
AcOH               
(volumes) 
Temp                 
(
o
C) 
τ          
(mins) 
Carboranyl             
Ethyl Ester  
 
(Cmpd 20)                
32.3 min 
 
(%AUC) 
29.3 
min 
Impurity 
A 
 
(%AUC) 
DESIRED 
Carboranyl 
Acid 
Product 
(Cmpd 22)              
28.8 min 
 
(%AUC) 
26.3 
min 
Impurity 
B 
(nido)             
Ester 
 
(%AUC) 
25.7 
min 
Impurity 
C     
(nido)            
Acid 
 
(%AUC) 
16.1 min 
Impurity 
D  
(arachno) 
Ester 
 
(%AUC) 
9.7-9.9 
min 
Impurity 
E 
(arachno) 
Acid 
 
(%AUC) 
%wt volumes 
PR075-
173 
70 325 650 200 5 0 2 28 8 1 0 0 
PR075-
174 
70 325 650 175 10 0 17 50 6 20 0 1 
PR075-
175 
70 325 650 
135 10 91 0 9 0 0 0 0 
160 +20 28 3 66 0 1 0 1 
PR075-
176 
70 325 650 150 
10 50 1 46 0 2 0 0 
20 28 2 65 0 3 0 1 
30 13 3 75 0 6 0 1 
PR074-
069-A 
70 77 154 150 30 46 0 51 0 1 0 0 
PR074-
069-B 
50 250 500 150 30 69 0 29 0 0 0 0 
PR074-
069-C 
70 250 500 150 30 48 0 49 0 1 0 0 
PR074-
069-D 
70 250 500 150 45 39 0 58 0 1 0 0 
PR074-
069-E 
70 250 500 150 60 33 0 63 0 1 0 0 
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PR074-
069-L 
70 125 250 150 60 33 0 64 0 1 0 0 
PR074-
069-F 
90 250 500 150 60 6 4 83 0 4 0 0 
PR074-
069-G 
90 125 500 150 60 33 1 63 0 1 0 0 
PR074-
069-H 
90 125 375 150 60 21 1 75 0 1 0 0 
PR074-
069-I 
90 125 250 150 60 1 9 78 0 8 0 0 
PR074-
069-K 
90 125 250 150 50 5 5 82 0 5 0 0 
PR074-
069-J 
90 125 250 140 60 28 1 68 0 1 0 0 
PR074-
069-M 
0 0 
250 
(AcOH) 
125 
(H2O) 
140-
145 
10 27 0 0 70 0 3 0 
PR074-
069-N 
0 0 
375 
(AcOH) 
250 
(H2O) 
150-
170 
10 0 0 0 67 0 23 0 
 
Section 4: Discussion about Results 
 Initial screening under microwave irradiation at 200oC resulted in rapid 
consumption of the carboranyl ethyl ester, however severe degradation 
occurred resulting in only 28% desired product with many unknown 
byproducts accompanying an undesirable stench. Decreasing the 
temperature to 175oC resulted in consumption of starting material and 
produced 50% desired product along with associated nido byproducts. 
Operating at 135oC for 10 minutes resulted in 91% unreacted starting 
material and 9% desired product, and subjecting the same reaction mixture 
to 160oC for an additional 20 minutes generated 66% desired carboxylic acid 
product, 28% unreacted starting material, and trace amounts of nido 
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species. Based on those observations, a convenient procedure is warranted 
for scaling the hydrolysis of carboranyl ethyl ester using continuous flow, the 
maximum operating temperature is restricted to 150 oC with the current flow 
chemistry configuration due to that sulfuric acid is employed and the thermal 
limitation of the PFA plug flow reactor is typically restricted to 150 oC for 
safety and durability considerations. The next phase was to evaluate 
microwave irradiation at 150 oC and to optimize the residence time (Tau or 
τ), minimize the formation of nido species, and evaluate the solvent volumes 
and concentration of sulfuric acid. It was found that performing the 
hydrolysis for 60 minutes using 90% sulfuric acid (125 volumes) and acetic 
acid (250 volumes) gave the best conversion to the desired carboranyl acid 
product (~80%), with near consumption of starting material, and <10% of 
nido impurities. Interestingly, when carrying out microwave heating using 
solely aqueous acetic acid (experiment PR074-069-M and -N), hydrolysis of 
the ethyl ester was not affected, however the only products formed were 
mono and di-deboronated compounds that were identified by HRMS to be 
nido-ester and arachno-ester adducts.  
 To confirm that the desired carboranyl acid was forming, one of the 
pilot reactions (PR074-069-C) was analyzed by HPLC followed by UPLC/MS. 
Before analysis, the pilot reaction (PR074-069) was concentrated to remove 
acetic acid under reduced pressure followed by adjusting the pH of the 
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sulfuric acid residue to pH 5-6 (by litmus paper) using saturated aqueous 
sodium bicarbonate solution and subsequently extracting the organic 
material with dichloromethane. Analysis of the organic layer by HPLC 
showed that the ratio of starting material carboranyl ester and desired 
carboranyl acid remained the same (see below). Furthermore, UPLC/MS of 
this mixture showed the correct molecular ion [M+H]+ = 602 m/z for the 
carboranyl acid, and this result confirmed that the carboranyl acid is forming 
under acid hydrolysis. The [M+H]+ = 631 m/z is unreacted carboranyl ethyl 
ester starting material. The UPLC/MS data is depicted in Figure 30 below. 
 
Figure 30. UPLC/MS - Carboranyl MMP-18 Carboxylic Acid (Compound 22) 
 
 Based on the microwave irradiation experiments, the next step was to 
evaluate the hydrolysis of carboranyl ethyl ester under continuous flow mode 
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using conditions developed with microwave batch irradiation. Under 
continuous flow mode at 150 oC for 60 minutes residence time, the 
formation of nido ester was significantly lower than microwave heating, 
however hydrolysis of the ethyl ester was slightly slower than expected. It 
was postulated that the heat transfer property under microwave heating is 
significantly higher than flow mode since glass has better heat transfer 
properties than PFA (Perfluoroalkoxy) tubing which is widely used in 
continuous mode application especially with corrosive or oxidizing agents. 
Furthermore, the higher levels of formation of the nido form under 
microwave heating is likely due to that the concentration of water (within 
the reaction medium) decreased since some of the water within the reaction 
was in the headspace of the microwave vessel as the vapor state.  The HPLC 
chromatogram for a residence time of 60 minutes is depicted in Figure 31. 
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Figure 31. Hydrolysis of Ethyl Ester Carborane under Continuous Flow at 150 
oC with τ = 60 mins 
 
 Given that the conversion was ~10-15% lower than conditions 
developed using microwave heating, the residence time was increased to 75 
minutes at 150 oC which provided the same conversion observed with 
microwave irradiation. The HPLC chromatogram for the hydrolysis at 150 oC 
for 75 minutes under continuous flow mode is illustrated in Figure 32. 
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Figure 32. Hydrolysis of Ethyl Ester Carborane under Continuous Flow at  
150 oC with τ = 75 mins 
 
 The use of continuous flow with a residence time of 75 minutes 
achieved 78-80% conversion to product that was substantially cleaner and 
contained 18-20% unreacted starting materiel ethyl ester which can be 
easily recovered by normal-phase chromatography and subsequently 
recycled for continuous flow processing.  
 With the desired carboranyl acid (Cmpd 22) in hand, the rest of the 
synthesis focused on preparation of the acid chloride, subsequently forming 
the protected hydroxamate using THPONH2 and lastly cleaving the THP 
group with acidic reagent to isolate the carboranyl MMP-18 salt. The scheme 
for this synthetic pathway is illustrated in Scheme 31.  
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 Formation of acid chloride and subsequent hydroxamate formation has 
not been pursued. Current efforts on this front will be addressed in due time. 
Scheme 31. Synthetic Pathway to access Carboranyl MMP-18 salt 
 
 
 
Section 5: Utilizing Click Chemistry to Attach Boron 
Cluster to THP-MMP-18 
 The scope of the next phase of this project revolved around the use of 
Click chemistry to attach boron clusters to the alkyne moiety of THP-MMP-18 
(Cmpd 9). There are a number of methods of employing Click chemistry to 
couple azides to alkynes either thermally or via copper or ruthenium 
catalysis (CuAAC or RuAAC, respectively).  Since we are targeting matrix 
metalloproteinases (MMPs), the use of copper has the potential to cause 
issues downstream since MMPs have a natural affinity to divalent metals 
(zinc, cobalt, copper).  Based on this, the thermal Click reaction (without 
metal catalysis) was used to prepare both the 1,4-disubstituted and 1,5-
disubstituted Click products. 
168 
 
 Synthesis of both the 1,4-disubstituted and 1,5-disubstituted Click 
products was accomplished by preparation of protected carboranyl propyl 
azide and subsequent Click reaction with THP-MMP-18 in toluene at elevated 
temperatures (120-140oC). The synthetic scheme for preparation of 
carboranyl propyl azide is shown in Scheme 32. 
Scheme 32. Preparation of TBDMS Propyl Azido Carborane (13) 
 
 
 Formation of 1-azido-iodopropane was accomplished based on 
literature precedent (reference: ACIEE, 56(26), 7420-7424; 2017) which 
entailed SN2 reaction of sodium azide and 1-bromo-3-chloropropane in DMF 
affording a 95% yield of 1-azido-3-chloropropane that contained ~15% of 1-
azido-3-bromopropane and was taken forward without further purification. 
The crude 1-azido-3-halopropane was subjected to Finkelstein conditions 
using sodium iodide in warm acetone that generated pure 1-azido-3-
iodopropane in 81% isolated yield after silica plug purification. The next 
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reaction involved preparation of the TBDMS-protected carborane derivative 
(13) which involved deprotonation of the o-carborane with n-butyllithium (n-
BuLi) generating the carborane anion which subsequently attacks TBDMSCl 
affording highly pure TBDMS carborane (10) in 94% isolated yield post silica 
plug purification. The last step to prepare the TBDMS propyl azido carborane 
(13) uses novel anion generating conditions not reported in literature for 
this particular reaction. The deprotonation was accomplished using lithium 
hexamethyldisilazide (LiHMDS) to generate the carboranyl anion that 
sequentially attacks 1-azido-3-iodo-propane to furnish pure TBDMS propyl 
azido carborane in 98% isolated yield post silica plug purification.    
 The thermal heating of an azide and an alkyne without copper or 
ruthenium agents generates a mixture of 1,4-disubstituted and 1,5-
disubstituted triazole products. Executing the Click chemistry on TBDMS 
propyl azido carborane (13) and THP-MMP-18 did confirm that a mixture of 
two products were formed as determined by TLC and HPLC analysis. In order 
to determine which Click product by TLC and HPLC correlated to the 1,4-
disubstituted triazole and 1,5-disubstituted triazole products, two separate 
reactions were carried out using copper to facilitate the selective formation 
of the 1,4-disubstiuted Click product and ruthenium catalysis to promote 
selective formation of the 1,5-disubstituted Click product. Scheme 33 depicts 
the thermal click reaction and Figure 35 also shows the HPLC profile of a 
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thermal Click reaction. Furthermore, Figures 33 and 34 provide the 
mechanism of how each regioisomer is formed. 
Scheme 33. Thermal click reaction between alkyne (9) and azide (13) 
 
 
Figure 33. Mechanism for 1,4-Click Product 
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Figure 34. Mechanism for 1,5-Click Product 
 
Figure 35. HPLC chromatogram of the thermal click reaction between Alkyne 
(9) and Azide (13) 
 Using stoichiometric copper sulfate and excess sodium ascorbate in 
aqueous THF at room temperature, the CuAAC reaction (Scheme 34) 
produced solely the 26.5 min component by HPLC (Figure 36) and confirmed 
that this component was the 1,4-disubstituted triazole. Figure 37 depicts the 
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mechanism for the formation of the 1,4-regioisomer under CuAAC 
conditions. 
Scheme 34. CuAAC Reaction of THP-MMP-18 Alkyne and Carboranyl Azide 
 
 
 
Figure 36. CuAAC Reaction of THP-MMP-18 Alkyne and Carboranyl Azide 
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Figure 37. CuAAC mechanism for the formation of the 1,4-disubstituted 
triazole 
 
 The RuAAC reaction (Scheme 35) generated the 27.5 minute 
component by HPLC (Figure 38) and verified that this component was the 
1,5-disubstituted triazole. The RuAAC affords predominately the 1,5-click 
product, but trace amounts (<2% AUC) of the 1,4-click product are 
produced when performing the reaction at ambient temperature. The 
mechanism for the formation of the 1,5-disubstituted triazole click product is 
shown in Figure 39.  
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Scheme 35:RuAAC Reaction of THP-MMP-18 Alkyne and Carboranyl Azide 
 
 
 
 
Figure 38.RuAAC Reaction of THP-MMP-18 Alkyne and Carboranyl Azide 
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 Figure 39.RuAAC mechanism for the formation of the 1,5-disubstituted 
triazole 
 
 To evaluate the RuAAC chemistry, two ruthenium catalysts were 
screened in toluene or tetrahydrofuran to determine which catalyst/solvent 
system was most effective in generating the 1,5-disubstituted triazole. The 
results of this screening are summarized in Table 9. It is apparent that the 
chloro(pentamethylcyclopentadienyl)(cyclooctadiene)ruthenium(II) 
(Cp*Ru(COD)Cl) catalyst was superior compared to 
pentamethylcyclopentadienylbis-(triphenylphosphine)ruthenium(II) chloride 
(Cp*Ru(PPh3)2Cl) catalyst, and performing the reaction in a polar solvent 
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(THF) generated higher conversion to the 1,5-click product compared to 
running the reaction in non-polar media such as toluene. Granted that the 
reaction could have been pushed to completion by adding in more catalyst, 
but this was not explored. It is expected that ruthenium catalysis may serve 
useful for future selective preparation of carboranyl Click products and even 
trace levels of ruthenium should not interfere with binding to MMPs or 
coordinate with the hydroxamate ligand of the MMP-18 scaffold.  
Table 9. RuAAC Reaction screening catalyst type and solvent 
 
Pilot 
Rxn 
Catalyst‡ Solvent 
Time 
(Temp) 
Alkyne 
SM                       
%AUC 
1,5-Click 
Product       
%AUC 
Pilot 1 
PR074-
035-A1 
Cp*Ru(COD)Cl THF 
40 h (RT)                              
65 h (50oC) 
48                                 
34 
49                                   
54 
Pilot 2 
PR074-
035-A2 
Cp*Ru(PPh3)2Cl Toluene 
40 h (RT)                              
65 h (50oC) 
88                           
73 
7                              
20 
Pilot 3 
PR074-
035-B1 
Cp*Ru(COD)Cl THF 
40 h (RT)                              
65 h (50oC) 
76                           
69 
22                                      
27 
Pilot 4 
PR074-
035-B2 
Cp*Ru(PPh3)2Cl Toluene 
40 h (RT)                              
65 h (50oC) 
86                                    
----- 
7                      
----- 
‡Catalyst loading was 0.025 equivalents. 
 The next phase was to optimize the thermal click reaction in toluene as 
the solvent. The goal of this phase was to determine the optimum 
temperature that provided good conversion to Click products and to 
minimize the formation of impurities such as nido species. Formation of nido 
species was expected since the starting material alkyne (Cmpd 9) does 
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contain an internal tertiary organic piperidine base and the resulting Click 
products are alkaline as well, although not as basic as the piperidine 
nitrogen, and with the combination of heat and basicity leads to formation of 
nido complexes. The temperatures screened for the thermal click reaction 
were 100 oC, 120 oC, and 140 oC and the HPLC results from the evaluated 
temperatures are illustrated in Table 9. It is evident that the Click reaction at 
100 oC is significantly slower compared to the reactions at 120 oC and 140 
oC. The reaction at 120 oC progressed to 62% conversion (sum of both Click 
regioisomers) after 42 h whereas the reaction at 140 oC for 19 h performed 
slightly better with a total conversion of 69% (sum of both Click 
regioisomers) and contained less starting material alkyne (22%). The 
formation of impurities (nido) was lower at 120 oC even after 42 h and 
slightly elevated at 140 oC after 19 h, however heating the mixture for 
longer periods of time at 140 oC does consume more starting material 
alkyne, but at the expense of forming significantly higher amount of nido-
like impurities which makes purification difficult downstream.  
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Table 10. Temperature Evaluation for the Thermal Click Reaction 
 
Pilot Rxn Temp Time 
Alkyne 
SM                       
%AUC 
1,4-Click 
Product     
%AUC 
1,5-Click 
Product       
%AUC 
Impurities         
%AUC 
Pilot 1         
PR074-023 
100 oC 
2.5 
days               
5 days                
12 
days             
15 
days 
79                       
70                           
29                       
24 
12                      
18                     
29                                
29 
7                  
10                                       
19                                           
20 
2          
2                       
23       
27 
Pilot 2        
PR074-036-
A 
120 
oC▲ 
19 h                             
42 h 
56         
34 
26                      
38 
16                                
24 
2                                 
4 
Pilot 3         
PR074-036-
B 
140 
oC▲ 
19 h                             
42 h 
22           
9 
42                            
32 
27                                              
23 
9                  
36 
▲ - Reaction was performed in a pressure vial. 
 
 Based on the development of the thermal click chemistry work, scaling 
this procedure was attempted in a microwave vessel, however the poor 
microwave absorption of toluene prohibited the reaction from proceeding 
smoothly. A safer and more efficient method that would allow the 
preparation of Click products would be to perform the Click reaction in 
continuous flow which will allow the reaction to be rapidly heated to target 
temperature, and also to safely handle organo-azides especially at elevated 
temperatures. Continuous flow was not evaluated at this time, therefore the 
Click regioisomers was executed on a gram scale using batch-type pressure 
vessels at 120oC for 58 h. HPLC analysis of the reaction after 58 h showed 
~65% conversion (sum of Click regioisomers) and indicated that there was 
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~20% unreacted alkyne. The reaction was deemed complete at this point to 
avoid degradation of product and introduction of nido-based impurities that 
are difficult to remove. Furthermore, HPLC analysis confirmed that the 
thermal Huisgen 1,3-dipolar cycloaddition reaction gives 1,4-Click and 1,5-
Click products with a ratio of 1.6 to 1, respectively, which agrees with 
Sharpless' study20 the component ratio of the click regioisiomers. 
 To access the final targets intended for assaying MMP inhibition and 
subsequent biodistribution studies, the protected carboranyl Click products 
(1,4- and 1,5-disubstituted) require deprotection of both the TBDMS and 
THP groups. Cleavage of the TBDMS group was executed using 1M 
tetrabutylammonium fluoride (TBAF) in THF which is shown in Scheme 36 
for the 1,4-Click regioisomer and in Scheme 37 for the 1,5-Click 
regioisomer. The reaction conditions require cooling the mixture to cryogenic 
conditions prior to charging 1M TBAF to control the exotherm and also to 
prevent deboronation. Once the TBAF was added, the reaction was allowed 
to warm temperature and the reaction was complete within 30 minutes at 
ambient temperature.  
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Scheme 36. Cleaving the TBDMS group of the 1,4-Click regioisomer 
 
Scheme 37. Cleaving the TBDMS group of the 1,5-Click regioisomer 
 
 The final stage of chemistry required the deprotection of the THP 
protecting group which was executed using 4N HCl in 1,4-dioxane as 
depicted in Schemes 38 and 39. The reaction was performed at room 
temperature and monitored by HPLC to ensure complete deprotection of THP 
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group, since TLC would lead to false interpretations of reaction completion 
since the starting material would simply form a hydrochloride salt and 
remain at the baseline along with desired product. Once the reaction was 
complete, the reaction mixture was concentrated, redissolved in 
dichloromethane, and subsequently precipitated using diethyl ether.   
Scheme 38. Cleaving the THP group of the 1,4-Click regioisomer 
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Scheme 39. Cleaving the THP group of the 1,5-Click regioisomer 
 
Section 6: Conclusion and MMP Inhibition Data of the Click Products 
 The two Click products (1,4-Click and 1,5-Click) that were synthesized 
as hydrochloride salts were tested against three MMP enzymes (MMP-1, 
MMP-2, and MMP-9). In parallel to testing the Click products, Compound 9 
was deprotected to produce the free hydroxamate as the hydrochloride salt 
and this sample was designed to be a control since it does not have a 
carborane cluster attached to it. The inhibition results shown in Table 10 
illustrate that the 1,4-Click product and 1,5-Click product remained highly 
potent against MMP-2 and MMP-9. It is worth noting that these Click 
products showed insignificant binding to MMP-1 which is a positive result 
since reduced binding of MMP-1 will avoid the musculoskeletal syndrome 
(MSS) side effects if administered to humans. The control sample 
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(Compound 9 deprotected) showed sub-nanomolar potency for MMP-2 and 
MMP-9 (0.24 and 0.3 nM) as well but did not spare MMP-1 (860 nM). It is 
interesting that the 1,5-Click product was more potent for MMP-2 and MMP-9 
compared to 1,4-Click product. A possible explaination of why the 1,5-Click 
product was more potent is that while being bound inside MMP-2 or MMP-9, 
the functionality extending from the piperidine nitrogen is essentially sticking 
out in solvent more than the 1,4-Click product. Furthermore, the 
regiochemistry is different between the 1,4 and 1,5-Click product and it 
could be that the carboranyl moiety of the 1,4-Click product is 
intramolecularly interacting with the hydroxamic acid through desirable lewis 
acid and lewis base chemistry since carboranes are lewis acidic and 
hydroxamic acids are lewis basic/chelators. 
 The results for the Click products positively indicate that the 
installation of the carborane moiety does not affect the host-guest 
interaction of MMP-2 and MMP-9 with 1,4 and 1,5-Click carboranyl 
substrates. In fact, it is likely that the carborane moiety is outside in solvent 
whereas the remaining of the substrate is acting as the pharmacophore and 
is bound tightly inside the active site of either MMP-2 and MMP-9.  
 In conclusion, this research has demonstrated that the two Click 
derived analogs can target MMP enzymes at nanomolar potency making 
BNCT a more viable route fighting and killing cancer cells.  
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Table 11.MMP Inhibition of Click Products vs. MMP-1, MMP-2, and MMP-9 
Compounds  
IC50 (µM) or % Inhibition 
MMP-1 MMP-2 MMP-9 
PRO74-092-12, 3 
Compound 9 
deprotected  
0.86 0.00024 0.0003 
PRO74-062-5 
1,4-Click Product  
>10µM, 
*NI at 10µM 
0.037 
>270x sel 
0.046 
>217x sel 
PRO74-088-2 
1,5-Click Product  
>10µM, 
20% at 10µM 
0.0098 
1020x sel 
0.013 
769x sel 
NNGH1 0.12 0.0027 0.0051 
1NNGH (BML-205) is N-Isobutyl-N-(4-methoxyphenylsulfonyl)glycyl hydroxamic acid 
standard MMP inhibitor. 
2PRO74-092-1 is compound 9 deprotected.   
3Literature MMPi for 9 deprotected [Becker, J. Med. Chem. 2010, 53, 6653-6680]: MMP-1 
IC50 = 2.6 μM, MMP-2 IC50 = <0.0001 μM, MMP-9 IC50 = 0.0001 μM.  
 
 
Section 7: Experimental 
Preparation of Bis(4-Florophenyl) disulfide (Compound 1) 
1) DMSO, 65 oC
2) Ice-water, -5 to 0 oC
3) Filtration
4-Fluorothiophenol
C
6
H
5
FS
128.17 g/mol
F
SH
Compound 1
Bis(4-Fluorophenyl) Disulfide
C
12
H
8
F
2
S
2
254.32 g/mol
F
S
S
F
Step 0
 
Procedure 
 The reaction consisted of heating a mixture of 4-fluorothiophenol 
(215.25 g, 1.68 moles) and DMSO (1.4 liters) at 65 oC for 8 hours. The 
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mixture was cooled to 15 oC and this mixture was added (via vacuum 
transfer using a PTFE transfer line) to a second reactor equipped with an 
overhead mechanical stirrer containing a mixture of ice/USP purified water 
(5 Kg) to afford a white slurry which was stirred overnight at 0-5 oC. The 
slurry was filtered, and the wetcake was washed with cold USP water (1.5 
L). Cmpd 1 was pulled dry overnight under a stream of nitrogen to provide 
white crystalline solids (Lot PR075-028-2, 207.4 g, low melting solid, 97.1% 
yield, HPLC purity: 100% AUC, 1H NMR and 13C NMR analysis: conforms to 
structure). Stored in the fridge under nitrogen. 
1H NMR (CDCl3, 400 MHz): δ = 7.44 (m, 4H), 7.00 (m, 4H). 
13C NMR (CDCl3, 100 MHz): δ = 163.96, 161.49, 132.32, 132.29, 131.43, 
131.34, 116.51, 116.29, 77.47, 77.16, 76.84. 
Preparation of 1-tert-butyl 4-ethyl 4-(4-fluorophenylthio)piperidine-
1,4-dicarboxylate (Compound 3) 
1) LDA, - 78 to -50 oC,  THF
2) Cool to 0 oC
3) then add Disulfide at -40 oC
4) Stir overnight at RT
Compound 1
Bis(4-Fluorophenyl) Disulfide
C
12
H
8
F
2
S
2
254.32 g/mol
F
S
S
F
+
N
CO2Et
BOC
Compound 2
Ethyl N-Boc-piperidine-4-carboxylate
C
13
H
23
NO
4
257.33 g/mol
N
CO2Et
BOC
S
F
Compound 3
Sulfide Adduct
C
19
H
26
FNO
4
S
383.48 g/mol
Step 1
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Procedure 
 A solution of Compound 2 (150.00 g, 0.58 moles) in anhydrous THF 
(1.8 liters) was cooled to -78 oC (dry ice/acetone). To this mixture was 
slowly added a solution of LDA (2.0 M in THF/Ethylbenzene, 350 mL, 0.70 
moles) over 22 minutes maintaining the temperature < -70 oC. The resulting 
mixture was allowed to warm to 0 oC, then cooled to -40 oC, and 
subsequently added a solution of Compound 1 (148.75 g, 0.583 mole) in 
anhydrous THF (600 mL) via addition funnel over 30 minutes. The mixture 
was allowed to warm to ambient temperature overnight. The following day, 
the reaction was deemed completed by HPLC analysis. The reaction mixture 
was quenched with a solution of acetic acid (7.7 g) in USP water (200 mL), 
concentrated under reduced pressure at 35-40 oC. The aqueous residue was 
extracted with ethyl acetate (3 x 450 mL) and the combined organic layers 
were successively washed with USP water (300 mL), and brine (500 mL). 
After drying with sodium sulfate, the solution was concentrated under 
reduced pressure to provide crude sulfide adduct (232.4 g). A silica plug (1.2 
Kg, 60-200 micron, 5:1 ratio) purification of crude sulfide using ethyl 
acetate/heptane provided Compound 3  as a light yellow oil (Lot PR075-036-
4, 192.26 g, 86.0% yield, HPLC purity: 99% AUC, 1H NMR and 13C NMR 
analysis: conforms to structure). 
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1H NMR (CDCl3, 400 MHz): δ =7.41 (m, 2H), 7.02 (m, 2H), 4.13 (q, 2H, J = 
14.4 Hz), 3.80 (bd, 2H), 3.09 (m, 2H), 2.09 (m, 2H), 1.76 (m, 2H), 2.12-
2.06 (m, 2H), 1.75 (m, 2H), 1.45 (s, 9H), 1.22 (t, 3H, J = 7.2 Hz). 
13C NMR (CDCl3, 100 MHz): δ = 171.72, 165.16, 162.67, 154.71, 139.17, 
139.08, 125.16, 125.13, 116.12, 115.90, 79.81, 77.48, 77.16, 76.84, 
61.33, 53.79, 33.17, 28.48, 14.16. 
Preparation of 1-tert-butyl 4-ethyl 4-(4-
fluorophenylsulfonyl)piperidine-1,4-dicarboxylate (Compound 4) - 
Alternative Route 
LDA, - 78 oC
THF
4-Fluorobenzenesulfonyl chloride
C
6
H
4
ClFO
2
S
194.61 g/mol
F
S
Cl
O
O
+
N
CO2Et
BOC
Compound 2
Ethyl N-Boc-piperidine-4-carboxylate
C
13
H
23
NO
4
257.33 g/mol
N
CO2Et
BOC
S
F
O
O
Compound 4
Sulfone Adduct
C
19
H
26
FNO
6
S
415.48 g/mol
Procedure 
 A pilot reaction was performed to determine if the sulfone adduct 
(Compound 4) can be easily accessible through anion generation of 
piperidine scaffold via LDA followed by addition of aryl sulfonyl chloride. The 
reaction proved to be successful cleanly producing 80% conversion to 
desired product. No workup was performed on this reaction as it was solely 
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for information only. For future preparation, this route can be used to 
directly access sulfone. 
Preparation of 1-tert-butyl 4-ethyl 4-(4-
fluorophenylsulfonyl)piperidine-1,4-dicarboxylate (Compound 4) 
1) UHP, Phthalic Anhydride
    EtOAc, room temp
2) Water, aq Sodium Sulfite
3) Adjust pH to 8
N
CO2Et
BOC
S
F
O
O
Compound 4
Sulfone Adduct
C
19
H
26
FNO
6
S
415.48 g/mol
N
CO2Et
BOC
S
F
Compound 3
Sulfide Adduct
C
19
H
26
FNO
4
S
383.48 g/mol
Step 2
 
Procedure 
 To a 5 L glass reactor (3-necked), equipped with an overhead 
mechanical stirrer, J-Kem thermocouple, cooling bath (water bath at 15-20 
oC) , nitrogen inlet, and an additional funnel, was charged with ethyl acetate 
(1.5 L), urea hydrogen peroxide (UHP, 132.61 g, 1.41 moles), and 
Compound 3 (180.00 g, 0.469 moles). Solid phthalic anhydride (209.16 g, 
1.41 moles) was added over 5 minutes and ethyl acetate (700 mL) was used 
as a rinse. The resulting mixture was allowed to stir overnight while the 
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cooling bath (15-20 oC) remained in place. After 18 hours, HPLC analysis 
showed complete conversion to sulfone. The reaction slurry was filtered (to 
remove urea and phthalic acid) and the filtrate was washed with a solution 
of aqueous 10% sodium sulfite (1.27 liters). The organic layer was digested 
with aqueous 10% sodium carbonate (800 mL), washed with brine, dried 
with sodium sulfate, concentrated and finally chased with heptane to provide 
Compound 4 (Lot PR075-042-2, off-white solid, 193.61 g, 99.3% yield, HPLC 
purity: 100% AUC, 1H NMR and 13C NMR analysis: conforms to structure). 
1H NMR (CDCl3, 400 MHz): δ =7.81 (m, 2H), 7.25 (m, 2H), 4.20 (m, 4H), 
2.63 (vbs, 2H), 2.30 (bs, 2H), 2.04 (td, 2H, J = 12.0, 4.0 Hz), 1.45 (s, 9H), 
1.25 (t, 3H, J = 8.0 Hz) 
13C NMR (CDCl3, 100 MHz): δ = 167.66, 166.7, 165.10, 154.40, 133.26, 
133.16, 131.11, 131.08, 116.41, 116.18, 80.26, 77.48, 77.16, 76.84, 
72.58, 62.77, 28.41, 27.80, 13.99, 0.05 
HRMS (ESI-ToF): m/z calcd for C19H26FNNaO6S
+ [M+Na]+: 438.1363, 
found 438.1361.  
m.p. 89-97 oC. 
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Preparation of ethyl 4-(4-fluorophenylsulfonyl)piperidine-4-
carboxylate hydrochloride (Compound 5) 
HCl (g)
IPAc
N
H
CO2Et
S
F
O
O
Compound 5 
C
14
H
19
ClFNO
4
S
351.82 g/mol
Compound 4
Sulfone Adduct
C
19
H
26
FNO
6
S
415.48 g/mol
Step 3
N
CO2Et
BOC
S
F
O
O
ClH
 
Procedure 
 The reaction consisted of sparging HCl gas (10.00 g) into a solution of 
Compound 4 (10.25 g, 24.7 mmoles) in isopropylacetate (IPAc, 120 mL) and 
the resultant mixture was allowed to stir overnight at room temperature. 
HPLC analysis confirmed that the reaction was complete and then the 
mixture was concentrated under reduced pressure to afford Compound 5 as 
a white solid (8.72 g, 100% yield, HPLC purity: 100% AUC, 1H NMR and 13C 
NMR analysis: conforms to structure. 
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1H NMR (DMSO-d6, 400 MHz): δ =9.65 (bs, 1H), 9.42 (bs, 1H), 7.89 (m, 
2H), 7.58 (t, 2H, J = 8.8 Hz), 4.13 (q, 2H,  J = 14.4 Hz), 3.41 (d, 2H J = 
13.2 Hz), 2.76 (bs, 2H), 2.32 (m, 4H), 1.10 (t, 3H, J = 7.2 Hz) 
13C NMR (CDCl3, 100 MHz): δ = 170.74, 167.94, 165.97, 165.36, 133.46, 
133.36, 130.33, 130.30, 116.79, 116.56, 77.47, 77.15, 76.84, 70.05, 
67.69, 63.58, 41.32, 25.12, 21.88, 21.50, 13.92, 0.05 
HRMS (ESI-ToF): m/z calcd for C14H19FNO4S
+ [M+H]+: 316.1019,  found 
316.1018. 
Preparation of ethyl 4-(4-fluorophenylsulfonyl)-1-(prop-2-
ynyl)piperidine-4-carboxylate (Compound 6) 
Propargylamine
K
2
CO
3
, DMF, rt
Compound 6 
Propargylamine Adduct
C
17
H
20
FNO
4
S
353.41 g/mol
Compound 5 
Sulfone Adduct HCl Salt
C14H19ClFNO4S
351.82 g/mol
Step 4
CO2Et
S
F
O
O
N
H
CO2Et
S
F
O
O
N
ClH
 
Procedure 
 The reaction was carried out in a 2-liter reactor which involved 
charging Compound 5 (30.00 g, 85.27 mmoles), anhydrous DMF (600 mL), 
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and potassium carbonate (23.8 g, 172.20 mmoles) and the resulting mixture 
was allowed to stir (mechanical stirring) for 10 minutes. Propargylamine 
(97% purity, 10.35 g, 87.00 mmoles) was added and the reaction was 
allowed to stir for 23 hours at room temperature in which HPLC analysis 
revealed 11.75% AUC of unreacted Compound 5 and 87.3%AUC of 
Compound 6. The reaction was charged with an additional portion of 
propargylamine (1.58 g, 1.00 mL, 8.41 mmoles) and the reaction was 
allowed to stir for an additional 1 hour at room temperature in which HPLC 
showed that the reaction was deemed complete (2.3% AUC of unreacted 
Compound 5 was noted and 96.3% AUC of Compound 6).  
 The reaction mixture was transferred to a 5-liter reactor and diluted 
with ice-cold USP purified water (2.5 liters) to initiate crystallization. The 
resulting slurry was stirred overnight at 0-5 oC via mechanical stirring, 
filtered, washed with  USP water (150 mL), and pulled dry under a stream of 
nitrogen to provide Compound 6 (28.44 g, 94.4% yield, Lot PR075-053-3, 
light beige solids, HPLC analysis: 99.81% AUC, 1H NMR and 13C NMR 
analysis: conforms to desired product).  
1H NMR (CDCl3, 400 MHz): δ = 7.82 (m, 2H), 7.23 (m, 2H), 4.21 (q, 2H, J 
= 12.0 Hz), 3.26 (d, 2H, J = 4.0 Hz), 2.90 (m, 2H), 2.39 (m, 2H), 2.20 (m, 
5H), 1.25 (t, 3H, J = 12.0 Hz) 
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13C NMR (CDCl3, 100 MHz): δ = 167.5, 166.8, 165.0, 133.2, 133.1, 131.4, 
116.3, 116.1, 78.2, 77.4, 77.1, 76.8, 73.5, 71.9, 62.5, 49.1, 46.6, 49.1, 
46.6, 28.1, 14.0 
HRMS (ESI-ToF): m/z calcd for C17H21FNO4S
+ [M+H]+: 354.1175,  found 
354.1176. 
Preparation of ethyl 1-(prop-2-ynyl)-4-(4-(4-
(trifluoromethoxy)phenoxy)phenylsulfonyl)piperidine-4-carboxylate 
(Compound 7) 
Milled K
2
CO
3
DMF, 90 oC
Compound 7
Diaryl Ether Adduct
C
24
H
24
F
3
NO
6
S
511.51 g/mol
Step 5 CO2Et
S
O
O
O
N
OCF3
Compound 6 
Propargylamine Adduct
C
17
H
20
FNO
4
S
353.41 g/mol
CO2Et
S
F
O
O
N
+
OH
OCF3
4-(trifluoromethoxy)phenol
C
7
H
5
F
3
O
2
178.11 g/mol
 
Procedure 
 To a 500-mL reactor equipped with an overhead mechanical stirrer, J-
Kem thermocouple, heating mantle, nitrogen inlet, and an additional funnel, 
was charged with Compound 6 (24.86 g, 70.34 mmoles), anhydrous DMF 
(125 mL), milled potassium carbonate (19.54 g, 141.38 mmoles), and 4-
(trifluoromethoxy)phenol (25.10 g, 140.69 mmoles). The reaction was 
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heated at 90 oC for 19 hours which HPLC analysis showed that the reaction 
was deemed complete. The reaction mixture was cooled to room 
temperature and DMF was removed on a rotary evaporator under reduced 
pressure at 40-60 oC. The residue was diluted with MTBE/Toluene (1:1, 300 
mL) and washed with 1M NaOH (2 x 250 mL), USP purified water (250 mL), 
brine (250 mL), dried with sodium sulfate, filtered, and concentrated to 
furnish Compound 7 (36.06 g, 100% yield, Lot PR075-058-4, yellow oil, 
HPLC analysis: 98.03% AUC, 1H NMR and 13C NMR analysis: conforms to 
desired product).  
1H NMR (CDCl3, 400 MHz): δ = 7.76 (m, 2H), 7.27 (m, 2H), 7.10 (m, 2H), 
7.06 (m, 2H), 4.23 (m, 2H), 3.25 (s, 2H), 2.90 (bs, 2H), 2.40 (bd, 2H), 2.19 
(m, 5H), 1.27 (m, 3H) 
13C NMR (CDCl3, 100 MHz): δ = 167.0, 162.5, 153.3, 146.1, 132.8, 129.6, 
123.0, 121.6, 117.3, 78.3, 77.4, 77.1, 76.7, 73.4, 72.0, 62.4, 49.3, 46.7, 
28.3, 14.0 
HRMS (ESI-ToF): m/z calcd for C24H25F3NO6S
+ [M+H]+: 512.1355,  found 
512.1353.  
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Preparation of ethyl 1-(prop-2-ynyl)-4-(4-(4-
(trifluoromethoxy)phenoxy)phenylsulfonyl)piperidine-4-carboxylate 
(Compound 8) 
1) NaOH, H
2
O
    EtOH, THF, 65 oC
2) 2M HCl
Compound 8
Diaryl Ether Free Acid
C
22
H
20
F
3
NO
6
S
483.46 g/mol
Step 6
CO2H
S
O
O
O
N
OCF3
Compound 7
Diaryl Ether Adduct
C
24
H
24
F
3
NO
6
S
511.51 g/mol
CO2Et
S
O
O
O
N
OCF3
 
Procedure 
 To a 2-Liter reactor equipped with an overhead mechanical stirrer, J-
Kem thermocouple, heating mantle, reflux condenser with nitrogen inlet, and 
an additional funnel, was charged with a solution of Compound 7 (28.50 g, 
55.72 mmoles) in EtOH/THF (1:1, 850 mL) and a solution of NaOH (22.30 g, 
557.17 mmoles) in USP water (425 mL). The reaction mixture was heated to 
65 oC and allowed to stir for 18 hours which HPLC analysis showed complete 
consumption of Compound 7. The mixture was allowed to cool to ambient 
temperature, diluted with USP water (300 mL), and concentrated at 45-50 
oC on a rotary evaporator to remove EtOH and THF. The aqueous residue 
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was diluted with USP water (600 mL) and the pH was adjusted to pH 2.25 
using 2M HCl (282 mL) providing a thick white slurry. The slurry was 
filtered, washed with USP water (750 mL), pulled dry, and dried further in a 
vacuum oven at 40 oC to provide Compound 8 (26.30 g, 97.6% yield, Lot 
PR075-063-2, white solid, HPLC analysis: 94.4% AUC, 1H NMR and 13C NMR 
analysis: conforms to desired product).  
1H NMR (CDCl3, 400 MHz): δ = 7.78 (m, 2H), 7.49 (d, 2H, J = 8.0 Hz), 7.31 
(m, 2H), 7.19 (m, 2H), 3.31 (s, 2H), 3.17 (s, 1H), 2.85 (d, 2H, J = 12.0 Hz), 
2.19 (d, 2H, J = 12.0 Hz), 2.11 (t, 2H, J = 12.0 Hz), 1.92 (td, 2H, J = 12.0, 
4.0 Hz) 
13C NMR (CDCl3, 100 MHz): δ = 167.5, 161.7, 153.3, 145.03, 145.01, 
132.8, 129.2, 123.32, 122.0, 117.4, 78.5, 76.3, 71.0, 48.4, 45.7, 27.5 
HRMS (ESI-ToF): m/z calcd for C22H21F3NO6S
+ [M+H]+: 484.1042,  found 
484.1042. 
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Preparation of 1-(prop-2-ynyl)-N-(tetrahydro-2H-pyran-2-yloxy)-4-
(4-(4-(trifluoromethoxy)phenoxy)phenylsulfonyl)piperidine-4-
carboxamide (Compound 9) 
Compound 9
MMP-18 THP Free Base
C
27
H
29
F
3
N
2
O
7
S
582.59 g/mol
Step 7
S
O
O
O
N
OCF3
N
H
O
OTHP
Compound 8
Diaryl Ether Free Acid
C
22
H
20
F
3
NO
6
S
483.46 g/mol
CO2H
S
O
O
O
N
OCF3
EDCI-HCl, THP-ONH
2
DMAP, DMF
 
Procedure 
 To a 500-mL reactor, equipped with a large magnetic stirring bar, J-
Kem thermocouple, cooling dewer, and nitrogen inlet, was charged with 
Compound 8 (20.00 g, 41.37 mmoles) and anhydrous DMF (180 mL). The 
mixture was allowed to stir for 10 minutes at ambient temperature then 
cooled the mixture to < 5 oC. To the cooled mixture was sequentially added 
O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine (7.50 g, 64.02 mmoles), EDCI-
HCl (10.00 g, 81.85 mmoles), and DMAP (8.00 g, 65.36 mmoles). The 
mixture was allowed to stir overnight and gradually warmed to room 
temperature while the reactor remained in the cooling bath. After 17 hours, 
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HPLC analysis revealed 16.1% of unreacted Compound 8 free acid. The 
cooling bath was removed and the reaction mixture was allowed to stir an 
additional 33 hours at room temperature whereby HPLC analysis confirmed 
that the reaction was deemed complete. The reaction was quenched with 
USP water (5 mL) and concentrated at 30 oC on a rotovap evaporator to 
remove DMF. The residue was diluted with ethyl acetate (350 mL) and 
subsequently washed with saturated aqueous sodium bicarbonate solution 
(200 mL), brine (200 mL), dried with magnesium sulfate, filtered, and 
concentrated under reduced pressure to provide crude Compound 9  
(34.31 g).  
Crude Compound 9 (34.31 g) was purified by silica gel 
chromatography using a glass gravity column (24 in x 3 in) and silica gel 
(680 g, 60-200 micron, Silicycle, equilibrated with 30% EtOAc in heptane). 
Crude Compound 9 was dissolved in ethyl acetate (20 mL) then diluted with 
heptane (20 mL) and subsequently loaded onto the silica bed. The column 
was eluted with an EtOAc/Heptane gradient (30% to 70%). Appropriate 
fractions were combined and concentrated to provide Compound 9 (21.78 g, 
90.4% yield, Lot PR075-070-9, white solid, HPLC analysis: 97% AUC, 1H 
NMR and 13C NMR analysis: conforms to desired product, Mass Spec 
analysis: [M+H]+ = 583.46 m/z, FTIR: conforms to desired product).  
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1H NMR (CDCl3, 400 MHz): δ = 9.40 (s, 1H), 7.80 (dd, 2H, J = 6.9, 2.0 Hz), 
7.27 (m, 2H), 7.12 (dd, 2H, J = 6.8, 2.3 Hz), 7.05 (dd, 2H, J = 6.9, 2.0 Hz), 
5.00 (t, 1H, J = 2.8 Hz), 4.00 (td, 1H, J = 11.2, 2.4 Hz), 3.69 (m, 1H), 3.23 
(d, 2H, J = 2.4 Hz), 2.92 (m, 2H), 2.35-2.30 (m, 3H), 2.25-2.20 (m, 4H), 
1.88-1.76 (m, 3H),  1.68-1.58 (m, 3H). 
13C NMR (CDCl3, 100 MHz): δ = 164.0, 162.8, 153.0, 146.1, 146.0, 132.6, 
128.0, 123.0, 121.8, 121.7, 119.2, 117.4, 102.0, 78.6, 73.4, 70.3, 62.3, 
49.0, 48.9, 46.6, 28.6, 28.4, 27.8, 25.0, 18.3. 
HRMS (ESI-ToF): m/z calcd for C27H30F3N2O7S
+ [M+H]+: 583.1726,  found 
583.1723. 
Preparation of ethyl 1-(prop-2-ynyl)-4-(4-(4-
(trifluoromethoxy)phenoxy)phenylsulfonyl)piperidine-4-carboxylate 
(Compound 8) 
1) NaOH, H
2
O
    EtOH, THF, 65 oC
2) 2M HCl
Compound 8
Diaryl Ether Free Acid
C
22
H
20
F
3
NO
6
S
483.46 g/mol
Step 6
CO2H
S
O
O
O
N
OCF3
Compound 7
Diaryl Ether Adduct
C
24
H
24
F
3
NO
6
S
511.51 g/mol
CO2Et
S
O
O
O
N
OCF3
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Procedure 
 To a 2-Liter reactor equipped with an overhead mechanical stirrer, J-
Kem thermocouple, heating mantle, reflux condenser with nitrogen inlet, and 
an additional funnel, was charged with a solution of Compound 7 (28.50 g, 
55.72 mmoles) in EtOH/THF (1:1, 850 mL) and a solution of NaOH (22.30 g, 
557.17 mmoles) in USP water (425 mL). The reaction mixture was heated to 
65 oC and allowed to stir for 18 hours which HPLC analysis showed complete 
consumption of Compound 7. The mixture was allowed to cool to ambient 
temperature, diluted with USP water (300 mL), and concentrated at 45-50 
oC on a rotary evaporator to remove EtOH and THF. The aqueous residue 
was diluted with USP water (600 mL) and the pH was adjusted to pH 2.25 
using 2M HCl (282 mL) providing a thick white slurry. The slurry was 
filtered, washed with USP water (750 mL), pulled dry, and dried further in a 
vacuum oven at 40 oC to provide Compound 8 (26.30 g, 97.6% yield, Lot 
PR075-063-2, white solid, HPLC analysis: 94.4% AUC, 1H NMR and 13C NMR 
analysis: conforms to desired product).  
1H NMR (CDCl3, 400 MHz): δ = 7.78 (m, 2H), 7.49 (d, 2H, J = 8.0 Hz), 7.31 
(m, 2H), 7.19 (m, 2H), 3.31 (s, 2H), 3.17 (s, 1H), 2.85 (d, 2H, J = 12.0 Hz), 
2.19 (d, 2H, J = 12.0 Hz), 2.11 (t, 2H, J = 12.0 Hz), 1.92 (td, 2H, J = 12.0, 
4.0 Hz) 
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13C NMR (CDCl3, 100 MHz): δ = 167.5, 161.7, 153.3, 145.03, 145.01, 
132.8, 129.2, 123.32, 122.0, 117.4, 78.5, 76.3, 71.0, 48.4, 45.7, 27.5 
HRMS (ESI-ToF): m/z calcd for C22H21F3NO6S
+ [M+H]+: 484.1042,  found 
484.1042. 
Preparation of 1-(prop-2-ynyl)-N-(tetrahydro-2H-pyran-2-yloxy)-4-
(4-(4-(trifluoromethoxy)phenoxy)phenylsulfonyl)piperidine-4-
carboxamide (Compound 9) 
Compound 9
MMP-18 THP Free Base
C
27
H
29
F
3
N
2
O
7
S
582.59 g/mol
Step 7
S
O
O
O
N
OCF3
N
H
O
OTHP
Compound 8
Diaryl Ether Free Acid
C
22
H
20
F
3
NO
6
S
483.46 g/mol
CO2H
S
O
O
O
N
OCF3
EDCI-HCl, THP-ONH
2
DMAP, DMF
 
Procedure 
 To a 500-mL reactor, equipped with a large magnetic stirring bar, J-
Kem thermocouple, cooling dewer, and nitrogen inlet, was charged with 
Compound 8 (20.00 g, 41.37 mmoles) and anhydrous DMF (180 mL). The 
mixture was allowed to stir for 10 minutes at ambient temperature then 
cooled the mixture to < 5 oC. To the cooled mixture was sequentially added 
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O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine (7.50 g, 64.02 mmoles), EDCI-
HCl (10.00 g, 81.85 mmoles), and DMAP (8.00 g, 65.36 mmoles). The 
mixture was allowed to stir overnight and gradually warmed to room 
temperature while the reactor remained in the cooling bath. After 17 hours, 
HPLC analysis revealed 16.1% of unreacted Compound 8 free acid. The 
cooling bath was removed and the reaction mixture was allowed to stir an 
additional 33 hours at room temperature whereby HPLC analysis confirmed 
that the reaction was deemed complete. The reaction was quenched with 
USP water (5 mL) and concentrated at 30 oC on a rotovap evaporator to 
remove DMF. The residue was diluted with ethyl acetate (350 mL) and 
subsequently washed with saturated aqueous sodium bicarbonate solution 
(200 mL), brine (200 mL), dried with magnesium sulfate, filtered, and 
concentrated under reduced pressure to provide crude Compound 9  
(34.31 g).  
Crude Compound 9 (34.31 g) was purified by silica gel 
chromatography using a glass gravity column (24 in x 3 in) and silica gel 
(680 g, 60-200 micron, Silicycle, equilibrated with 30% EtOAc in heptane). 
Crude Compound 9 was dissolved in ethyl acetate (20 mL) then diluted with 
heptane (20 mL) and subsequently loaded onto the silica bed. The column 
was eluted with an EtOAc/Heptane gradient (30% to 70%). Appropriate 
fractions were combined and concentrated to provide Compound 9 (21.78 g, 
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90.4% yield, Lot PR075-070-9, white solid, HPLC analysis: 97% AUC, 1H 
NMR and 13C NMR analysis: conforms to desired product, Mass Spec 
analysis: [M+H]+ = 583.46 m/z, FTIR: conforms to desired product).  
1H NMR (CDCl3, 400 MHz): δ = 9.40 (s, 1H), 7.80 (dd, 2H, J = 6.9, 2.0 Hz), 
7.27 (m, 2H), 7.12 (dd, 2H, J = 6.8, 2.3 Hz), 7.05 (dd, 2H, J = 6.9, 2.0 Hz), 
5.00 (t, 1H, J = 2.8 Hz), 4.00 (td, 1H, J = 11.2, 2.4 Hz), 3.69 (m, 1H), 3.23 
(d, 2H, J = 2.4 Hz), 2.92 (m, 2H), 2.35-2.30 (m, 3H), 2.25-2.20 (m, 4H), 
1.88-1.76 (m, 3H),  1.68-1.58 (m, 3H). 
13C NMR (CDCl3, 100 MHz): δ = 164.0, 162.8, 153.0, 146.1, 146.0, 132.6, 
128.0, 123.0, 121.8, 121.7, 119.2, 117.4, 102.0, 78.6, 73.4, 70.3, 62.3, 
49.0, 48.9, 46.6, 28.6, 28.4, 27.8, 25.0, 18.3. 
HRMS (ESI-ToF): m/z calcd for C27H30F3N2O7S
+ [M+H]+: 583.1726,  found 
583.1723. 
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Preparation of TBDMS Carborane (Compound 10)  
 
EXPECTED CHARGES 
 Reagent MW 
Loading 
eq 
amount   
g 
amount         
mL 
mmole 
o-Carborane 144.23 1.00 3.00 
---------
- 
20.80 
Toluene (anhydrous) 
---------
- 
---------- 
---------
- 
12.00 
---------
- 
Diethyl Ether  
(anhydrous with BHT) 
---------
- 
---------- 
---------
- 
6.00 
---------
- 
nBuLi (1.66 M in hexanes) 
---------
- 
1.05 
---------
- 
13.16 21.84 
TBDMSCl 150.72 1.10 3.45 
---------
- 
22.88 
USP Water 
---------
- 
---------- 
---------
- 
45.00 
---------
- 
Diethyl Ether  
(3 extractions each) 
---------
- 
---------- 
---------
- 
30.00 
---------
- 
   Theoretical Yield of Product  
(in grams) 
5.38 
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Procedure 
To a 100 mL RBF was added 3.00 g of o-carborane, 12 mL anhydrous 
Toluene, and 6 mL anhydrous Et2O. Stirred at room temperature until 
completely dissolved then cooled to < 5oC. Added nBuLi solution (1.66M, 
13.2 mL) over about 5 minutes to give a murky turbid white mixture. 
Removed cooling bath after 5 minutes and allowed to store at room 
temperature. After 2.5 hours, solid TBDMSCl (3.47 g) was added at room 
temperature as one portion which addition was endothermic. Reaction is a 
murky while solution. After 22.5 hours, the reaction slurry was analyzed by 
TLC (80% Hexane and 20% Et2O) and showed a trace amount of starting 
material and the reaction was deemed complete. The reaction mixture was 
quenched reaction with 30 mL of USP purified H2O, then extracted with Et2O 
(3x30 mL). The combined organic layers were dried with MgSO4, filtered and 
concentrated to give crude product 7.07g (pale yellow oil, lot PR075-190-2). 
The crude oil was purified over silica gel as follows. To a glass gravity fitted 
column (12x2in) was added sand, n-hexane, a slurry of 140 g of silica gel 
(60-200 micron) in n-hexane, further packed under a positive pressure of 
nitrogen, and lastly placed a layer of sand on top of the silica bed. Loaded 
neat crude product (7.07 g) onto glass gravity column and used n-hexane as 
a rinse. The column was eluted with n-hexane (250 mL) and 10% 
Et2O/hexane (825 mL). Collected 10 fractions (each approximately 75 mL). 
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Analyzed fractions using TLC. Appropriate fractions were combined and 
concentrated on rotovap at 25-30oC to give 5.05 g of Compound 10 as white 
crystalline solids (Lot PR075-190-3, 93.9% yield). Literature reference that 
this procedure was followed: J. Med. Chem. 2011, 54, pg 2368. 
1H NMR (CDCl3, 400 MHz): δ = 3.44 (bs,1H), 2.87-1.54 (m, 10H), 1.02 (s, 
9H), 0.23 (s, 6H). 
11B NMR (Decoupled, 100 MHz): δ = 0.34, -1.76, -7.02, -10.73, -12.31, -
13.26 
11B NMR (Coupled, 100 MHz): δ = 1.01, -0.94, -2.57, -6.29, -7.87, -9.99, -
11.62, -12.41, -13.2, -14.26 
Preparation of 1-azido-3-chloropropane (Compound 11) 
Safety Note on Handling Azido Compounds (refer to references 1, 2, 3 
below) 
 
Handling Sodium Azide 
Sodium azide is extremely toxic (LC50 Inhalation = 37 mg/m
3 for rats, LD50 
Dermal = 20mg/kg for 
rabbits) and very soluble in water (>30 g/100 mL at 0 °C). Sodium azide 
can be easily absorbed 
dermally and consequently must be handled with appropriate personal 
protection equipment (PPE). 
Sodium azide decomposes above 275 °C, generating highly reactive sodium 
metal. Sodium 
azide is not compatible with any acid as it spontaneously forms highly 
explosive hydrazoic acid on contact, even in dilute solution. 
 
Low Molecular Weight Organic Azides 
Low molecular weight organic azides are potentially explosive substances 
that can decompose with a slight input of external energy (heat, friction, 
pressure etc). Although there has not been any documented explosions on 
this end of work, any organic azides where the weight attributed to the azido 
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group exceeds 25% of the molecular weight should be handled with 
significant caution. It is recommended that a blast shield be used during 
synthesis and avoid of very large-scale reactions when dealing with these 
substances.  
 
1. Sigma-Aldrich, Sodium Azide; MSDS No. 13412 [Online]; Auckland, NZ, 
Nov 05, 2012 
http://www.sigmaaldrich.com/catalog/product/sial/13412 (accessed March 
29, 2017). 
 
 2. T. Archibald in Managing Hazardous Reactions and Compounds in Process 
Chemistry, Vol. 1181 
(Eds.: J. A. Pesti, A. F. Abdel-Magid), American Chemical Society: 
Washington, DC, 2014; pp. 87- 
109. 
 
3. T. Keicher, S. Löbbecke in Organic Azides: Syntheses and Applications; 
(Eds.: S. Bräse, K. Banert),Wiley: Chichester, U.K., 2010; pp 3. 
 
Procedure 
To a 250 mL round bottomed flask was added 100 mL of anhydrous 
DMF and 10.02 g of 1-bromo-3-chloropropane and then 4.2 g of sodium 
azide. The reaction was placed in an ambient water bath and stirred 
overnight (16 hrs) at room temperature. The reaction mixture was diluted 
with 50 mL of Et2O and 50 mL USP purified water. Stirred 2-3 minutes then 
separated the organic layer (top). Extracted the bottom aqueous layer with 
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Et2O (2x 60 mL). The combined organic layers were washed with USP 
purified water (3x 50 mL), dried with Na2SO4, filtered and concentrated at 
25-30oC under reduced pressure to give Compound 11 as a colorless oil, lot 
PR075-191-1 (7.21g), 95% crude yield which was taken forward without any 
further purification. This gives a mixture of 1-azido-3-chloropropane as the 
major product (81%) and does contain ~19% of 1-azido-3-bromopropane. 
The next step involves iodide formation which under Finkelstein conditions 
will convert chloro/bromo to iodo as the sole product. Precedent: 
Angewandte Chemie International Edition, 56(26), 7420-7424; 2017 
1H NMR (CDCl3, 400 MHz): δ = 3.64 (t, 2H, J = 8.0 Hz), 3.51 (t, 3H, J =  
8.0 Hz), 2.02 (p, 2H, J = 12.0, 4.0 Hz) 
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Procedure for 1-azido-3-iodopropane (Compound 12) 
 
 
EXPECTED 
CHARGES 
 Reagent MW Density 
Loading 
eq 
amount   
g 
amount         
mL 
mmole 
Crude 1-azido-3-
chloropropane 
119.55 
---------
- 
1.00 7.50 
---------
- 
62.74 
Acetone  
---------
- 
---------
- 
---------
- 
---------- 187.50 
---------
- 
Sodium Iodide 149.89 
---------
- 
2.00 18.81 
---------
- 
125.47 
Silica Gel  
(60-200 micron) 
---------
- 
---------
- 
---------
- 
---------- 75.00 
---------
- 
   Theoretical Yield of Product 
12 
(in grams) 
13.24 
 
Procedure for 1-azido-3-iodopropane (Compound 12) 
 To a 1000 mL round bottomed flask (3-necked) was added 19.35 g of 
NaI, 7.5 g of crude 1-azido-3-chloropropane, and 190 mL of acetone. Purged 
with N2 and heated to 52⁰C. Covered with foil.  After 40 hours, the reaction 
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was allowed reaction to cool to room temperature. The reaction mixture 
(yellow slurry) was filtered over a pad of Celite, washed funnel and flask 
with acetone (~100mL), then concentrated the yellow filtrate on a rotavap 
at 25-30⁰C to remove acetone. After concentration, an orange-yellow 
residue was obtained (oily solids, 26.2 g). Added 50 mL hexane to oil/solid 
residue (yellowish-orange) which changed the color to a greenish solid. 
Stirred the slurry overnight at room temperature then passed over a short 
silica plug(65g) packed in hexane. Flushed with n-Hexane to collect fractions 
(each 50-70 mL). Appropriate fractions were combined and concentrated at 
25⁰C to give 10.77 g of Compound 12 as a colorless oil (81.3% yield, Lot 
PR074-018-3). Precedent: Angewandte Chemie International Edition, 
56(26), 7420-7424; 2017 
1H NMR (CDCl3, 400 MHz): δ= 3.44 (t, 2H), 3.25 (t, 2H), 2.04 (p, 2H) 
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Preparation of TBDMS Propyl Azido Carborane (Compound 13) 
 
EXPECTED CHARGES 
 Reagent MW Density 
Loading 
eq 
amount   
g 
amount         
mL 
mmole 
TBDMS Carborane 258.49 
---------
- 
1.00 2.00 
---------
- 
7.74 
THF (anhydrous) for 
Carborane 
---------
- 
---------
- 
---------
- 
---------
- 
10.00 
---------
- 
LiHMDS (1M in THF) 
---------
- 
---------
- 
1.25 
---------
- 
9.67 9.67 
THF (anhydrous)  
for LiHMDS 
---------
- 
---------
- 
---------
- 
---------
- 
20.00 
---------
- 
1-azido-3-
iodopropane 
211.00 
---------
- 
1.30 2.12 
---------
- 
10.06 
THF (anhydrous) 
---------
- 
---------
- 
---------
- 
---------
- 
12.00 
---------
- 
   Theoretical Yield of Product 13  
(in grams) 
2.64 
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Procedure 
 To a dry 100 mL round bottomed flask under a nitrogen atmosphere 
was added anhydrous THF (18 mL) and 1M LiHMDS (9.7 mL). The mixture 
was cooled to -78 oC. A solution of TBDMS Carborane (2.00 g) in anhydrous 
THF (10 mL) was added to the cryogenic mixture via syringe over 5 mins 
such that the temperature was maintained < -65 oC. The reaction mixture 
was allowed to stir an additional 5 minutes at -78 oC then allowed to warm 
to 0⁰C, stirred an additional 1.25 hrs at 0 oC, and cooled to -78 oC. A solution 
of 1-azido-3-iodopropane (2.15 g) in anhydrous THF (12 mL) was added 
over 3 minutes at -78 oC. The reaction was allowed reaction to stir at -78 oC 
for 10 minutes then allowed to warm to room temperature and stirred an 
additional 1.25 hours at ambient temperature. The reaction was cooled to 
0⁰C, quenched with USP purified water (5 mL), concentrated under reduced 
pressure, extracted with diethyl ether (2x 20mL). The combined organic 
layers were dried with sodium sulfate, filtered and concentrated under 
reduce pressure to give a crude yellow oil (3.13 g). The crude oil (3.13 g) 
was dissolved in DCM/n-hexane (3.5 mL, 25/75, v/v) and passed through a 
large silica plug (40g) packed in DCM/n-hexane (25/75, v/v). The silica plug 
was flushed with DCM/n-hexane (200 mL, 25/75, v/v) to collect 8 fractions 
(each about 10-15 mL). Fractions 2-6 were combined and concentrated to 
213 
 
give 2.58 g of Compound 13 (97.7% yield, white solid). Stored in fridge (5-
10⁰C). This is a novel compound. 
1H NMR (CDCl3, 400 MHz): δ = 3.32 (t, 2H), 3.15-1.5 (m, 14H), 1.07 (s, 
9H), 0.34 (s, 6H) 
11B NMR (Decoupled, 100 MHz): δ = 0.29, -3.76, -7.29, -10.18 
11B NMR (Coupled, 100 MHz): δ = 0.99, -0.56, -3.13, -4.62, -6.57, -8.16, -
9.48, -11.24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
214 
 
Preparation of 1,4 and 1,5-Disubstituted Click Products via Thermal 
Click Reaction(Compound 14 and Compound 17) 
 
EXPECTED CHARGES 
 Reagent MW 
Loading 
eq 
amount   
g 
amount         
mL 
mmole 
TBDMS Propyl Azido 
Carborane 
341.58 1.00 1.000 ---------- 2.928 
THP-MMP-18 585.59 0.90 1.543 ---------- 2.635 
Toluene (anhydrous) ---------- ---------- ---------- 50.00 ---------- 
      Theoretical Yield of TBDMS Product  2.44 g 
Corrected Theo based on recovered 
SM, see below in procedure 
1.87 g 
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Procedure for the Thermal Click Products (Compounds 14 and 17): 
 To a 100 mL round bottomed flask was added carboranyl azide (1.00 
g), THP-MMP-18 alkyne (1.54 g) and anhydrous toluene (50 mL). The 
mixture was stirred for 10 minutes at ambient temperature and the mixture 
was equally portioned into 6 different pressure vials (ChemGlass, 40 mL) 
where each vial contained 8.3-8.5 mL of mixture. Each mixture was purged 
with argon, placed on a heating block at 120 oC, and allowed to stir at 120 
oC for 58 hours. HPLC analysis of each reaction vial indicated that there was 
~20% unreacted alkyne and the reaction was deemed complete at this point 
to avoid degradation of product and introduction of impurities that are 
difficult to remove downstream. Furthermore, HPLC analysis confirmed that 
the thermal Huisgen 1,3-Dipolar Cycloaddition reaction gives 1,4-Click and 
1,5-Click products with a ratio of 1.6 to 1, respectively, which agrees with 
Sharpless' study (Sharpless, Angew. Chem. Int. Ed., 2002, 41, 2596-2599) 
of determining the component ratio of the regioisiomers. 
 All six reactions (at room temperature) were combined and 
concentrated under reduced pressure to provide a crude oil (2.76 g). The 
crude oil was dissolved in DCM (30 mL), treated with silica gel (6.9 g, 60-
200 micron, Silicylcle), and concentrated to dryness to give dry-loaded 
material on silica which was placed and packed in a 65 g solid loading 
cartridge. An 80 g RediSep Rf Gold silica gel column cartridge was 
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equilibrated with ethyl acetate/n-hexane (40/60, 2CV), 100% ethyl acetate 
(1CV), and ethyl acetate/n-hexane (40/60, 2CV). The purification was 
accomplished using a ethyl acetate/n-hexane step-gradient from ethyl 
acetate/n-hexane (40/60) to 100% ethyl acetate. The elution of components 
were in the following order: starting material, 1,5-Click product (Compound 
17), and lastly 1,4-click product (Compound 14). Appropriate fractions were 
combined and concentrated to isolate recovered starting material (THP-MMP-
18/Compound 9, 0.36 g, colorless oil, TLC Rf = 0.51 using 100% EtOAc), 
1,5-click product (Compound 17, colorless glass solid, 0.60 g, 32.1% yield, 
corrected yield for recovered SM, TLC Rf = 0.35 using 100% EtOAc), and 
1,4-click product (Compound 14, white solid, 0.90 g, 48.1% yield, corrected 
yield for recovered SM, TLC Rf = 0.15 using 100% EtOAc). 
Analytical data for 1,4-Click (Compound 14) and 1,5-Click (Compound 17) 
Products: 
 (1,4-Click) - Compound 14 
HPLC purity: 96% AUC (retention time: 26.5 mins). 
1H NMR (CDCl3, 400 MHz): δ =  9.38 (s, 1H), 7.80 (m ,2H), 7.41 (s, 1H), 
7.28 (d, 2H), 7.11 (d, 2H), 7.04 (d, 2H), 4.99 (s, 1H), 4.33 (t, 2H, J = 6.4 
Hz), 3.99 (bt, 1H, J = 10.3 Hz), 3.68 (bd, 1H), 3.59 (s, 2H), 2.93 (bs, 2H), 
2.40-1.20 (m, 26H), 0.98 (s, 9H), 0.23 (s, 6H). 
13C NMR (CDCl3, 100 MHz): δ =164.1, 162.9, 152.9, 146.1, 145.3, 132.5, 
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128.5, 123.0, 122.3, 121.8, 117.4, 102.1, 79.8, 77.4, 77.2, 77.0, 76.7, 
76.2, 70.5, 62.4, 52.9, 49.8, 49.8, 49.2, 34.9, 30.7, 28.5, 28.3, 27.8, 27.4, 
24.9, 20.3, 18.24, -2.60. 
11B NMR (Decoupled, 100 MHz): δ = 0.27, -3.86, -7.47, -10.51 
11B NMR (Coupled, 100 MHz): δ = 1.09, -0.59, -3.17, -4.34, -6.64, -8.41, -
9.41, -10.81 
HRMS (ESI-ToF): m/z calcd for C38H61B10F3N5O7SSi
+ [M+H]+: 926.4944,  
found 926.5007. 
FTIR: 2941.1, 2863.3, 2575.8, 1686.5, 1587, 1501.4, 1488.6, 1316.7, 
1244.2, 1220.2, 1185.8, 1149.4, 1133.2, 1086.5, 1038.0, 944.4, 896.8, 
858.2, 838.3, 752.8, 731.2, 677.0 cm-1. 
 (1,5-Click) - Compound 17 
HPLC purity: 95% AUC (retention time: 27.4 mins) 
1H NMR (CDCl3, 400 MHz): δ = 9.43 (s, 1H), 7.8 (d, 2H), 7.49 (s, 1H), ? (?, 
3H), 7.1 (d,2H), 7.05 (d,2H), 5.01 (bs,1H), 4.39 (t, 2H), 3.99 (bt,1H), 3.7 
(d, 1H), 3.49 (s, 2H), 2.8 (?, 2H), 1.58-2.30 (c, 24H), 1.25 (s, 1H), 1.00 (s, 
9H) 
13C NMR (CDCl3, 100 MHz): δ = 164.16, 162.91, 152.91, 1461, 134.74, 
132.63, 132.42, 127.82, 123.03, 121.80, 121.71, 117.50, 101.87, 80.13, 
77.35, 77.23, 77.03, 76.71, 76.35, 70.15, 62.30, 50.20, 49.93, 49.74, 
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47.42, 35.04, 30.11, 28.30, 28.10, 27.77, 27.43, 24.92, 20.32, 18.12, -
2.59. 
11B NMR (Decoupled, 100 MHz): δ = 0.37, -3.85, -7.43, -10.47 
11B NMR (Coupled, 100 MHz): δ = 0.94, -0.47, -4.55, -6.70, -8.43, -10.83 
HRMS (ESI-ToF): m/z calcd for C38H61B10F3N5O7SSi
+ [M+H]+: 926.4944,  
found 926.4999. 
FTIR: 2939.8, 2869.6, 2579.3, 1685.9, 1586.8, 15014, 1488.7, 1319.0, 
1295.5, 1220.0, 1243.6, 1185.7, 1149.9, 1134.3, 1086.8, 1037.2, 957.7, 
944.6, 896.9, 873.3, 858.7, 838.3, 818.4, 732.1, 677.3 cm-1 
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Preparation of the THP MMP-18 1,4-Click Product (Compound 15) 
 
EXPECTED CHARGES   
 Reagent MW 
Loading 
eq 
amount   
g 
amount         
mL 
mmole 
1,4-Click Product TBDMS-
THP Protected 
924.17 1.00 0.128 ---------- 0.139 
1M TBAF in THF ---------- 1.20 ---------- 0.17 0.166 
Anhydrous THF ---------- ---------- ---------- 1.28 ---------- 
   
Theoretical Yield of Product 15 (in g) 0.112 
 
Procedure 
 To 1,4-click TBDMS protected product (Compound 14, 128 mg) was 
added anhydrous THF (1.25 mL) and the resulting mixture was cooled 
solution to  –78⁰C. To the cryogenic mixture was added a solution of 1M 
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TBAF in THF (0.17 mL) over approximately 30 seconds. After 5 minutes, the 
cooling bath was removed and then the reaction was permitted to warm to 
room temperature. After 30 minutes at room temperature, TLC analysis 
(100% EtOAc) showed complete consumption of starting material. The 
reaction mixture was concentrated to a crude oil residue which was dissolved 
in ethyl acetate (2 mL) and washed with water (1 mL, pH 7-7.5). The 
aqueous phase was extracted ethyl acetate (1 mL). The combined organic 
layers were washed with water (pH 7-7.5, 1 mL), dried with sodium sulfate, 
filtered, and concentrated under reduced pressure to give crude product 
(108 mg , lot PR074-055-2). The crude oil (108 mg) was dissolved in ethyl 
acetate (0.5 mL) and passed through a silica plug (0.27 g) in ethyl acetate. 
The plug was flushed with ethyl acetate. Appropriate fractions were 
combined and concentrated to afford desired 1,4-click THP protected product 
(Compound 15, 88 mg, 78.6% yield, colorless oil that solidifies upon 
standing) which was taken forward without any further purification since it 
contains residual tert-butyldimethylsilyl fluoride (which will be removed 
downstream).  
HPLC purity: 92.3% AUC (retention time: 24.1 mins) 
HRMS (ESI-ToF): m/z calcd for C32H47B10F3N5O7S
+ [M+H]+: 812.4079,  
found 812.4131. 
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FTIR: 2946.6, 2850.4, 2586.7, 1682.0, 1587.0, 1501.5, 1488.4, 1461.3, 
1293.7, 1219.9, 1244.5, 1185.9, 1132.6, 1149.0, 1086.1, 1037.5, 1021.5, 
956.2, 944.2, 896.0, 873.1, 835.1, 816.0, 754.5, 
722.7, 678.9, 645.0 cm-1 
Preparation of 1,4-Click Carboranyl MMP-18 HCl Salt (Compound 16) 
 
EXPECTED 
CHARGES   
 Reagent MW 
Loading 
eq 
amount   
g 
amount         
mL 
mmole 
THP Protected  
1,4-Click Product  
809.91 1.00 0.088 ---------- 0.109 
Dioxane 
(anhydrous) 
---------- ---------- ---------- 0.88 ---------- 
4N HCl in Dioxane ---------- 5.00 ---------- 0.14 0.543 
   
Theoretical Yield of Product 16 (in 
g) 
0.083 
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Procedure 
 To a 10 mL vial containing THP protected 1,4-Click product (Compound 
15, 88 mg) under nitrogen atmosphere was added anhydrous dioxane (0.9 
mL) and allowed mixture to stir until complete dissolution was achieved. To 
the solution was added 4N HCl in dioxane (0.14 mL) and the reaction was 
allowed to stir for 2 hours at room temperature where HPLC analysis 
revealed that the reaction was deemed complete. The reaction mixture was 
concentrated under reduced pressure at 30 + 5 oC to give a crude oil. The 
crude oil was dissolved in dichloromethane (1 mL) and diethyl ether (3 mL) 
was added to generate a white slurry. The slurry was allowed to stir at 
ambient temperature for 1.5 hours, filtered, and the filter cake was washed 
with diethyl ether (2 mL) and n-heptane (5 mL), pulled dry under nitrogen, 
and further dried in vacuo at room temperature to provide the title 1,4-Click 
Carboanyl MMP-18 HCl salt (Compound 16, 60 mg, white solids, 72.2% 
yield, Lot PR074-062-5).  
HPLC purity: 95.1% AUC (retention time: 22.7 mins) 
11B NMR (Decoupled, 100 MHz): δ = 18.56, -2.94, -6.09, -9.67, -12.20,  
-13.17 
11B NMR (Coupled, 100 MHz): δ = 18.56, -2.15, -3.64, -5.21, -6.32, -8.91, 
-11.08, -12.95, -13.86 
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HRMS (ESI-ToF): m/z calcd for C27H39B10F3N5O6S
+ [M+H]+: 728.3504,  
found 728.3540. 
X-Ray crystallography: PENDING 
 
Preparation of the THP MMP-18 1,5-Click Product (Compound 18) 
 
EXPECTED CHARGES   
 Reagent MW 
Loading 
eq 
amount   
g 
amount         
mL 
mmole 
1,5-Click Product  
TBDMS-THP Protected 
924.17 1.00 0.071 ---------- 0.077 
1M TBAF in THF ---------- 1.20 ---------- 0.092 0.092 
Anhydrous THF ---------- 
---------
- 
---------- 0.71 ---------- 
   
Theoretical Yield of Product 18 (in g) 0.062 
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Procedure 
 
 To 1,5-click TBDMS protected product (Compound 17, 71 mg) was 
added anhydrous THF (0.9 mL) and the resulting mixture was cooled 
solution to  –78⁰C. To the cryogenic mixture was added a solution of 1M 
TBAF in THF (90 µL). After 5 minutes, the cooling bath was removed and 
then the reaction was allowed to warm to room temperature. After 75 
minutes at room temperature, TLC analysis (100% EtOAc) showed complete 
consumption of starting material. The reaction mixture was concentrated to 
a crude oil residue which was dissolved in ethyl acetate (2 mL) and washed 
with water (1 mL, pH 7-7.5). The aqueous phase was extracted ethyl acetate 
(2 mL). The combined organic layers were washed with water (pH 7-7.5, 1 
mL), dried with sodium sulfate, filtered, and concentrated under reduced 
pressure to give crude desired product Compound 18 (82 mg , lot PR074-
080-2, theoretically 62 mg present) which was taken forward without any 
further purification since it contains residual tert-butyldimethylsilyl fluoride 
(which will be removed downstream).  
HPLC purity: 95.2% AUC (retention time: 26.4 mins) 
HRMS (ESI-ToF): m/z calcd for C32H47B10F3N5O7S
+ [M+H]+: 812.4079,  
found 812.4139. 
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Preparation of 1,5-Click Carboranyl MMP-18 HCl Salt (Compound 19) 
 
EXPECTED CHARGES   
 Reagent MW 
Loading 
eq 
amount   
g 
amount         
mL 
mmole 
THP Protected 1,5-Click 
Product                                   
(crude, contains residual 
TBDMS Fluoride) 
809.91 1.00 0.082 
---------
- 
0.101 
Dioxane (anhydrous) 
---------
- 
---------
- 
---------
- 
0.82 
---------
- 
4N HCl in Dioxane 
---------
- 
5.00 
---------
- 
0.13 0.506 
   
Theoretical Yield of Product 19 (in g) 0.077 
Corrected Theo yield based on 62 mg 
SM since TBDMSF is present (in g) 
0.0584 
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Procedure 
 To a 10 mL vial containing crude THP protected 1,5-Click product 
(Compound 18, 82 mg) under nitrogen atmosphere was added anhydrous 
dioxane (0.9 mL) and allowed mixture to stir until complete dissolution was 
achieved. To the solution was added 4N HCl in dioxane (0.14 mL) and the 
reaction was allowed to stir for 2.5 hours at room temperature where HPLC 
analysis revealed that the reaction was deemed complete. The reaction 
mixture was concentrated under reduced pressure at 30 + 5 oC to give a 
crude oil. The crude oil was dissolved in dichloromethane (0.5 mL) and 
diethyl ether (3 mL) was slowly added to generate a white slurry. The slurry 
was allowed to stir at ambient temperature for 20 mins, filtered, and the 
filter cake was washed with diethyl ether (2.5 mL) and n-hexane (5 mL), 
pulled dry under nitrogen, and further dried in vacuo at room temperature to 
provide the title 1,5-Click Carboanyl MMP-18 HCl salt (Compound 19, 58 mg, 
white solids, 99% yield, Lot PR074-088-2).  
HPLC purity: 92.2% AUC (retention time: 23.2 mins) 
11B NMR (Decoupled, 100 MHz): δ = 18.55, -2.90, -6.26, -9.74, -12.24, -
13.14 
11B NMR (Coupled, 100 MHz): δ = 18.58, -2.13, -3.71, -8.99, -11.11, -
12.88 
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HRMS (ESI-ToF): m/z calcd for C27H39B10F3N5O6S
+ [M+H]+: 728.3504,  
found 728.3538. 
X-Ray crystallography: PENDING 
Preparation of MMP-18 Carboranyl Ethyl Ester (Compound 20) 
 
EXPECTED CHARGES 
 Reagent MW 
Loading 
eq 
amount   
g 
amount         
mL 
mmole 
Decaborane, 11B10H14 122.22 1.20 0.860 NA 7.04 
Acetonitrile (anhydrous) 41.05 100.00 24.08 30.63 586.50 
Toluene (anhydrous) for 
11B10H14 
-------- -------- -------- 45.00 -------- 
Toluene (anhydrous) for MMP-
18 Ester 
-------- -------- -------- 15.00 -------- 
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MMP-18 Ethyl Ester  
(Cmpd 7) 
511.51 1.00 3.00 NA 5.86 
  
Theoretical Yield of Product 20  
(in grams) 
3.69 
 
Procedure 
 A 250 mL round bottomed flask (1-necked) was equipped with a 
Claisen adapter, reflux condenser with nitrogen inlet, magnetic stirring bar, 
and a J-Kem thermocouple. To the reactor under nitrogen was added white 
decaborane (0.90 g), anhydrous toluene (45 mL), and anhydrous ACN (31 
mL). The mixture was purged with nitrogen and the reaction flask was 
covered with foil. Heated the mixture to reflux (temp 82⁰C) for 80 minutes 
followed by cooling the mixture to room temperature. To the reaction 
mixture (light yellow solution) at ambient temperature was added a solution 
of MMP-18 Ethyl Ester (Compound 7, 3.13 g) in anhydrous toluene (10 mL) 
and additional anhydrous toluene (5 mL) was used to quantitatively transfer 
all ester to the reactor. The reactor was purged with nitrogen and heated to 
reflux. After 19 hours, the reaction was a dark yellowish-orange solution and 
the reaction was sampled for HPLC analysis (8 drops of reaction mixture was 
concentrated and dissolved in 4 mL of ACN). HPLC analysis indicated that 
the starting material alkynyl ester (18.4 mins) was completely consumed. 
The reaction mixture was cooled to room temperature and was concentrated 
under reduced pressure at 40-50⁰C to give crude Compound 20 as an orange 
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foam (4.29 g, Lot PR074-057-2). Crude product (lot PR074-057-2) was 
analyzed by HPLC and TLC*. 
TLC Analysis of PR074-057-2 (crude, EtOAc/hept 40/60). TLC analysis was 
done using a glass backed TLC plate visualizing with UV and 0.4% PdCl2 in 
3M HCl: 
 
 
 
Purification of PR074-057-2 via flash chromatography: 
 Crude product (PR074-057-2, 4.29 g) was dissolved in DCM and 
transferred to a 250 mL round bottomed flask. To the flask was added silica 
gel (10.0 g, 60-200 micron, Silicycle) and this mixture was concentrated to 
dryness on rotovap at 25-30⁰C to provide dry-loaded crude product. The 
dry-loaded crude product was loaded into a 65 g solid loading cartridge. An 
80 g Redisep Rf Gold silica gel cartridge column was equilibrated with n-
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hexane (165 mL), ethyl acetate/n-hexane (50/50, 195 mL), and n-hexane 
(275 mL). Purification on an Isco Rf unit was accomplished using an ethyl 
acetate/n-hexane gradient (0/100 to 100/0) over 16.5 column volumes. 
Collected fractions were analyzed by HPLC (refer to the table below for 
information regarding purity of the fraction analyzed. 
Table: HPLC Analysis of Fractions from Flash Chrom. Purification 
Fraction 
% AUC 
Product 
(32.4 min) 
% AUC 
26.4 min 
Impurity 
Comments 
1 0 0 Toluene (100% AUC, 17.4 mins) 
3 
100 
(97 mAu) 
0 N/A 
5 
100 
(237 mAu) 
0 N/A 
7 
100 
(180 mAu) 
0 N/A 
9 
97.4 
(111 mAu) 
0 2.6% (28.7 mins) 
11 
100 
(72 mAu) 
0 N/A 
13 
100 
(47 mAu) 
0 N/A 
15 
90.6 
(32 mAu) 
0 9.4% (30.3 mins) 
17 
78.9 
(25 mAu) 
0 9.4% (30.3 mins), 14.1% (30.9 mins) 
19 
75.5 
(23 mAu) 
0 24.5% (22.5 mins) 
21 
38.1 
(12 mAu) 
0 61.9% (25.2 mins) 
23 
30.7 
(9 mAu) 
0 47.8% (25.2 mins), 21.5% (28.2 mins) 
25 
10.9 
(7 mAu) 
0 
13.5% (24.6 mins), 14.0% (25.2 mins), 
61.5% (28.2 mins) 
27 
8.8 
(8 mAu) 
0 
17.5% (24.6 mins), 15.5% (25.2 mins), 
33.5% (26.9 mins), 24.6% (28.2 mins) 
29 0 
90.4 
(816 
Many small impurities present 
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Fraction 
% AUC 
Product 
(32.4 min) 
% AUC 
26.4 min 
Impurity 
Comments 
mAu) 
31 0 
73.6 
(212 
mAu) 
Other small impurities present 
33 0 
28.5 
(23 mAu) 
Many small impurities present 
35 0 
29.5 
 (6 mAu) 
70.5% (27.5 mins) 
37 0 trace N/A 
40 0 trace N/A 
 
Fractions 3-14 were combined and concentrated under reduced 
pressure to give desired carboranyl ethyl ester product (Compound 20, 1.30 
g, 33.8% yield, white foam solid, Lot PR074-057-3). 
HPLC purity: 98.9% AUC (retention time: 32.4 mins) 
1H NMR (CDCl3 -7.04 (m, 
4H), 4.18 (q, 2H, J = 8.0 Hz), 3.91 (s, 1H), 3.10-1.50 (complex, 20H), 1.24 
(t, 3H,  J = 8.0 Hz) 
13C NMR (CDCl3 166.87, 162.67, 153.06, 146.07, 146.06, 
132.62, 128.77, 123.05, 121.71, 121.66, 119.15, 117.17, 77.34, 77.02, 
76.71, 74.45, 71.41, 62.62, 58.16, 51.96, 13.95 
DEPT135: 132.62, 123.06, 121.67, 117.18, 62.63, 58.17, 51.95, 13.96  
C13APT: 166.87, 162.67, 153.06, 146.06, 132.62, 128.78, 123.06, 121.67, 
117.18, 77.35, 77.03, 76.71, 74.45, 71.41, 62.62, 58.17, 51.96, 13.96 
11B NMR (Decoupled, 100 MHz): δ = -2.82, -5.21, -8.98, -11.69, -12.89 
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11B NMR (Coupled, 100 MHz): δ = -2.10, -3.73, -5.97, -8.20, -9.83, -12.35 
HRMS (ESI-ToF): m/z calcd for C24H35B10F3NO6S
+ [M+H]+: 632.3068,  
found 632.3112. 
Fractions 28-32 were pooled and concentrated to give 0.80 g of 
Compound 21 as a yellow foam solid (Lot PR074-057-5) which is assigned to 
be the nido-form of carboranyl ethyl ester product. 
HPLC purity: 68.7% AUC (retention time: 26.4 mins) 
HRMS (ESI-ToF): m/z calcd for C24H34B9F3NO6S
 + [M+H]+: 620.2896,  
found 620.3022. 
Hydrolysis of MMP-18 Carboranyl Ethyl Ester via Continuous Flow 
Mode (Compound 22) 
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EXPECTED CHARGES   
 Reagent MW 
Loading 
eq 
amount   
g 
amount         
mL 
mmole 
MMP-18 Carboranyl Ethyl 
Ester, Cmpd 20 
629.70 1.00 0.600 NA 0.96 
Acetic Acid 41.05 100.00 157.50 150.00 -------- 
87.4 wt% H2SO4 -------- -------- -------- 75.00 -------- 
   
Theoretical Yield of Product 21 
 (in grams) 
0.575 
 
Procedure 
 MMP-18 Carboranyl Ethyl Ester (Compound 20, 0.60 g) was dissolved 
in acetic acid (150 mL) and allowed to stir at room temperature until 
complete dissolution was achieved. The solution of ester was diluted with 
87% sulfuric acid (75 mL), stirred for 10 minutes at room temperature, then 
processed through a Vapourtec plug flow reactor (10 mL) at 150 oC with a 
flow rate of 0.133 mL/min providing a residence time of 75 minutes. Once all 
the starting material feed was processed, the flow reactor was flushed with 
glacial acetic acid at 150 oC at 2 mL/min for 30 minutes. The collected crude 
product was concentrated at 60 oC under reduced pressure to remove acetic 
acid. The resulting sulfuric acid residue was diluted with DCM (300 mL) and 
then placed in a cooling bath (10 oC). The mixture was carefully diluted with 
saturated sodium bicarbonate solution (300 mL) followed by slow addition of 
234 
 
solid sodium bicarbonate (210 g) to achieved a pH of 3.5. The mixture was 
further diluted with 300 mL of USP purified water and then extracted with 
DCM (2 x 200 mL). The combined organic layers were dried with sodium 
sulfate, filtered, and concentrated to give 0.52 g of crude Compound 22.  
Formation of THP protected Hydroxamate hydrochloride salt: 
HCl salt formation of THP-protected MMP-18 (Compound 9) via 
addition of 4N HCl in Dioxane into a solution THP-protected MMP-18 in 
isopropyl acetate was unsuccessful and only generated free MMP-18 
hydroxamic acid and some minor impurities (refer to PR075-074).  
However, treating a solution of THP-protected MMP-18 (Compound 9, 150 
mg) in isopropyl acetate (1.5 mL) and 3,4-Dihydro-2H-pyran (1.0 mL) with 
4N HCl in dioxane (0.25 mL) provided THP-protected MMP-18 HCl salt (159 
mg, 97.5% yield, HPLC purity: 95% THP HCl salt, and 3% Free Hydroxamic 
acid). Refer to PR075-075 for this interesting work where THP group 
remained stable! 
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Salt formation of THP-MMP-18 (Compound 9) was also successful by 
treating a solution of THP-MMP-18 in ethyl acetate with a solution of oxalic 
acid dihydrate (1.1 eq) in EtOH/EtOAc. Refer to PR075-075 for this work 
regarding oxalate salt formation! 
Section 8: Acknowledgements 
It is with utmost pleasure to acknowledge Dr. Marta Wenzler for her 
contributions for attaining HRMS data for all BNCT compounds and 
intermediate, and we are extremely grateful. Additionally, it is with great 
pleasure to acknowledge Andre Colorina for his significant contributions in 
assisting with synthesis of BNCT compounds. Furthermore, many thank to 
Dr. Narayan Hosmane for performing 11B NMR analyses on carborane 
compounds. 
236 
 
 
 
 
 
 
 
 
 
 
APPENDIX A 
SUPPLEMENTAL DATA FOR CHAPTER TWO 
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HPLC for Racemic CTV-Lactam (19) 
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1H NMR Spectra for Racemic CTV-Lactam (19) 
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Achiral HPLC of Recrystallized CTV-Menthyloxyacetic acid Imide (23) 
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IR of CTV lactam menthyloxyacetic acid imide (23) 
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1H NMR Spectra for Different Lots of CTV lactam menthyloxyacetic 
acid imide (23) 
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Overlap of 1H NMR spectra of hydrolyzed 23 to 19 and analyzing the 
same NMR sample over 20 min shown below.  
 
When the chiral auxiliary group was cleaved, concentrated, dissolved in 
CDCl3 and added Chirabite (0.30 eq), the sample was analyzed by 1H NMR 
analysis over time to determine if there was any change. The figure above 
clearly shows that there wasn't any change and this result further proves 
that racemization occurs fast. 
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1H NMR - Compound 5 
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263 
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13C NMR - Compound 5 
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Achiral HPLC - Compound 5 
  
268 
 
HRMS - Compound 5 
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1H NMR - Compound 6 
 
270 
  
271 
 
MS - Compound 6 
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HRMS - Compound 6 
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1H NMR - Compound 7 
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13C NMR - Compound 7 
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HRMS - Compound 7 
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Achiral HPLC - Compound 8a 
 
  
283 
 
1H NMR - Compound 8a 
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13C NMR - Compound 8a 
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HRMS - Compound 8a 
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Achiral HPLC - Compound 9a 
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Chiral HPLC - Compound 9a 
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1H NMR - Compound 9a 
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13C NMR - Compound 9a 
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HRMS - Compound 9a 
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1H NMR - Amino Methyl Ester 
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13C NMR - Amino Methyl Ester 
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HRMS - Amino Methyl Ester 
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1H NMR - Compound 10a 
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HRMS - Compound 10a 
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1H NMR - Compound 1a.HCl 
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HRMS - Compound 1a.HCl 
 
315 
 
Achiral HPLC - Compound 8b 
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1H NMR - Compound 8b 
 
317 
  
318 
  
319 
 
 
320 
 
13C NMR - Compound 8b 
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HRMS - Compound 8b 
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Achiral HPLC - Compound 9b 
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Chiral HPLC - Compound 9b 
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1H NMR - Compound 9b 
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13C NMR - Compound 9b 
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330 
 H 
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MS - Compound 9b 
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UPLC/MS - Amino Acid Intermediate 10b 
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HRMS - Amino Acid Intermediate 10b 
 
334 
 
Chiral HPLC - Compound 10b  
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1H NMR - Compound 10b 
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13C NMR - Compound 10b 
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HRMS - Compound 10b 
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Chiral HPLC - Compound 1b.TFA on a Chirosil SCA(-) column (150 
mm x 4.6 mm, 5 micron) 
 
342 
 
Chiral HPLC - Compound 1b.TFA on a RegisPack column (250x4.6 
mm, 5 micron) 
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1H NMR - Compound 1b.TFA 
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13C NMR - Compound 1b.TFA 
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347 
  
348 
 
HRMS - Compound 1b.TFA 
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HPLC (achiral) - Compound 12 
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1H NMR - Compound 12 
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HRMS - Compound 12 
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1H NMR - Compound 13 
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355 
 
 
 
356 
 
HRMS - Compound 13 
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1H NMR - Compound 18 
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H NMR - Bis(4-Fluorophenyl) Disulfide (Compound 1) 
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1H NMR - Bis(4-Fluorophenyl) Disulfide (Compound 1) 
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13C NMR - Bis(4-Fluorophenyl) Disulfide (Compound 1) 
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13C NMR - Bis(4-Fluorophenyl) Disulfide (Compound 1) 
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HPLC - Isolated Sulfide Adduct (Compound 3) 
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1H NMR - Isolated Sulfide Adduct (Compound 3) 
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1H NMR - Isolated Sulfide Adduct (Compound 3) 
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1H NMR - Isolated Sulfide Adduct (Compound 3) 
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1H NMR - Isolated Sulfide Adduct (Compound 3) 
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13C NMR - Isolated Sulfide Adduct (Compound 3) 
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HPLC - Sulfone Adduct (Compound 4) 
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1H NMR - Sulfone Adduct (Compound 4) 
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1H NMR - Sulfone Adduct (Compound 4) 
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1H NMR - Sulfone Adduct (Compound 4) 
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13C NMR - Sulfone Adduct (Compound 4) 
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HRMS - Sulfone Adduct (Compound 4) 
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HPLC - Sulfone Adduct HCl Salt (Compound 5) 
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1H NMR - Sulfone Adduct HCl Salt (Compound 5) 
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1H NMR - Sulfone Adduct HCl Salt (Compound 5) 
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13C NMR - Sulfone Adduct HCl Salt (Compound 5) 
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13C NMR - Sulfone Adduct HCl Salt (Compound 5) 
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HRMS - Sulfone Adduct HCl Salt (Compound 5)  
 
  
384 
 
HPLC - Propargylamine Adduct (Compound 6) 
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1H NMR - Propargylamine Adduct (Compound 6) 
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1H NMR - Propargylamine Adduct (Compound 6) 
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1H NMR - Propargylamine Adduct (Compound 6) 
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13C NMR - Propargylamine Adduct (Compound 6) 
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HRMS - Propargylamine Adduct (Compound 6) 
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HPLC - Diaryl Ether Adduct (Compound 7) 
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1H NMR - Diaryl Ether Adduct (Compound 7) 
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1H NMR - Diaryl Ether Adduct (Compound 7) 
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1H NMR - Diaryl Ether Adduct (Compound 7) 
 
394 
 
13C NMR - Diaryl Ether Adduct (Compound 7) 
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HRMS - Diaryl Ether Adduct (Compound 7) 
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HPLC - MMP-18 Carboxylic Acid (Compound 8) 
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1H NMR - MMP-18 Carboxylic Acid (Compound 8) 
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1H NMR - MMP-18 Carboxylic Acid (Compound 8) 
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1H NMR - MMP-18 Carboxylic Acid (Compound 8) 
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13C NMR - MMP-18 Carboxylic Acid (Compound 8) 
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HRMS - MMP-18 Carboxylic Acid (Compound 8) 
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HPLC - THP-MMP-18 (Compound 9) 
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1H NMR - THP-MMP-18 (Compound 9) 
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1H NMR - THP-MMP-18 (Compound 9) 
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1H NMR - THP-MMP-18 (Compound 9) 
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13C NMR - THP-MMP-18 (Compound 9) 
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HRMS - THP-MMP-18 (Compound 9) 
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1H NMR - TBDMS Carborane (Compound 10) 
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1H NMR - TBDMS Carborane (Compound 10) 
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11B NMR (Coupled) - TBDMS Carborane (Compound 10) 
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11B NMR (Decoupled) - TBDMS Carborane (Compound 10) 
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1H NMR - Crude Chloro Propyl Azide (Compound 11) 
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1H NMR - Crude Chloro Propyl Azide (Compound 11) 
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1H NMR - Crude Chloro Propyl Azide (Compound 11) 
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1H NMR - Iodo Propyl Azide (Compound 12) 
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1H NMR - Carboranyl Propyl Azide (Compound 13) 
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1H NMR - Carboranyl Propyl Azide (Compound 13) 
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11B NMR (Coupled) - Carboranyl Propyl Azide (Compound 13) 
 
419 
 
11B NMR (Decoupled) - Carboranyl Propyl Azide (Compound 13) 
 
420 
 
HPLC - 1,4-Disubstituted Click Product (TBDMS and THP Protected) 
(Compound 14) 
 
421 
 
FTIR - 1,4-Disubstituted Click Product (TBDMS and THP Protected) 
(Compound 14) 
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1H NMR - 1,4-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 14) 
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1H NMR - 1,4-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 14) 
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1H NMR - 1,4-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 14) 
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13C NMR - 1,4-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 14) 
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13C NMR - 1,4-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 14) 
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13C NMR - 1,4-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 14) 
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13C NMR - 1,4-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 14) 
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HRMS - 1,4-Disubstituted Click Product (TBDMS and THP Protected) 
(Compound 14) 
 
 
  
430 
 
HRMS - 1,4-Disubstituted Click Product (TBDMS and THP Protected) 
(Compound 14) 
 
 
 
  
431 
 
11B NMR (Coupled) - 1,4-Disubstituted Click Product (TBDMS/THP 
Protected) (Cmpd 14) 
 
432 
 
11B NMR (Decoupled) - 1,4-Disubstituted Click Product (TBDMS/THP 
Protected) (Cmpd 14) 
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HPLC - THP MMP-18 1,4-Click Product (Compound 15) 
 
434 
 
FTIR - THP MMP-18 1,4-Click Product (Compound 15) 
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HRMS - THP MMP-18 1,4-Click Product (Compound 15) 
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HRMS - THP MMP-18 1,4-Click Product (Compound 15) 
 
 
  
437 
 
HPLC - 1,4-Click Carboranyl MMP-18 HCl Salt (Compound 16) 
 
438 
 
HRMS - 1,4-Click Carboranyl MMP-18 HCl Salt (Compound 16) 
 
 
  
439 
 
HRMS - 1,4-Click Carboranyl MMP-18 HCl Salt (Compound 16) 
 
 
  
440 
 
11B NMR (Coupled) - 1,4-Click Carboranyl MMP-18 HCl Salt 
(Compound 16) 
 
 
441 
 
11B NMR (Decoupled) - 1,4-Click Carboranyl MMP-18 HCl Salt 
(Compound 16) 
 
442 
 
HPLC - 1,5-Disubstituted Click Product (TBDMS and THP Protected) 
(Compound 17) 
 
443 
 
FTIR - 1,5-Disubstituted Click Product (TBDMS and THP Protected) 
(Compound 17) 
 
444 
 
1H NMR - 1,5-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 17) 
 
445 
 
1H NMR - 1,5-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 17) 
 
446 
 
1H NMR - 1,5-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 17) 
 
447 
 
1H NMR - 1,5-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 17) 
 
448 
 
13C NMR - 1,5-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 17) 
 
449 
 
13C NMR - 1,5-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 17) 
 
450 
 
13C NMR - 1,5-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 17) 
 
451 
 
13C NMR - 1,5-Disubstituted Click Product (TBDMS and THP 
Protected) (Compound 17) 
 
452 
 
HRMS - 1,5-Disubstituted Click Product (TBDMS and THP Protected) 
(Compound 17) 
 
453 
 
HRMS - 1,5-Disubstituted Click Product (TBDMS and THP Protected) 
(Compound 17) 
 
454 
 
11B NMR (Coupled) - 1,5-Disubstituted Click Product (TBDMS/THP 
Protected) (Compound 17) 
 
455 
 
11B NMR (Decoupled) - 1,5-Disubstituted Click Product (TBDMS/THP 
Protected) (Cmpd 17) 
 
456 
 
HPLC - THP MMP-18 1,5-Click Product (Compound 18) 
 
457 
 
HRMS - THP MMP-18 1,5-Click Product (Compound 18) 
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HPLC - 1,5-Click Carboranyl MMP-18 HCl Salt (Compound 19) 
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HRMS - 1,5-Click Carboranyl MMP-18 HCl Salt (Compound 19) 
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HRMS - 1,5-Click Carboranyl MMP-18 HCl Salt (Compound 19) 
 
461 
 
11B NMR (Coupled) - 1,5-Click Carboranyl MMP-18 HCl Salt 
(Compound 19) 
 
462 
 
11B NMR (Decoupled) - 1,5-Click Carboranyl MMP-18 HCl Salt 
(Compound 19) 
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HPLC - Carboranyl MMP-18 Ethyl Ester (Compound 20) 
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1H NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20) 
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1H NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20) 
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1H NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20) 
 
467 
 
13C NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20) 
 
468 
 
13C NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20) 
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13C NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20) 
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13C APT NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20) 
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13C DEPT135 NMR - Carboranyl MMP-18 Ethyl Ester (Compound 20) 
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HRMS - Carboranyl MMP-18 Ethyl Ester (Compound 20) 
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HRMS - Carboranyl MMP-18 Ethyl Ester (Compound 20) 
 
  
474 
 
11B NMR (Coupled) - Carboranyl MMP-18 Ethyl Ester (Compound 20) 
 
475 
 
11B NMR (Decoupled) - Carboranyl MMP-18 Ethyl Ester (Compound 
20) 
 
476 
 
HPLC - Nido Carboranyl MMP-18 Ethyl Ester from B10H14 Reaction 
(Compound 21) 
 
477 
 
HRMS (Positive Mode) - Nido Carboranyl MMP-18 Ethyl Ester from 
B10H14 Reaction (Compound 21) 
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HPLC - Nido Carboranyl MMP-18 Ethyl Ester from microwave heating 
(Compound 21) 
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HRMS (Negative Mode) - Nido Carboranyl MMP-18 Ethyl Ester from 
microwave heating (Compound 21) 
 
 
 
  
480 
 
HPLC - Carboranyl MMP-18 Carboxylic Acid (Compound 22) 
 
 
UPLC/MS - Carboranyl MMP-18 Carboxylic Acid (Compound 22) 
 
  
481 
 
HRMS - Carboranyl MMP-18 Carboxylic Acid (Compound 22) 
 
 
  
482 
 
HRMS (Negative Mode) - Nido Carboranyl MMP-18 Ethyl Ester 
(Compound 21) 
 
 
  
483 
 
HRMS - Arachno Carboranyl MMP-18 Ethyl Ester (Compound 24) 
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